Epigenetic control of the post-bariatric phenotype: the role of microRNAs by Alkandari, Abdullah
1 
 
 
 
 
 
Epigenetic control of the post-bariatric 
phenotype: The role of microRNAs 
 
 
A thesis submitted for a Doctor of Philosophy 
Abdullah Alkandari 
2015 
 
 
Department of Surgery and Cancer 
Imperial College London 
 
2 
 
Statement of Originality 
The work presented in this thesis is my own unless otherwise stated. All other work is appropriately 
referenced.  
 
Copyright 
The copyright of this thesis rests with the author and is made available under a Creative Commons 
Attribution Non-Commercial Non-Derivatives licence. Researchers are free to copy, distribute or 
transmit the thesis on the condition that they attribute it, that they do not use it for commercial 
purposes and that they do not alter, transform or build upon it. For any reuse or distribution, 
researchers must make clear to others the license terms of this work. 
 
 
 
 
 
 
 
 
 
3 
 
Abstract 
The rising obesity pandemic and the concomitant rise in its co-morbidities are leading causes of 
global morbidity and mortality. Bariatric surgery is a form of gastrointestinal surgery that leads to 
sustained weight loss, diabetes resolution, reduction in cancer risk and other improvements in 
health. MicroRNAs are a family of small, endogenous, non-coding RNAs that regulate gene 
expression at the post-transcriptional level. MicroRNAs control expression of over half the human 
transcriptome and are involved in processes fundamental to both normal physiology and disease, 
including obesity and diabetes. This study hypothesizes that microRNAs are biomarkers for health 
improvements following bariatric surgery. Using quantitative PCR, a microRNA baseline was 
established in the serum and urine of an obese human population and increases in three anti-fibrotic 
microRNAs were found in urine following bariatric surgery. Circulating microRNA profiles were 
characterised in Roux-en-Y gastric bypass patients preoperatively and at 5 timepoints 
postoperatively. Roux-en-Y gastric bypass significantly altered circulating microRNA profiles in a time 
dependent manner. Relative to preoperative levels, of the 159 circulating microRNAs assayed 2 were 
significantly deregulated 1 month postoperatively, 5 were deregulated at 3 months, 10 at 6 months, 
28 at 9 months and 31 at 12 months. Target prediction and pathway analysis revealed that these 
differentiated microRNAs regulate biological pathways that are involved in obesity and that 
microRNAs may contribute to the development of the beneficial post-bariatric phenotype. Both 
circulating and urinary post-bariatric microRNA levels correlated with measured clinical biomarkers 
such as BMI and blood glucose. These results indicate that bariatric operations fundamentally alter 
microRNA expression both in urine and in circulation and suggest that microRNAs represent not only 
potentially novel biomarkers for improvements in health following surgery, but are possible 
biological effectors that contribute to the mechanisms behind bariatric surgery. MicroRNA 
expression profiles could potentially be used to monitor operative outcomes and understanding the 
role of these differentially expressed microRNAs could shed light behind the mechanism by which 
bariatric surgery improves health.   
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1 Introduction 
1.1 Obesity 
Obesity is a global pandemic with prevalence having more than doubled since 1980 [1]. The number 
of overweight and obese individuals rose from 857 million in 1980 to 2.1 billion in 2013 [2]. In the 
United Kingdom prevalence of obesity was 24.4% in adult males and 25.1% in adult females in 2013, 
a sharp increase from 1993 when 13.2% of men and 16.4% of women were obese [3]. Unlike other 
global health risks such as tobacco, alcoholism and malnutrition, obesity is not decreasing and is now 
established as one of the leading public health challenges of the 21st century. If the current 
trajectory holds approximately half of the world will be overweight or obese by 2030 [4].  
Obesity is excessive weight in the form of fat and is measured through the body mass index (BMI), 
which is calculated by dividing weight in kilograms by height in metres squared. The World Health 
Organisation (WHO) defines healthy weight as a BMI between 18.5 and 25, overweight as a BMI 
between 25 and 30 and obesity as a BMI over 30 (Table 1.1). Obesity is caused by an energy 
imbalance where calorific intake exceeds expenditure. Globally there’s been an increase in intake of 
high fat food and a decrease in physical activity due to environmental and societal changes caused 
by the rapid urbanisation and industrialisation of the 20th century.  
 
Table ‎1.1: The WHO classification of obesity 
Classification BMI 
Underweight <18.50 
Normal weight 18.50-24.99 
Overweight 25-29.99 
Obese (Obese Class I) 30-34.99 
Severely Obese (Obese Class II) 35-39.99 
Morbidly Obese (Obese Class III) >40 
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Obesity is a risk factor for a number of other disorders including type 2 diabetes mellitus, 
cardiovascular disease and cancer [5]. Together, obesity and its co-morbidities form a cluster of 
related physiological disorders collectively known as the metabolic syndrome, and are leading 
causes of global morbidity and mortality, imposing substantial burdens on health services. Relative 
to individuals with a healthy BMI, severely and morbidly obese individuals have a higher all cause 
mortality [6, 7]. Over 3 million deaths were caused by excessive weight in 2010, leading to almost 4% 
of years of life lost [2]. In 2012/13 there were 10,957 hospital admissions in England with a primary 
diagnosis of obesity, a 9 fold increase from 2002/03 (1,275). There were 292,404 admissions with a 
primary or secondary diagnosis in 2012/13 [3]. There were 34,100 deaths attributed to obesity in 
2004, equating to 6.8% of all deaths in England [8]. Obesity mortality statistics are thought to be 
underestimated as obesity is not always cited as a cause of death even when it’s an important 
underlying cause [9]. 
The direct cost of obesity and related disorders to the National Health Service (NHS) in England was 
£4.2 billion in 2007, up from £470 million in 1998 [10]. Between 2 and 7% of health care funding is 
used to treat obesity in developed countries. That figure rises to 20% when factoring in the cost of 
obesity-associated disorders [4].  The indirect global socioeconomic cost of obesity is estimated to 
be $2 trillion, or 2.8% of global gross domestic product (GDP). That is roughly equivalent to the cost 
of smoking or armed conflict. In the UK, the economic impact of obesity is almost £50 billion, or 3% 
of national GDP [4]. The direct healthcare costs were calculated by applying population attributable 
fractions (PAF) to GP consultation rates, hospital admissions and outpatient attendances [10]. PAF is 
defined by the WHO as the proportional reduction in population disease or mortality that would 
occur if exposure to a risk factor was reduced to an alternative ideal exposure scenario (i.e. no 
obesity) [11]. Disability due to obesity leads to lost work days, physical limitations and decreased 
productivity [12]. The indirect costs of obesity and related disorders on years of working life lost and 
estimated lost earnings were calculated from age and sex-specific obesity mortality and morbidity 
rates [10].  
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1.1.1 Obesity co-morbidities 
1.1.1.1 Type 2 diabetes 
The emerging obesity epidemic has lead to a concomitant rise in prevalence of type 2 diabetes 
mellitus (T2DM), obesity’s principal co-morbidity. T2DM is a chronic, progressive metabolic disease 
that manifests as hyperglycaemia and is caused by diminished insulin secretion and pancreatic β-cell 
function and increased insulin resistance and glucagon synthesis. Obesity contributes to the 
development of T2DM as adipose tissues in obese individuals release increased amounts of fatty 
acids, glycerols, hormones and pro-inflammatory cytokines that lead to insulin resistance [13].   
Diabetes increases the risk of cardiovascular disease and stroke and is one of the leading causes of 
kidney failure [14]. Type 2 diabetes accounts for 90% of all diabetic cases and approximately 80-90% 
of all type 2 diabetics are overweight or obese [15]. The risk of developing diabetes is elevated with 
excess weight, increasing 5 fold with a BMI between 25 and 30 and 93 fold with a BMI over 35 [16]. 
Global prevalence of T2DM is 8.3%. There are 382 million diabetics worldwide and prevalence is 
expected to rise to 592 million by 2035 [17]. About half of those living with type 2 diabetes are 
undiagnosed. In the UK over 3 million people are diabetic, with prevalence at 6%. The NHS spends 
approximately £10 billion on diabetes annually [18].  
1.1.1.2 Cancer 
There were 14 million cases and 8.2 million deaths in 2012 due to cancer, another disease in which 
obesity is an established independent risk factor [19]. An epidemiological study initiated by the 
American Cancer Society in 1959 reported higher cancer mortality in individuals 40% above the 
average weight [20]. More recently obesity has been shown to increase cancer death rates by 52% in 
men and 62% in women [21]. In the UK a large study of 1 million women over a 5 year period 
revealed a significant association between obesity and cancer risk, especially in postmenopausal 
women [22]. Obesity increases the risk of developing colorectal, endometrial, breast, renal, 
oesophagus, pancreatic, gallbladder, liver and haematological cancers, including lymphoma, 
22 
 
leukaemia and myeloma [23-25]. The direct and indirect mechanisms linking obesity and cancer risk 
are multi-factorial and include obesity-related hormones and growth factors, impaired insulin 
signalling, regulation of energy balance, calorie restriction, signalling pathways and inflammation 
[26]. 
1.1.1.3 Cardiovascular disease 
Obesity also has adverse effects on cardiac health. Over 17 million people died from cardiovascular 
disease (CVD) in 2008 and this is projected to rise to over 23 million by 2030 [27]. Obesity is an 
independent risk factor of CVD. A large prospective study found that obese individual were twice as 
likely to have heart failure than healthy weight individuals, and that the risk of heart failure increases 
between 5 and 7% for every increasing unit of BMI [28]. Excessive BMI is significantly associated with 
the development of angina, myocardial infarction, ischemic heart disease and heart failure [29, 30]. 
In addition, obesity also indirectly promotes cardiovascular disease by promoting intermediate risk 
factors including hypertension, dyslipidemia, insulin resistance, inflammation and endothelial 
dysfunction [31]. 
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1.1.2 Treatment of obesity 
A holistic public policy initiative is being implemented to prevent obesity and halt its pandemic rise. 
These include taxation of high fat foods, advertisement restriction, regulation of portion sizes and 
attempts to increase social awareness [32]. When obesity is established, the first line of therapy is 
often intensive lifestyle intervention which encompasses dietary restrictions, physical activity and 
cognitive behavioural therapy. Dietary programmes are designed to simply limit calorie intake or 
limit specific macronutrients such as carbohydrates, fat and glycaemic load. There is no significant 
difference in the efficacy of specific diets and choice of diet is down to preference, ease of 
adherence and the need to control specific co-morbid conditions [33]. Studies have shown lifestyle 
interventions can be successful at inducing modest weight loss and reducing risk of developing co-
morbidities [34, 35]. However, long-term many patients return to baseline weight levels [36]. 
Physical activity alone is insufficient at inducing weight loss in obese individuals but is vital for long-
term weight management and improving cardiovascular health [37, 38]. Regular exercise maintains 
weight loss achieved through behavioural therapy at significantly greater levels [39].   
Obesity can also be treated pharmaceutically by altering appetite or the absorption of nutrients. 
Orlistat is a pancreatic and gastric lipase inhibitor that decreases the hydrolysis of ingested 
triglycerides and is currently the only anti-obesity agent approved in Europe. Lorcaserin and 
phentermine plus topiramate are approved by the American Food and Drug Administration (FDA) 
and suppress appetite by targeting the central nervous system [34]. All three when used together 
with lifestyle intervention are effective at inducing modest reductions in weight over 12 months [34, 
40]. However, adverse side effects are common and up to 60% of patients don’t respond to the 
medication [40]. Tachyphylaxis can also occur and weight is often regained when the drug is 
withdrawn. There is also no concrete evidence that obesity drugs have any impact on co-morbid 
conditions [34]. The history of obesity drug therapy is beset with failure. Despite early promise 
fenfluramine, sibutramine and rimonabant have been discounted due to safety fears [41]. 
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1.2 Bariatric surgery 
The most effective treatment for morbid obesity is the surgical approach. Termed bariatric surgery, 
weight-loss operations typically incorporate gastric restriction with a possible bypass of part of the 
small intestine. Bariatric operations achieve greater and sustained weight loss when compared to 
non-surgical treatments [42]. In addition, they result in improvements in a host of co-morbid 
conditions including type 2 diabetes and cardiovascular disease [43]. Once seen as a drastic last-
resort, bariatric surgery is increasingly recognised as an important strategy in treating morbid 
obesity. The last decade has seen a steep rise in the number of bariatric surgeries. There were over 
450,000 bariatric procedures performed worldwide in 2013 [44], a figure that has more than tripled 
since 2003 [45]. The vast majority (95.7%) of operations are performed laparoscopically [44] and 
overall mortality due to surgery is well under 1% [46]. The rate of bariatric complications, the most 
common of which include staple line leaks, stenosis and reflux, is also low [47]. In the UK over 6,000 
bariatric operations are performed annually with the majority being a Roux-en-Y gastric bypass [48]. 
The National Institute for Health and Care Excellence (NICE) recommends bariatric surgery as a 
treatment option in the UK for the morbidly obese with a BMI of 40 kg/m2 or greater or between 35 
kg/m2 and 40 kg/m2 if accompanied by a significant co-morbid disease and if behavioural and/or 
pharmacological therapies have proved unsuccessful [49]. This is identical to the criteria set by the 
National Institute of Health in the US [50]. However, given the profound benefits of bariatric surgery, 
particularly with regards to the resolution of co-morbid conditions, there have been recent calls to 
expand the guidelines for surgery [51]. NICE have recently updated their bariatric criteria and now 
recommend that bariatric surgery be considered as a treatment option for obese individuals with a 
BMI between 30 and 35 kg/m2 and a recent onset of type 2 diabetes [52]. In 2013 0.01% of the 
world's population underwent a bariatric procedure, a figure that is dwarfed by the estimated 10% 
of the world that is obese [44]. 
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1.2.1 Types of bariatric procedures 
The three most common bariatric procedures performed globally are the Roux-en-Y gastric bypass 
(45%), the sleeve gastrectomy (37%)  and the adjustable gastric band (10%). Other minimally 
performed procedures include the biliopancreatic diversion (with or without duodenal switch) and 
the vertical banded gastroplasty [44]. A recent meta-analysis of 19 randomised controlled bariatric 
trials found that although all bariatric procedures resulted in greater weight loss compared to non-
surgical treatment, the biliopancreatic diversion induced the most amount of weight loss, followed 
by the sleeve gastrectomy, the Roux-en-Y gastric bypass and lastly banding procedures [53]. 
Improvements in co-morbidities is also greatest following biliopancreatic diversion, followed by 
Roux-en-Y gastric bypass and banding procedures [42]. 
1.2.1.1 Roux-en-Y gastric bypass 
First developed in the 1960s [54] and modified in the 1970s [55], the Roux-en-Y gastric bypass 
(RYGB) has become the most common bariatric procedure worldwide. A small gastric pouch (15-
30mL) is created and separated from the larger stomach remnant. The jejunum is then incised from 
the duodenum and anastomised to the small stomach pouch forming a distinctive ‘Y’ shape that 
gives this procedure its name [56]. The duodenum is anastomised to the distal end of the jejunum. 
This allows nutrients to bypass the majority of the stomach as well as the duodenum. Gastric, 
pancreatic and biliary secretions mix with nutrients when they enter the small intestine (Figure 
1.1A). RYGB is the most commonly performed bariatric procedure worldwide. Almost 200,000 RYGB 
are performed a year [44], over 9,000 in the UK alone [48]. 
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1.2.1.2 Sleeve gastrectomy 
The sleeve gastrectomy (SG) requires simpler surgical technique compared to RYGB. The procedure 
was originally described in 1993 as an alternative stomach resection to improve biliopancreatic 
diversion results [57]. A longitudinal gastric sleeve is created running from the oesophagus to the 
small intestine that is separated for the larger excised stomach (Figure 1.1B). This procedure reduces 
the stomach size by approximately 75%. A relatively new procedure, the SG has gained in popularity 
over the last decade. In 2013, 172,320 SG were preformed [44], an 852% increase from 2008 [58]. 
No SG were performed in 2003 [45]. These procedures are the second most common bariatric 
operations in the world and the most common in North America and Asia [44].  
1.2.1.3 Adjustable gastric band 
Once the preferred weight loss operation, the adjustable gastric band (AGB) has lost favour of late. 
In 2008 42.3% of bariatric procedures worldwide were the AGB. In 2013 the percentage of AGB 
procedures had fallen to 10% [44]. Almost two-thirds of bariatric procedures in the North America 
were AGB in 2003 [45]. The AGB consists of an inflatable silicone band placed laparoscopically 
around the upper stomach that can be readily and repeatedly adjusted to restrict gastric size by 
injecting or withdrawing saline through a subcutaneous port (Figure 1.1C). 
 
Figure ‎1.1: Bariatric procedures.  
(A) Roux-en-Y gastric bypass, (B) sleeve gastrectomy and (C) adjustable gastric band. Adapted from 
[59]. 
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1.2.2 Bariatric outcomes 
1.2.2.1 Weight loss 
Bariatric surgery results in greater weight loss than non-surgical treatment. The Swedish Obese 
Subjects (SOS) study was a prospective trial of 4,047 obese individuals treated either surgically 
(banding or gastric bypass) or non-surgically. They reported a mean maximum weight loss of 1% in 
non-surgical patients compared to 38% in gastric bypass, 26% in vertical banded gastroplasty and 
21% in gastric banding patients [60]. Ten, fifteen and twenty years following intervention non-
surgical patients had remained at baseline weight whereas surgical patients had maintained a 
statistically significant amount of their postoperative weight loss [60-62]. Other studies on adjusted 
gastric banding, gastric bypass, sleeve gastrectomy and biliopancreatic diversion patients have also 
reported greater weight loss when compared to obese patients treated medically [63-66]. Three 
meta-analyses of bariatric studies conducted in 2005 [67], 2009 [42] and 2013 [68] all concluded that 
surgical treatment for obesity is the most effective strategy at inducing and maintaining substantial 
weight loss.  
1.2.2.2 Resolution of diabetes 
The anti-diabetic effects of bariatric surgery were first observed by Pories and colleagues in 1995 
who reported normal plasma glucose, glycated haemoglobin (HbA1c) and insulin in diabetics 
following RYGB [69]. The SOS study reported 72% of diabetics were in remission 2 years following 
bariatric surgery and that surgery reduces the incidence of non-diabetics developing type 2 diabetes 
by approximately 75%, figures much higher than in the control, non-surgical group [60]. Buchwald et 
al. reported a 57% remission in diabetics after AGB and an 80% remission after RYGB [42]. RYGB, SG 
and AGB have all been shown to be more effective at achieving glycaemic control than conventional 
drug therapy in randomised trials [63-66, 70]. These studies differ in the percentage of diabetics 
achieving remission, likely due to the variable definition of remission used. For example, the Buse 
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criteria defines remission as a HbA1c level under 6% and a fasting glucose level of under 100mg/dl 
[71], while the American Diabetes Association defines remission as a HbA1c level under 5.6% [72].  
However, recurrence of diabetes has been reported at a rate of 19-35% 5 years [73, 74] and 50% 10 
years following surgery [60]. Remission and recurrence rates appear to correlate with preoperative 
duration of diabetes and the level of glycaemic control [73, 74]. Preoperative BMI did not predict 
diabetes remission [75] and improvements in diabetes are often independent of weight loss [76]. In 
fact, preliminary data has suggested bariatric surgery is effective at treating type 2 diabetes in 
individuals with a BMI 35 or under [77, 78]. Additionally, bariatric surgery also improves renal 
function and prevents or delays end-organ diabetic complications such as nephropathy and 
retinopathy [79]. 
1.2.2.3 Other outcomes 
Bariatric surgery has other health benefits beyond weight loss and diabetes remission. 
Epidemiological data has shown that RYGB, SG and to lesser degree AGB resolves hypertension [80-
82]. Remission of dyslipidemia, characterised by high levels of low-density lipoprotein (LDL) and 
triglycerides and low levels of high-density lipoproteins (HDL), has been reported in almost 70% of 
RYGB patients [83]. An increase in HDL and decrease in triglycerides levels have also been shown 
following bariatric surgery in randomised trials [66, 84]. As diabetes, hypertension and dyslipidemia 
are all risk factors of cardiovascular disease, it is not surprising that their remission following 
bariatric surgery leads to improved cardiac health. The SOS study reported fewer cardiovascular 
events and deaths in the surgical compared to the non-surgical group [62].  Other studies have also 
found reduced cardiovascular risks and mortality [85-87]. Another study reported that the metabolic 
syndrome was presented preoperatively by 87% of bariatric patients. Less than 4 years following 
RYGB the metabolic syndrome was only present in 29% of patients. In comparison prevalence of the 
metabolic syndrome in non-surgical patients only decreased from 85% to 75% over the same period 
[88]. Bariatric surgery also resolves obstructive sleep apnea in patients with the condition 
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preoperatively [89]. Cancer events, cancer risk and mortality all decrease following surgery, 
particularly in women [61, 90, 91]. Overall, all-cause mortality is also reduced between 24-89% in 
surgical patients compared to non-surgical controls [61, 86, 87]. Bariatric surgery also improves 
quality of life [92] and is cost-effective long-term based on both direct and indirect savings [93]. 
1.2.3 Mechanisms 
Bariatric surgery is often referred to as metabolic surgery in acknowledgments of its multiple 
beneficial results with regards to overall health. The mechanistic elements behind this process are 
multi-factorial and likely intertwined [94, 95]. They can be broadly summarised as the BRAVE effects 
- bile flow alteration, reduction of gastric size, anatomical gut rearrangement and altered flow of 
nutrients, vagal manipulation and enteric gut hormone modulation with the associated modulation 
of the gut microbiome [96]. 
1.2.3.1 Gastric restriction  
It was initially thought that the beneficial results of bariatric surgery were in large part due to a 
reduction in gastric size and malabsorption in procedures that include intestinal bypass. However, 
the evidence supporting the notion that the volume of the gastric pouch or sleeve influences weight 
loss is inconsistent [95]. Gastric emptying appears to have a bigger role following surgery with the 
rapid delivery of nutrients into the gut initiating a neurohormonal cascade reducing hunger and 
ameliorating glycaemic mismanagement. Counter-intuitively gastric emptying is faster in SG than 
RYGB [97], but in RYGB nutrients bypass the duodenum and enter the distal small intestine faster 
than usual. In AGB, patients reach satiation faster when the band is optimally adjusted compared to 
when the band in partially or completely deflated, suggesting AGB does not restrict meal size but 
reduces hunger [98, 99]. The contribution of malabsorption has also been dismissed [94]. As such it 
appears the perception of bariatric surgery as malabsorptive and/or restrictive procedures is 
outdated and it’s metabolic changes that drive the mechanisms underlying the surgeries.  
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1.2.3.2 Food appetite and preference  
The failure of dietary interventions in sustaining long-term weight loss has been attributed to an 
evolutionary compensatory programming that attempts to maintain energy homeostasis [100]. 
Patients attempting to restrict calorie intake often report increase in appetite [101]. In contrast 
bariatric patients report less hunger and reach satiation quicker [98, 102]. RYGB patients also 
develop distaste for food high in fat or sugar [103, 104], as do rats in an animal RYGB and SG models 
[105, 106]. In fact, some RYGB patients report nauseousness and abdominal pain after eating food 
high in sugar or fat, a phenomenon referred to as dumping syndrome [107]. Neuroimaging has also 
demonstrated decreased activation of brain reward areas in response to eating or seeing calorific 
food [108, 109]. The underlying mechanisms behind these changes in appetite and food preference 
are still not fully understood but there have been some suggestions that changes in gut hormones 
could play a role. 
1.2.3.3 Gut hormones  
There is increasing evidence that bariatric surgery modifies hormonal gut-brain signalling. Preserving 
the vagus nerve, which links the brain stem to the abdomen, leads to greater and more sustained 
loss in animal RYGB models [110] and inflating the AGB in rodents stimulates vagal afferents [111]. 
Peptide YY (PYY) and glucagon-like peptide-1 (GLP-1) are gut hormones secreted by the L cells of the 
small bowel after a meal and act on the vagus nerve. PPY signals satiety, decreases food intake, 
increases energy expenditure and slows gastric emptying [112]. GLP-1 plays a similar role to PYY but 
also inhibits glucagon release and promotes pancreatic insulin secretion. This is known as the 
incretin effect. The postprandial levels of both in RYGB and SG patients are increased within days 
and in the case of RYGB remain high for at least 10 years postoperatively. PPY and GLP-1 are not 
increased following AGB or dietary therapy and inhibiting PPY increases food intake following RYGB 
but not AGB. It has been suggested that the bypass of the small intestine in RYGB and the rapid 
gastric emptying in SG could be the reason for the increase in gut hormone levels. Blocking a GLP-1 
receptor during a meal test decreases glucose tolerance. A third gut hormone, Ghrelin, is also 
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thought to contribute to the effects of bariatric surgery. Ghrelin is secreted during fasting by the 
stomach and acts to increase food intake. Levels are decreased following SG and RYGB, although its 
increase has also been reported following RYGB [113-115]. 
1.2.3.4 Hindgut and foregut theories 
Gut hormones have a central role in the hindgut mechanism behind diabetes resolution, which 
theorises that the direct entry of nutrients into the distal gut following bariatric surgery increases 
secretion of PPY and GLP-1. The foregut mechanism theorises that the bypass of the proximal small 
intestine prevents the release of, as of yet, undiscovered ‘anti-incretin’ agents resulting in an anti-
diabetic effect [116]. A study involving the bypass of the duodenum in Goto-Kakizaki rats 
demonstrated improved glycaemic control when compared to sham operated rats, independent of 
weight loss [117]. A similar study in mice resulted in increased intestinal gluconeogenesis, increased 
glucose levels in the portal vein and enhanced glucose sensing. This led to improved glucose 
tolerance when compared to AGB mice [118]. However, mice deficient in glucose-transporter-2 
(GLUT2) did not improve glucose tolerance following duodenal bypass. Neither did mice with 
impaired portal-vein signalling, suggesting intestinal gluconeogenesis improves glucose tolerance in 
a GLUT2-dependent hepatoportal sensory pathway [118]. Recently, it has also been shown that the 
exposure of the Roux limb to undigested nutrients leads to a reprogramming of intestinal glucose 
metabolism, increasing aerobic glycolysis and glucose uptake through glucose-transporter-1 
(GLUT1), rendering the intestine a major user of glucose, improving glycaemic control in the process 
[119]. Duodenal-jejunal exclusion also leads to glycaemic improvements in humans [120]. This has 
led to the development of the EndoBarrier, an impermeable duodenojejunal plastic sleeve. 
Preliminary data is promising, indicating the EndoBarrier improves glycaemic control by decreasing 
HbA1c and increasing insulin sensitivity [121]. 
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1.2.3.5 Bile 
Bile acids are synthesised in the liver from cholesterol or oxysterols and can regulate food intake, 
energy expenditure and glucose metabolism by acting on the bile acid receptors Farnesoid X 
receptor and TGR5 in the liver and intestine [122, 123]. Fasting and postprandial bile acid levels are 
increased in circulation following RYGB [124, 125], with an accompanied decrease in conjugated bile 
acids [126]. These negatively correlate with postprandial glucose concentrations [124]. Patients who 
demonstrated remission of diabetes following RYGB had larger increases in bile acids than patients 
who failed to achieve remission or non-diabetics [127]. Recently plasma bile levels have also been 
shown to be increased in a mouse VSG model with associated changes in gut microbiota. Knocking-
out FXR attenuates weight loss and improvements in glucose tolerance [128], suggesting bile acids 
have an important role in promoting the beneficial results of bariatric surgery.  
1.2.3.6 Gut microbiota 
The role of gut bacterial composition in obesity is being increasingly recognised. Gut microbial 
composition differ between lean and obese individuals and the colonisation of certain bacteria that 
have an increased ability to harvest energy alters host metabolism and promotes obesity [129]. 
RYGB shifts gut microbiota in humans and rodents [130-132], and the transfer of bacteria from the 
gut of RYGB mice to the gut of un-operated, germ-free mice led to weight loss in the later [133]. This 
suggests that altered gut microbiota contributes to the beneficial bariatric phenotype and is not 
merely a consequence of surgery. 
1.2.3.7 Energy expediture 
Bariatric surgery also modifies the way the body expends energy. Whereas energy expended during 
rest is either reduced or stable after bariatric surgery [95], postprandial energy expenditure is 
increased following RYGB [134, 135]. 
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Figure ‎1.2: Mechanisms of obesity co-morbidities and the beneficial effects following bariatric 
surgery.  
Red lines represent mechanisms of obesity. Blue lines represent mechanisms following bariatric 
surgery. Solid lines indicate improvement, dashed lines indicate impairment. 
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1.3 MicroRNAs  
MicroRNAs (miRNA) are a family of endogenous, non-coding RNAs that regulate gene expression at 
the post-transcriptional level. These evolutionally conserved super-regulators bind to target 
messenger RNA (mRNA) silencing their translation to protein. Since their discovery in the nematode 
Caenorhabditis elegans (C. elegans) in 1993 [136], thousands of miRNAs have been identified across 
organisms. The mirBASE database lists almost 2,600 mature miRNA sequences in humans [137]. 
Biogenesis of the archetypical microRNA is a multi-step process which is initiated by the 
transcription of primary miRNA (pri-miRNA) from introns or intergenic transcripts by RNA 
polymerase II/III [138]. Pri-miRNA is then cleaved into an 80-100 nucleotide hairpin structure called 
precursor miRNA (pre-miRNA) by a nuclear microprocessor composed of the RNA endonuclease 
Drosha and the RNA-binding protein DGCR8. Pre-miRNAs are exported from the nucleus into the 
cytoplasm by exportin 5 and undergo further processing by a second endonuclease, Dicer, into 
mature, double stranded miRNAs 18-22 nucleotides in length [139]. The knock-out of Dicer [140]  
and DGCR8 [141] in mice results in defective embryonic development, indicating microRNAs are 
essential for mammalian development.  
One strand of the mature miRNA is then loaded into an RNA-induced silencing complex (RISC), a 
multi-protein complex at the heart of which lies a member of the Argonaute protein subfamily. RISC 
directs the seed region (nucleotides 2-7) of miRNA into binding to 3’ UTR (untranslated region) of its 
target mRNA, although there is evidence to suggest that microRNAs can also bind to other regions of 
a target mRNA. Perfect, complementary hybridisation leads to cleavage of the mRNA by RISC. 
Imperfect binding leads to an inhibition of translation and mRNA degradation [142, 143]. This allows 
each miRNA to target multiple mRNAs and each mRNA to be targeted by multiple microRNAs. 
Distinct microRNAs can also share targets, regulating certain genes in unison. MicroRNAs therefore 
form a complex layer of post-transcriptional regulation, controlling the expression of over half the 
human transcriptome [144]. 
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Figure ‎1.3: MicroRNA biogenesis and function. 
 
However, the concept of microRNAs as purely negatively regulators of translation has recently been 
challenged. MicroRNAs can switch between repressing and activating translation under certain 
conditions such as cell cycle arrest [145]. During amino acid starvation the microRNA miR 10a can 
also interact with 5’ UTR of mRNAs encoding for ribosomal protein increasing their translation and 
global protein synthesis in the process [146]. Another study has also shown that miR 328 can 
indirectly increase translation by binding to an mRNA translational regulator independent of its seed 
sequence [147]. As such it would appear that microRNAs do not simply silence but fine-tune gene 
expression. 
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1.3.1 MicroRNAs, obesity and the metabolic syndrome 
Given their comprehensive role in gene regulation it is not surprising that microRNAs are involved in 
processes fundamental to both normal physiology and disease. MicroRNAs regulate cell 
proliferation, cell signalling and apoptosis [148] and have been widely implicated in a range of 
disorders including cancer [149], cardiovascular disease [150] and neurological disorders [151]. This 
has led to interest in microRNAs as potential novel therapeutics [152].  
The evidence linking miRNAs to obesity is vast and is summarised in Table 1.2. The dysregulation of 
microRNAs has been linked to virtually every process involved in the progression and complications 
of obesity, diabetes and the metabolic syndrome. The roles of microRNAs in adipogenesis, insulin 
secretion and resistance and lipid metabolism is particularly extensive [153].  
1.3.1.1 Adipogenesis 
Adipocytes are a primary source of free fatty acid storage and release during consumption and 
fasting and are responsible for the synthesis of leptin. A number of studies have shown that 
microRNA expression profiles differ between obese and lean white adipose tissue in mice and 
humans, both in diabetics and non-diabetics, the preeminent of which is miR 221. Multiple 
microRNAs also have reported involvement both in the promotion and inhibition of adipogensis 
[154]. MiR 146b is upregulated during differentiation of the mouse adipocyte cell line 3T3-L1 [155]. 
Another microRNA that regulates adipose differentiation is miR 143, which reportedly inhibits 
adipogenesis in the earlier clonal stage and promotes adipogenesis in the later terminal stages [156]. 
Both miR 26a and miR 196a promote brown adipocyte differentiation while miR 21 is differentially 
expressed in white adipose tissue [157-159]. Inhibitors of adipogenesis include miR 27, which targets 
brown adipose tissue transcription factors [160]. Another inhibitor of brown adipose tissue 
adipogenesis is miR 155 [161]. MiR 540 also inhibits adipogenesis by binding the 3'UTR of PPARγ 
[162]. 
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1.3.1.2 Insulin secretion and resistance 
Poy et al. were the first to link microRNAs with diabetes when they demonstrated the key regulatory 
role of miR 375 in insulin secretion [163]. MiR 375 is now known to be essential for maintaining 
pancreatic α and β-cell function and glycaemic control as its knockout results in hyperglycaemia and 
glucose intolerance [164]. Since then more microRNAs have demonstrated regulatory roles in 
pancreatic β-cell development, insulin secretion and resistance. MicroRNAs 126 and 193b are 
downregulated in subcutaneous adipose tissue of obese individuals. Both inhibit CCL2, a cytokine 
release during obesity induced inflammation, and as such guard against the development of insulin 
resistance [165]. On the other hand, miR 221 is upregulated in subcutaneous adipose tissue and 
promotes insulin resistance, reportedly by targeting ADIPOR1, a receptor for adiponectin [166]. MiR 
130a-3p improves glucose homeostasis by targeting the growth factor receptor bound protein 
GRB10 [167]. High levels of miR 802 are linked with glucose intolerance and insulin resistance [168], 
whereas the overexpression of miR 26a improves insulin sensitivity [169]. MiR 93, a regulator of the 
glucose transporter GLUT4, is upregulated in patients with polycystic ovary syndrome, which is 
associated with insulin resistance [170]. MicroRNAs have also been shown to have regulatory roles 
in other diabetic complications including diabetic nephropathy and diabetic cardiomyopathy [171].  
1.3.1.3 Lipid metabolism 
The most abundant microRNA in the liver is miR 22, which regulates cholesterol and fatty acid 
metabolism. Blocking miR 122 in mice on both normal and high-fat diets inhibits fatty-acid and 
cholesterol synthesis in the liver and decreases plasma triglycerides levels [172]. MiR 27b also 
regulates lipid metabolism through its target PPARγ. Plasma levels of miR 27b correlates strongly 
with hyperlipidemia [173]. MiR 33 is another key regulator of lipid and cholesterol homeostasis. MiR 
33 targets various members of the cholesterol synthesis and transport pathway, increasing 
intracellular cholesterol concentrations. MiR 33 also raises intracellular lipid concentrations by 
regulating fatty acid oxidation and insulin signalling  [174, 175]. In fact, blocking miR 33 reduces 
hyperlipidemia in mouse models [176]. Inhibiting miR 33 also improves lipid metabolism in primates 
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[177], solidifying miR 33's candidacy as an attractive therapeutic target against lipid metabolism 
dysfunction. 
Table ‎1.2: MicroRNAs associated with the metabolic syndrome. 
  MicroRNA References 
Process Up Down 
Adipogenesis 146b 27 [154-162] 
 
143 155 
26a 540 
196a   
21   
β-cell development and Insulin Secretion 375 221 [163-171] 
 
 
126 802 
193b 93 
26a   
130a   
Diabetic Nephropathy 192 192 [178-187] 
200 200 
377 29 
21 215 
Diabetic Cardiomyopathy 21 29 [188-191] 
206 30 
1   
Lipid Metabolism  122 [172-177] 
 
  27b 
  33 
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1.3.2 MicroRNAs as biomarkers 
MicroRNA expression profiles offer a wealth of biological information, as the changes in the 
regulation of several core physiological processes can be seen in the expression of a few microRNAs 
that regulate them. MicroRNAs are relatively abundant and stable in tissue and biofluids are able to 
withstand numerous freeze-thaw cycles allowing for long-term storage [192]. They can also be 
measured with speed, ease and sensitivity through a number of platforms including quantitative 
Polymerase Chain Reaction (PCR), next generation deep sequencing and microarray hybridisation 
[193, 194]. As a result microRNAs have become the focus of rigorous research over the past decade 
and their expression profiles have been used to map species development and tissue differentiation 
[195, 196] and can predict type, origin and prognosis of cancer [197-201].  
Their expression in extracellular biofluids is of particular interest given the potential of novel non- or 
minimally invasive biomarkers. Extracellular microRNAs are packaged in membrane-covered 
exosomes or are present in complexes with high-density lipoproteins or argonaute protein 
protecting them from ribonuclease degradation, and circulating miRNAs can be taken up in active 
form by recipient cells, suggesting a potential hormonal tissue-to-tissue communicative role [202-
204]. Circulating miRNAs have been proposed as potential novel biomarkers of cancer [192], 
cardiovascular disease [205] and tissue injury [206]. Distinct obese and diabetic circulating microRNA 
profiles have also recently been characterised. The metabolic syndrome is characterised by the 
deregulation of 7 circulating miRNAs [207] and a number of miRNAs have been put forward as 
candidate biomarkers of obesity including miR 15a, miR 142-3p and miR 221 in men [208] and miR 
28-3p and miR 130b in children [209]. Similarly, microRNAs, including miR 192 and miR 125b, have 
been proposed as circulating biomarkers of T2DM [210]. Urinary microRNAs have also been reported 
markers of disease including type 1 diabetes-induced nephropathy [211], bladder cancer [212] and 
drug-induced nephrotoxicity [213].  
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1.4 Hypothesis  
MicroRNAs are biomarkers of the beneficial effects of bariatric surgery. 
The premise of this thesis is that bariatric surgery modulates the expression of microRNAs in 
extracellular biofluids and this can in turn explain some of the beneficial effects of these operations. 
A bariatric circulating microRNA signature has recently been characterised in a rat bariatric model 
and the downregulation of miR 122, a key player in lipid and glucose metabolism, was found [214]. 
MiR 122 has also been reported to be downregulated in human circulation following RYGB [208]. 
However, this is the extent of the published work with regards to role of microRNAs in bariatric 
surgery. To investigate this hypothesis studies were conducted assessing: 
1. Urinary and circulating microRNAs associated with obesity 
2. Urinary microRNA biomarkers after bariatric surgery2 
3. Circulating microRNA biomarkers after bariatric surgery 
All urinary and circulating microRNAs assessed at the obesity baseline were assessed in the 
subsequent bariatric studies. 
 
Figure ‎1.4: A flow chart outlining the structure of this thesis. 
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2 Circulating and urinary microRNAs in obesity 
2.1  Justification 
Circulating and urinary microRNAs are reported biomarkers for obesity and diabetes [208, 210]. The 
objectives of this chapter were to establish a microRNA obesity baseline in serum and urine, 
anchoring the phenotypic setting for subsequent bariatric chapters, to correlate microRNA levels 
with standard clinical blood biochemistry markers, and to potentially identify novel microRNA 
biomarkers of obesity. 
2.2 Aims 
1. To establish an obesity microRNA baseline in serum and urine 
2. To correlate microRNA expression with clinical parameters 
3. To identify circulating and/or urinary obesity microRNA biomarkers 
2.3 Study design 
Samples were collected from 47 volunteers in collaboration with Prof. Stephen Atkin at the 
University of Hull under ethics approval 09/H1304/46 with the informed consent of each participant. 
Individuals in this dataset had BMIs ranging from 19 to 47 and were stratified into 5 BMI groups, 9 to 
11 each in the under 25, 25-30, 30-35 and 35-40 BMI groups and 7 in the over 40 BMI group. Table 
2.1 provides a study summary. Participants donated serum and urine samples and were subject to a 
blood biochemistry profile, the complete results of which are summarised in Table 2.1. RNA was 
obtained from all samples and the expression levels of 8 microRNAs were determined in serum and 
3 microRNAs in urine using quantitative PCR. These microRNAs were chosen for three reasons; (a) 
due to their reported association with the metabolic syndrome, (b) due to their known presence in 
circulation/urine and (c) because they have been previously identified to be deregulated in obesity 
and its co-morbidities (Table 2.2). Figure 2.1 is a flowchart outlining Chapter 2’s study design. 
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Table ‎2.1: Study summary and blood biochemistry ⱡ. 
  BMI 
Total Under 25  25-30 30-35 35-40 Over 40 
n 47 10 11 9 10 7 
BMI (kg/m2) 31.9 (7.59) 22.0 (1.68) 27.2 (1.34) 32.4 (1.34) 37 (1.23) 44.4 (2.15) 
Weight (kg) 90.1 (23.3) 63.3 (11.4) 76.7 (6.82) 99 (11.1) 104.4 
(11.4) 
125.1 (10.5) 
Age 48.2 (16) 39.2 (16.4) 42.4 (16.3) 51.2 (12.7) 56 (16) 55.4 (11.9) 
% female 57.4 80 50 50 60 42.9 
Fasting glucose 
(mmol/L) 
5.69 (1.92) 4.63 (0.31) 5.97 (2.85) 5.9 (1.61) 5.04 (0.4) 7.12 (2.46) 
Insulin (µIU/mL) 14.5 (13.4) 3.65 (1.1) 7.11 (4.87) 22.4 (17.3) 21.3 (10.6) 20.5 (14.1) 
CRP (mg/L) 2.85 (2.76) 1.92 (2.1) 1.37 (1.8) 2.68 (2.77) 4.28 (3.05) 4.62 (3.44) 
Hb (g/L) 13.8 (1.37) 13.4 (1.17) 13.9 (1.63) 14 (1.29) 13.4 (1.44) 14.5 (1.52) 
WCC (x10^9/L) 5.86 (1.43) 5.63 (1.62) 5.54 (0.99) 6.11 (2.04) 6.22 (1.04) 5.94 (1.45) 
Platelet Count 
(x10^9/L) 
234.5 
(59.3) 
239 (47.9) 219 (52.3) 237 (90) 263 (32.9) 218 (61) 
Sodium (mmol/L) 139 (1.67) 138 (1.63) 140 (1.51) 139 (1.77) 140 (1.1) 139 (2.07) 
Potassium 
(mmol/L) 
4.27 (0.33) 4.2 (0.29) 4.26 (0.3) 4.23 (0.39) 4.4 (0.43) 4.34 (0.3) 
Chloride (mmol/L) 104.5 
(2.57) 
104 (2.43) 106 (1.51) 104 (2.37) 106 (3.46) 104 (2.95) 
BiCarb (mmol/L) 27.3 (2.42) 27.6 (2.57) 27.6 (1.81) 27.7 (1.25) 27.2 (1.92) 26 (4.53) 
Urea (mmol/L) 4.89 (1.42) 4.84 (1.91) 4.47 (1.16) 4.56 (1.15) 4.98 (1.81) 5.94 (0.66) 
Creatinine (umol/L) 75.3 (17.8) 74.4 (17) 74.1 (10.4) 75.3 (18.6) 80 (27.9) 73.4 (21.3) 
eGFR (mL/min) 81.8 (10.4) 79.4 (11.2) 85.7 (4.08) 82.4 (9.18) 80 (18.7) 81.2 (10.8) 
Calcium (mmol/L) 2.31 (0.08) 2.34 (0.09) 2.28 (0.06) 2.33 (0.07) 2.34 (0.08) 2.29 (0.13) 
Phospate (mmol/L) 1.19 (0.19) 1.32 (0.14) 1.22 (0.13) 1.21 (0.23) 1 (0.18) 1.15 (0.13) 
Bilirubin (umol/L) 15.3 (5.41) 17.1 (6.82) 15.4 (3.87) 16.3 (7.61) 12.8 (3.03) 13.4 (3.37) 
Alk Phos (iu/L) 57.5 (19.3) 44.1 (7.48) 51.9 (14) 56.6 (21.3) 79.6 (24.3) 63.6 (11.2) 
Albumin (g/L) 40.4 (2.85) 42.1 (3.44) 38.7 (1.89) 42 (2.08) 40.2 (1.48) 38.4 (3.05) 
Total protein (g/L) 67.7 (4.85) 67.4 (4.54) 64.4 (5.68) 68.6 (3.69) 71.4 (2.51) 67.8 (5.72) 
Cholestrol (mmol/L) 4.6 (1.07) 4.58 (0.88) 4.64 (1.18) 4.83 (1.24) 4.23 (1.57) 4.37 (0.3) 
Triglycerides 
(mmol/L) 
1.72 (1.14) 0.74 (0.21) 1.38 (0.29) 1.76 (1.39) 2.05 (0.76) 2.97 (1.35) 
HDL (mmol/L) 1.24 (0.49) 1.80 (0.75) 1.17 (0.23) 1.14 (0.42) 1.12 (0.31) 0.94 (0.13) 
LDL (mmol/L) 2.57 (0.86) 2.6 (0.33) 2.84 (1.06) 2.89 (0.79) 2.18 (1.16) 2.08 (0.72) 
L-Tyr (µM) 73.7 (18.4) 67.4 (19.9) 67.9 (16.2) 78.7 (16.7) 77.3 (27.2) 76.7 (15.1) 
L-Phe (µM) 78.2 (12.6) 77.3 (14.1) 76.3 (19.9) 79 (8.73) 79.2 (8.56) 79.4 (13.7) 
L-Phe : L-Tyr Ratio 1.1 (0.22) 1.2 (0.27) 1.12 (0.13) 1.04 (0.23) 1.11 (0.33) 1.04 (0.05) 
GLP-1 (pM) 29 (13.6) 21.7 (7.65) 21.6 (10.1) 30.1 (12) 34.1 (16.1) 38.1 (17.9) 
GIP (pg/mL) 78.7 (33.1) 58.9 (26.6) 81.5 (28.5) 90.6 (42.2) 69.5 (29) 89.7 (29.7) 
ⱡValues represent mean unless otherwise stated. Standard deviation in parentheses. 
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Table ‎2.2: Targeted microRNAs and their involvement in obesity and associated co-morbidities. 
MicroRNA Expression measured in   Involved in References 
15a Serum  Insulin biosynthesis [208] 
22-5p Serum   Haematopoietic malignancies [209, 210] 
122 Serum  Cholesterol and fatty-acid 
metabolism 
[184] 
125b Serum   Adipocyte differentiation [211, 212] 
142-3p Serum  Diabetic cardiomyopathy [213] 
145-5p Serum   Lipolysis [214] 
192 Serum and Urine  Diabetic nephropathy [170, 173, 174] 
200a Urine   Diabetic nephropathy [172, 215] 
200b Urine  Diabetic nephropathy [172, 215] 
221 Serum   Diabetes-associated CVD [216] 
 
 
Figure ‎2.1: A flow chart illustrating the workflow of Chapter 2. 
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2.4 Materials and methods 
2.4.1 Samples 
Serum was obtained using standard venipuncture and centrifugation technique at the University of 
Hull. Urine samples were received neat in urine donation tubes and were filtered through a 0.2µm 
filter prior to analysis. All samples were aliquoted into 0.2ml and 0.5ml centrifuge tubes and stored 
in -80⁰C until use. Clinical parameters, including BMI and blood biochemistry, were obtained in 
collaboration with the University of Hull. 
2.4.2 Serum RNA extraction 
RNA was extracted from serum using the mirVana PARIS kit (Ambion, Paisley, UK). In this procedure 
an organic extraction is followed by immobilisation of RNA on glass-fibre filters to allow purification. 
The manufacturer’s protocol was followed with slight modifications. Briefly, samples were thawed 
on ice and 100µl cell disruption buffer was added to 100µl of serum. Pre-warmed 200µl of 
denaturing solution was added and the mixture was incubated on ice for 10 minutes. Following 
denaturation 30 attomoles of synthetic C. elegans (cel.) microRNA 39 (Ambion) was spiked into the 
mixtures for normalisation purposes. C. elegans miR-39 was selected due to its lack of sequence 
homology with endogenous human microRNAs. The optimal concentration of cel. miR-39 spike-in 
was determined through method development on archived serum. Equal volume (400µl) of Acid-
Phenol:Chloroform was then added and the mixture was vortexed and centrifuged at 10,000g for 5 
minutes, separating RNA (upper aqueous phase) from DNA (lower phase) and protein (interphase). 
The aqueous upper phase was transferred to a fresh centrifuge tube and 1.25X 100% ethanol was 
added. Lysate/ethanol mixture was then loaded onto a silica filter cartridge placed within a 
centrifuge tube and centrifuged briefly at 1,000g for 30 seconds to immobilise total RNA. The flow-
through was discarded and the filter was washed once with 700µl Wash Solution 1 and then twice 
with 500 µl Wash Solution 2/3 to purify RNA. RNA was then eluted in 100µl nuclease-free water 
preheated to 95⁰C. RNA extracts were stored at -20⁰C until use.  
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2.4.3 Urinary RNA extraction 
RNA was extracted from urine samples using the mirVana PARIS kit (Ambion). Extraction was as 
described in 2.4.2 for serum with a couple of modifications. RNA was extracted from 250µl of urine. 
To normalise 30 femtomoles of synthetic C. elegans miR-39 (Ambion) was spiked into urine samples 
following denaturing. The optimal concentration of cel. miR-39 spike-in was determined through 
method development on archived urine. As with serum RNA was eluted in 100µl nuclease free water 
and stored at -20⁰C until use.  
2.4.4 Polymerase Chain Reaction (PCR) 
MicroRNA quantification in serum and urine was determined through reverse transcription PCR (RT-
PCR) using TaqMan Small RNA assays (Applied Biosystems, Paisley, UK). This was a two-step process 
[215]: 
1. RT Step – Small miRNA-specific, stem-loop RT primers hybridise to the 3’ end of miRNA and 
are then reverse transcribed to produce complementary DNA (cDNA) through the enzymatic 
action of reverse transcriptase. 
2. PCR Step – cDNA is amplified with the use of fluorescent microRNA probes, which anneal 
complementarily to specific targets. Each probe has a 6-carboxyfluorescein (FAM) 
fluorescent reporter dye and a non-fluorescent quencher. The quencher suppressors the 
reporter fluorescence when not bound. Once the probe hybridises to the target it is cleaved 
by DNA polymerase, separating the reporter dye from the quencher, resulting in increased 
fluorescence by the reporter. This only occurs following complimentary hybridisation, 
eliminating non-specific amplification. Fluorescence is captured real-time and corresponds 
to the amount of cDNA product amplified.  
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2.4.4.1 cDNA synthesis through reverse transcription 
cDNA was synthesised from extracted RNA by reverse transcription (RT) through the reverse 
transcriptase enzyme contained in the TaqMan MicroRNA Reverse Transcription kit (Applied 
Biosystems). The manufacture’s protocol was followed. A master mix was initially made consisting of 
deoxynucleotides (dNTPs), reverse transcriptase, 10X reverse transcriptase buffer, RNase Inhibitor 
and nuclease-free water as described in Table 2.3. 
Table ‎2.3: RT Master Mix components 
Component Volume, per reaction (µl) 
100mM dNTPs (with dTTP) 0.15 
Reverse Transciptase 50 U/µl 1 
10X Reverse Transcriptase Buffer 1.5 
RNase Inhibitor, 20U/µl 0.19 
Nuclease-free water 4.19 
Total volume 7 
 
Once created the master mix was manually mixed and 7µl was dispensed into a 0.2ml PCR 
polypropylene reaction tube per reaction. To this 5µl of RNA and 3 µl of the relevant 5X TaqMan 
microRNA RT primer was added to produce a 15µl RT reaction. Reaction tubes were loaded onto a 
MJ Research PTC-200 Thermo Cycler (GMI, Ramsey, MN, USA) and reactions were incubated at 16⁰C 
for 30 minutes, then 42⁰C for another 30 minutes, 85⁰C for 5 minutes and finally 4⁰C until the 
samples tubes were retrieved. cDNA products were stored at -20⁰C until use. 
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2.4.4.2 Quantitative Polymerase Chain Reaction (qPCR) 
cDNA product was amplified through qPCR using TaqMan Fast Universal Master Mix. A master mix 
was made consisting of 10µl of Universal PCR Master Mix, 1µl relevant 20X TaqMan microRNA PCR 
probe and 6µl nuclease-free water per reaction. Master mix was manually mixed and 17µl was 
dispensed into a 0.2ml PCR polypropylene reaction tube per reaction, to which 3µl of cDNA per 
reaction was added. The 20µl reaction mixture was then loaded into an assigned well of a 96-well 
PCR plate, which was sealed when fully loaded with optical film. The PCR plate was then centrifuged 
briefly before being run on Applied Biosystems 7500 Fast System PCR machine. The PCR reaction 
consisted of 95⁰C for 10 minutes to activate the enzyme followed by 40 cycles of 95⁰C for 15 seconds 
to denature and 60⁰C for 60 seconds to anneal/extend. PCR reactions were run with three technical 
replicates and one no-template control reaction, with nuclease-free water replacing cDNA, to ensure 
the absence of contaminants. 
2.4.4.3 Data analysis 
A graphical representation of typical PCR amplification curves can be found in Figure 2.2. cDNA 
product is doubled with each reaction cycle for a total of 40 cycles and until the exhaustion of 
reaction reagents. A threshold of 0.2 ΔRn (Rn is the fluorescence of the reporter dye divided by the 
fluorescence of a passive reference dye) was arbitrarily set and this remained consistent for every 
PCR reaction. Ct (threshold cycle) was obtained for every reaction, measured as the point the 
threshold is met by the amplification curve.  
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Figure ‎2.2: Typical PCR amplification curves.  
Levels are detected during the exponential phase when a threshold is met. 
PCR data was analysed through the 2-∆Ct method, first described by Livak and Schmittgen [216]. In 
this method ΔCt was calculated for each sample by subtracting the Ct of the reference microRNA (cel. 
miR-39) from the Ct of the target microRNA. ΔCt was then linearised by log-transformation (2
-∆Ct). 
The mean was calculated within a biological group and fold change was calculated relative to a 
control group. 
2.4.4.4 Normalisation 
The purpose of normalisation is to minimise technical variation in data not related to biological 
changes. Accuracy of results and the validity of the interpretation that follows are largely dependent 
on accurate data normalisation. This is particularly important when assessing biofluids as yields 
following RNA extraction can be too low to accurately quantify using standard spectrophotometry 
techniques. The absence in the circulation of consistently stable reference microRNAs and small 
RNAs to normalise microRNA expression means there is no general consensus as to how to best 
normalise circulating microRNA data. Serum and urinary microRNA expression measured through 
TaqMan PCR was normalised to cel. miR-39 spike-in levels. Urinary microRNA expression was further 
normalised to creatinine to correct for diuretic effect. 
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2.4.5 Creatinine normalisation 
Creatinine is a product of creatine and creatine phosphate metabolism in the muscle, which is 
sourced from the diet and through de novo synthesis from arginine, glycine and methionine in the 
kidney and liver [217, 218]. Creatinine production is non-enzymatic and irreversible. Under normal 
conditions creatinine diffuses into circulation and is excreted by the kidneys into urine at a relatively 
constant rate. In human, approximately 2% of creatine is converted to creatinine daily [217]. 
Therefore, urinary biomarkers including markers of kidney damage are frequently normalised to 
urinary creatinine, and serum creatinine is used to determine estimated glomerular filtration rate 
[219]. 
Urinary creatinine levels were determined using a creatinine assay kit (R&D Systems, Abingdon, UK). 
When treated with picric acid in an alkaline solution creatinine produces quantitatively an orange 
colour through the Jaffe reaction [220]. Briefly, creatinine standards (0-20mg/dl) were prepared by 
serial dilution and 50µl was dispensed into assigned wells of a 96 well plate. Urine samples were 
diluted 1 in 20 in nuclease-free water and dispensed into assigned wells and 100µl of alkaline picrate 
solution was added to each well. The plate was incubated at room temperature for 30 minutes. 
Absorbance was then read at 490nm. Urinary creatinine levels were determined using a standard 
curve.  
2.4.6 Statistical analysis 
PCR data is expressed as fold change relative to a control group. Data is represented as mean ± 
standard error of mean (SEM). Statistical significance was determined using one-way analysis of 
variance (ANOVA) with a linear trend and Student’s t-test where appropriate. The relationship 
between microRNA expression and clinical parameters was determined by Pearson’s correlation. 
Significance was considered as p<0.05. Statistical analysis was performed using GraphPad Prism (La 
Jolla, CA, USA). 
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2.5 Results 
2.5.1 Method optimisation 
Synthetic C. elegans microRNA 39 was spiked into all samples during RNA extraction to act as an 
internal standard, necessitated by the lack of a stable, endogenous microRNA in biofluids. Optimal 
cel. mIR 39 spike-in concentration was determined by method development on archived serum and 
urine samples. In serum, 30 femtomole of cel. miR-39 was initially spiked in, which corresponded to 
a raw Ct value of 16-18, whereas endogenous, circulating miR 122 and miR 223 Ct levels came in 
between 23 and 32 (Figure 2.3A). Spike in concentration was then decreased to 30 attomole, which 
corresponded to a more comparable miR 122 and miR 223 raw Ct value of 23-25 (Figure 2.3B). It was 
therefore determined that 30 attomole was the optimal cel. miR-39 spike in level in serum. 
 
Figure ‎2.3: Optimal serum cel. miR-39 spike-in. 
Raw Ct values as determined by qPCR of miR-122, miR-221, miR-223 and spiked in cel. miR-39 in 
archived serum samples. (A) cel miR-39 spike in level of 30 femtomoles. (B) cel. miR-39 spike in level 
of 30 attomoles. 
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Thirty attomole of cel. miR-39 resulted in inconsistent and variable expression levels of both target 
microRNAs and cel. miR-39 in urine (Figure 4A). A fivefold increase to 150 attomole resulted in 
similar inconsistency (Figure 4B). A further increase to 30 femtomole produced consistent and 
reproducible expression (Figure 4C). At higher concentrations cel. miR-39 appears to act as an RNA 
carrier, required due to the scarcity of endogenous microRNA in urine. Indeed, subsequent to this 
study Exiqon’s commercially available microRNA extraction kit specific to biofluids was released and 
recommends the use of a bacterial plasmid as an RNA carrier [221]. In urinary RNA extraction 
optimised here cel. miR-39 appears to act both as an internal standard and an RNA carrier. It was 
therefore determined that 30 femtomole was the optimal cel. miR-39 spike in level in urine. 
 
Figure ‎2.4: Optimal urinary cel. miR-39 spike-in.  
Raw Ct values as determined by qPCR of miR 122, miR 223 and spiked in cel. miR 39 in archived urine 
samples. (A) cel miR 39 spike in level of 30 attomoles. (B) cel. miR 39 spike in level of 150 attomoles. 
(C) cel miR 39 spike in level of 30 femtomoles. 
 
 
 
 
 
52 
 
2.5.2 Creatinine normalisation 
To correct for diuretic effect, all urinary microRNAs were normalised to urinary creatinine. There was 
no difference in mean urinary creatinine levels across the 5 BMI groups (Figure 2.5A) and no 
correlation was observed between creatinine and BMI (Figure 2.5B, r=-0.14, p=0.35, Pearson 
correlation). These findings confirm the suitability of creatinine as an internal urinary standard and 
all urinary microRNA expression data in this report are shown relative to urinary creatinine 
concentration. 
 
Figure ‎2.5: Urinary creatinine levels versus BMI.  
(A) Urinary creatinine levels across 5 BMI groups. Data represents mean ± SEM. n=7-10 for BMI 
urine.  (B) Pearson correlation between creatinine and BMI. n=47 
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2.5.3 Serum microRNA 
The circulating levels of 8 microRNAs were measured in serum – miR 15a, miR 22-5p, miR 122, miR 
125b, miR 142-3p, miR 145-5p, miR 192 and miR 221. These levels were correlated with BMI and 
clinical results from a standard blood biochemical profile. 
2.5.3.1 miR 22-5p  
A negative correlation was observed between miR 22-5p and BMI. Relative to levels in healthy 
individuals with a BMI under 25, levels of miR 22-5p remained virtually unchanged (0.99 fold) in 
individuals with a BMI between 25-30, but then miR 22-5p expression decreased with increasing 
BMI. Levels decreased 0.78 fold in individuals with a BMI between 30-35, decreased significantly 
0.31 fold in individuals with a BMI between 35-40 and decreased 0.27 fold in morbidly obese 
individuals with a BMI over 40 (Figure 2.6A, p values 0.97, 0.58, 0.031 and 0.089 respectively, 
Student’s t-test). The negative linear trend between miR 22-5p and increasing BMI was significant 
(p=0.0107, one-way ANOVA) and a statistically negative correlation was found between circulating 
levels of miR 22-5p and BMI (Figure 2.6B, r=-0.41, p=0.0109, Pearson correlation). Unsurprisingly, a 
similar correlation was found between miR 22-5p and weight (Figure 2.6C, r=-0.46, p=0.0037, 
Pearson).  
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Figure ‎2.6: Serum miR 22-5p expression.  
All microRNA data is represented as fold change relative to the under 25 BMI group. (A) miR 22-5p 
across 5 BMI groups. n=7-10 per group. Data represents mean ± SEM. *p<0.05 by Student’s t-test. 
(B) Pearson correlation between miR 22-5p and BMI. (C) Pearson correlation between miR 22-5p and 
weight. n=30-47, *p<0.05, **p<0.01. 
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2.5.3.2 miR 145-5p  
Similarly, a significant negative correlation was observed between circulating levels of miR 145-5p 
and BMI. Relative to levels in healthy individuals with a BMI under 25, levels of miR 145-5p 
decreased 0.55 fold in individuals with a BMI between 25-30, decreased 0.48 fold in individuals with 
a BMI between 30-35, decreased 0.28 fold in individuals with a BMI between 35-40 and decreased 
0.27 fold in morbidly obese individuals with a BMI over 40 (Figure 2.7A). Although comparative two-
way fold changes were not statistically significant (p values 0.34, 0.28, 0.13 and 0.18 respectively, 
Student’s t-test), the linear trend with increasing BMI was statistically significant (p=0.031, one-way 
ANOVA). There was also a significant negative correlation between circulating levels of miR 145-5p 
and BMI (Figure 2.7B, r=-0.33, p=0.028, Pearson correlation) and weight (Figure 2.7C, r=-0.37, 
p=0.012, Pearson). Positive correlations were also observed between miR 145-5p serum levels and 
both baseline HDL (Figure 2.7D, r=0.42, p=0.019, Pearson) and baseline L-Phe:L-Tyr ratio (Figure 
2.7E, r=0.37, p=0.039, Pearson). 
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Figure ‎2.7: Serum miR 145-5p expression.  
All microRNA data is represented as fold change relative to the under 25 BMI group. (A) miR 145-5p 
across 5 BMI groups. n=7-10 per group. Data represents mean ± SEM. (B) Pearson correlation 
between miR 145-5p and BMI. (C) Pearson correlation between miR 145-5p and weight. (D) Pearson 
correlation between miR 145-5p and baseline HDL. (E)  Pearson correlation between miR 145-5p and 
baseline L-Phenylalanine:L-Tyrosine ratio. n=31-47, *p<0.05, **p<0.01. 
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2.5.3.3 miR 122  
In contrast, no statistically significant relationship was also observed between circulating levels of 
miR 122 and BMI. Relative to levels in healthy individuals with a BMI under 25, levels of miR 122 
decreased 0.89 fold in individuals with a BMI between 25-30, decreased 0.77 fold in individuals with 
a BMI between 30-35, decreased 0.53 fold in individuals with a BMI between 35-40 and decreased 
0.41 fold in morbidly obese individuals with a BMI over 40 (Figure 2.8A). None of these fold changes 
were statistically significant (p values 0.88, 0.75, 0.46 and 0.45 respectively, Student’s t-test). The 
linear trend was also not statistically significant (p=0.19, one-way ANOVA). Also, no significant 
correlation was found between circulating levels of miR 122 and BMI (Figure 2.8B, r=-0.19, p=0.2, 
Pearson correlation). However, miR 122 levels did correlate with fasting blood glucose (Figure 2.8C, 
r=0.38, p=0.032, Pearson) and baseline triglycerides (Figure 2.8E, r=0.42, p=0.018, Pearson) as well 
as bilirubin (Figure 2.8D, r=0.42, p=0.016, Pearson). 
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Figure ‎2.8: Serum miR 122 expression.  
All microRNA data is represented as fold change relative to the under 25 BMI group. (A) miR 122 
across 5 BMI groups. n=7-10 per group. Data represents mean ± SEM. (B) Pearson correlation 
between miR 122 and BMI. (C) Pearson correlation between miR 122 and fasting glucose. (D) 
Pearson correlation between miR 122 and bilirubin. (E) Pearson correlation between miR 122 and 
baseline triglycerides. n=30-47, *p<0.05. 
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2.5.3.4 miR 142-3p  
No significant trend was observed between circulating levels of miR 142-3p and BMI. Relative to 
levels in healthy individuals with a BMI under 25, levels of miR 142-3p increased 1.58 fold in 
individuals with a BMI between 25-30, decreased 0.78 fold in individuals with a BMI between 30-35, 
decreased 0.45 fold in individuals with a BMI between 35-40 and decreased 0.84 fold in morbidly 
obese individuals with a BMI over 40 (Figure 2.9A). None of these fold changes were statistically 
significant (p values 0.31, 0.54, 0.097 and 0.72 respectively, Student’s t-test). The linear trend was 
also not statistically significant (p=0.16, one-way ANOVA), and no statistically significant correlation 
was found between circulating levels of miR 142-3p and BMI (Figure 2.9B, r=-0.25, p=0.09, Pearson 
correlation). However, a significant negative correlation was found with weight (Figure 2.9C, r=-0.31, 
p=0.033, Pearson). Positive correlations were also found between serum levels of miR 142-3p and 
blood sodium (Figure 2.9D, r=0.37, p=0.036, Pearson). 
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Figure ‎2.9: Serum miR 142-3p expression.  
All microRNA data is represented as fold change relative to the under 25 BMI group. (A) miR 142-3p 
across 5 BMI groups. n=7-10 per group. Data represents mean ± SEM. (B) Pearson correlation 
between miR 142-3p and BMI. (C) Pearson correlation between miR 142-3p and weight. (B) Pearson 
correlation between miR 142-3p and sodium. n=30-47, *p<0.05. 
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2.5.3.5 miR 192  
As with miR 142-3p, a significant negative correlation was found between circulating miR 192 levels 
and weight, but not BMI. Relative to levels in healthy individuals with a BMI under 25, levels of miR 
192 increased 1.2 fold in individuals with a BMI between 25-30, decreased 0.73 fold in individuals 
with a BMI between 30-35, decreased 0.51 fold in individuals with a BMI between 35-40 and 
decreased 0.73 fold in morbidly obese individuals with a BMI over 40 (Figure 2.10A). None of these 
fold changes were statistically significant (p values 0.61, 0.58, 0.13 and 0.49 respectively, Student’s t-
test). The linear trend was also not statistically significant (p=0.15, one-way ANOVA). Also, no 
statistically significant correlation was found between circulating levels of miR 192 and BMI (Figure 
2.10B, r=-0.26, p=0.17, Pearson correlation). In contrast, miR 192 levels significantly decreased with 
increasing weight (Figure 2.10C, r=-0.40, p=0.029, Pearson). A significant positive association was 
also found with blood bilirubin levels (Figure 2.10D, r=0.45, p=0.043, Pearson). 
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Figure ‎2.10: Serum miR 192 expression.  
All microRNA data is represented as fold change relative to the under 25 BMI group. (A) miR 192 
across 5 BMI groups. n=5-7 per group. Data represents mean ± SEM. (B) Pearson correlation 
between miR 192 and BMI. (C) Pearson correlation between miR 192 and weight. (D) Pearson 
correlation between miR 192 and bilirubin. n=30-47, *p<0.05. 
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2.5.3.6 miR 221 
There was no significant relationship found between BMI and circulating miR 221. Relative to levels 
in healthy individuals with a BMI under 25, levels of miR 221 increased 2 fold in individuals with a 
BMI between 25-30, decreased 0.96 fold in individuals with a BMI between 30-35, increased 1.34 
fold in individuals with a BMI between 35-40 and increased 4.94 fold in morbidly obese individuals 
with a BMI over 40 (Figure 2.11A). However, none of these fold changes were statistically significant 
(p values 0.27, 0.93, 0.68 and 0.25 respectively, Student’s t-test). The linear trend was also not 
statistically significant (p=0.13, one-way ANOVA).  
 
Figure ‎2.11: Serum miR 221 expression.  
All microRNA data is represented as fold change relative to the under 25 BMI group. (A) miR 221 
across 5 BMI groups. n=7-10 per group. Data represents mean ± SEM. (B) Pearson correlation 
between miR 221 and BMI. n=30-47. 
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2.5.3.7 miR 15a 
Levels of miR 15a were not found to be differentially expressed with BMI. Relative to levels in 
healthy individuals with a BMI under 25, levels of miR 15a increased 1.26 fold in individuals with a 
BMI between 25-30, decreased 0.53 fold in individuals with a BMI between 30-35, decreased 0.31 
fold in individuals with a BMI between 35-40 and increased 1.03 fold in morbidly obese individuals 
with a BMI over 40 (Figure 2.12A). None of these fold changes were statistically significant (p values 
0.59, 0.25, 0.078 and 0.95 respectively, Student’s t-test). The linear trend was also not statistically 
significant (p=0.3, one-way ANOVA). Also, no statistically significant correlation was found between 
circulating levels of miR 15a and BMI (Figure 2.12B, r=-0.2, p=0.17, Pearson correlation) or any blood 
biochemistry marker.  
2.5.3.8 miR 125b  
No relationship was found between BMI and circulating miR 125b. Relative to levels in healthy 
individuals with a BMI under 25, levels of miR 125b decreased 0.69 fold in individuals with a BMI 
between 25-30, decreased 0.95 fold in individuals with a BMI between 30-35, decreased 0.63 fold in 
individuals with a BMI between 35-40 and decreased 0.62 fold in morbidly obese individuals with a 
BMI over 40 (Figure 2.12C). None of these fold changes were statistically significant (p values 0.32, 
0.9, 0.26 and 0.31 respectively, Student’s t-test). The linear trend was also not statistically significant 
(p=0.24, one-way ANOVA), and no statistically significant correlation was found between circulating 
levels of miR 125b and BMI (Figure 2.12D, r=-0.17, p=0.27, Pearson correlation). No significant 
correlations were found with any blood biochemistry marker.  
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Figure ‎2.12: Serum microRNA expression of miR 15a and miR 125b. 
(A-B) MiR 15a and (C-D) MiR 125b. Left panel illustrates microRNA fold change expression 
across 5 BMI groups. Fold change relative to under 25 BMI, n=7-10 per group. Data 
represents mean ± SEM. Right panel illustrates Pearson correlation between of BMI and fold 
change. n=30-47. 
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2.5.4 Urine 
In the corresponding BMI urine samples expression of 3 miRNAs, miR 192, miR 200a and miR 200b, 
were measured. All three are kidney expressed miRNAs associated with the metabolic syndrome 
[178, 222]. 
2.5.4.1 miR 192 
Urinary levels of miR 192 decreased with BMI but this was not statistically significant. Relative to 
levels in healthy individuals with a BMI under 25, urinary levels of miR 192 decreased 0.56 fold in 
individuals with a BMI between 25-30, decreased 0.39 fold in individuals with a BMI between 30-35, 
decreased 0.55 fold in individuals with a BMI between 35-40 and decreased 0.52 fold in morbidly 
obese individuals with a BMI over 40 (Figure 2.13A). None of these fold changes were statistically 
significant (p values 0.33, 0.17, 0.33 and 0.32 respectively, Student’s t-test). There was also no linear 
trend (p=0.25, one-way ANOVA) and no correlation between urinary levels of miR 192 and BMI 
(Figure 2.13B, r=-0.23, p=0.13, Pearson correlation). However, a negative correlation was found with 
blood levels of urea (Figure 2.13C, r=-0.45, p=0.011, Pearson). 
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Figure ‎2.13: Urinary miR 192 expression.  
All microRNA data is represented as fold change relative to the under 25 BMI group. (A) miR 192 
across 5 BMI groups. n=7-10 per group. Data represents mean ± SEM. (B) Pearson correlation 
between miR 192 and BMI. (C) Pearson correlation between miR 192 and urea. n=30-47, *p<0.05.  
 
 
 
 
 
68 
 
2.5.4.2 miR 200a 
There appeared to be a negative correlation between BMI and urinary levels of miR 200a, albeit this 
was not significant. Relative to levels in healthy individuals with a BMI under 25, urinary levels of miR 
200a decreased 0.45 fold in individuals with a BMI between 25-30, decreased 0.16 fold in individuals 
with a BMI between 30-35, decreased 0.15 in individuals with a BMI between 35-40 and decreased 
0.05 fold in morbidly obese individuals with a BMI over 40 (Figure 2.14A). However, none of these 
fold changes were statistically significant (p values 0.57, 0.44, 0.39 and 0.33 respectively, Student’s t-
test). There was also no significant linear trend (p=0.15, one-way ANOVA) and no correlation 
between urinary levels of miR 200a and BMI (Figure 2.14B, r=-0.33, p=0.07, Pearson). There was a 
significant negative correlation found with weight, however (Figure 2.14C, r=-0.37, p=0.041, Pearson 
correlation). A positive correlation was observed between urinary miR 200a and baseline L-Phe:L-Tyr 
levels (Figure 2.14D, r=0.5, p=0.026, Pearson).  
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Figure ‎2.14: Urinary miR 200a expression.  
All microRNA data is represented as fold change relative to the under 25 BMI group. (A) miR 200a 
across 5 BMI groups. n=7-10 per group. Data represents mean ± SEM. (B) Pearson correlation 
between miR 200a and BMI. (C) Pearson correlation between miR 200a and weight. (D) Pearson 
correlation between miR 200a and L-Phenylalanine:L-Tyrosine ratio. n=30-47, *p<0.05.  
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2.5.4.3 miR 200b 
Similarly, there was a negative correlation between urinary levels miR 200b and BMI but this was not 
significant. Relative to levels in healthy individuals with a BMI under 25, urinary levels of miR 200b 
decreased 0.34 fold in individuals with a BMI between 25-30, decreased 0.21 fold in individuals with 
a BMI between 30-35, decreased 0.12 in individuals with a BMI between 35-40 and decreased 0.01 
fold in morbidly obese individuals with a BMI over 40 (Figure 2.15A). However, none of these fold 
changes were statistically significant (p values 0.45, 0.38, 0.31 and 0.34 respectively, Student’s t-
test). There was also no significat linear trend (p=0.13, one-way ANOVA) and no correlation between 
urinary levels of miR 200b and BMI (Figure 2.15B, r=-0.29, p=0.0502, Pearson test). Urinary miR 200b 
did significantly correlate with weight, however (Figure 2.15C, r=-0.31, p=0.036, Pearson 
correlation). A correlation was also found with urea (Figure 2.15D, r=-0.35, p=0.049, Pearson 
correlation).  
Complete tabulated Pearson correlations between all assessed circulating and urinary microRNAs 
and blood biochemistry markers can be found in the appendices (Tables 7.1-7.11). 
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Figure ‎2.15: Urinary miR 200b expression.  
All microRNA data is represented as fold change relative to the under 25 BMI group. (A) miR 200b 
across 5 BMI groups. n=7-10 per group. Data represents mean ± SEM. (B) Pearson correlation 
between miR 200b and BMI. (C) Pearson correlation between miR 200b and weight. (D) Pearson 
correlation between miR 200b and urea. n=30-47, *p<0.05.  
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2.6 Discussion 
In this chapter a method to measure and normalise miRNA expression in serum and urine was 
developed and validated. Synthetic cel. miR-39 was used as an internal standard and urinary 
microRNA levels were normalised to creatinine concentrations to correct for diuretic effect. Baseline 
expression of select miRNAs associated with obesity and the metabolic syndrome was determined in 
both serum and urine. Circulating levels of miR 22-5p and miR 145-5p were found to be negatively 
correlated with BMI, suggesting they’re biological effectors and may represent novel biomarkers for 
obesity. Serum miR 142-3p and miR 192 and urinary miR 200a and 200b were found to inversely 
correlate with weight. 
Extensive published evidence has implicated miR 22 in cancer, both as an oncogene and a tumour 
suppressor. Cellular senescence, a state of permanent cell cycle arrest and a barrier to cancer 
progression, is induced by miR 22 in both human normal and cancer cells [223]. MiR 22 is also a 
reported tumour suppressor in colon cancer, inhibiting p21 and selectively determining p-53 induced 
apoptosis in response to cellular stress [224]. Additionally, miR 22 also inhibits the oncogene c-Myc 
by silencing c-Myc binding protein in a proliferation positive feedback loop [225]. However, miR 22 
also reportedly inhibits the tumour suppressor PTEN [226] and displays oncogenic properties in 
haematological and breast cancers [227, 228]. MiR-22 is upregulated in myelodysplastic syndrome 
(MDS) and leukaemia and expression correlations with poor survival in both [227]. Transgenic mice 
conditionally expressing miR 22 in the haematopoietic compartment developed MDS and 
haematological malignancies [227]. In breast cancer miR 22 overexpression is associated with 
increased mammary hyperplasia, tumour development and poor survival [228]. The proto-oncogenic 
activity of miR 22 is exhibited through the direct targeting and inactivating TET2, which catalyses the 
conversion of 5-methylcytosine to 5-hydroxymethylcytosine. Mutations of TET2 are common in MDS 
and other malignancies and its overexpression has been found during haematopoietic differentiation 
[227, 229, 230].  
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The reported oncogenic and tumour suppressive functions of miR 22 underscores the multifaceted 
and complex nature of microRNA regulation, where each microRNA has multiple targets involved in 
a variety of pathways, and the biological function of microRNAs appears pleiotropic, specific to 
tissue and pathway. MiR 22 is reportedly upregulated in the gums of obese patients with periodontal 
disease [231]. This appears to be the only reported direct link between miR 22 and obesity as of yet. 
However, given that obesity is a well established risk factor to a number of different cancers [232], 
the inverse correlation found here between circulating expression of miR 22-5p and BMI supports 
the reported anti-cancer role of miR 22.  
There is on the other hand evidence implicating miR 145 with obesity. Mir 145 is upregulated in the 
liver of genetic and dietary mouse models of obesity, and deficiency in miR 143-145 cluster leads to 
immunity from obesity-associated insulin resistance in mice [233]. MiR 145 has been found to be 
downregulated in isolated fat cells and intact subcutaneous white adipose tissue in obesity [165]. 
MicroRNA 145 expression is decreased in adipocyte cell differentiation and subcutaneous fat 
expression of miR 145 correlates with HDL-cholesterol and 2 hour oral glucose tolerance test levels 
[234]. MicroRNA 145 also reportedly promotes lipolysis by increasing the production and release of 
TNF-α (tumour necrosis factor α) and glycerol release through the activation of p65, a NF-κB (nuclear 
factor-κB) complex member. Lipolysis, the hydrolysis of triglycerides to into fatty acids and glycerol, 
is decreased in obesity resulting in the accumulation of fat mass [235]. MiR-145 also increases 
membrane bound TNF-α by targeting ADAM17, part of the metalloproteinase family [236]. There is 
also a reported negative correlation between miR 145 and leptin receptors in abdominal 
subcutaneous fat of morbidly obese individuals [237].  All this evidence is consistent with the inverse 
correlation between BMI and miR 145-5p found here. Interestingly, miR 145 has also been reported 
to be upregulated in the urinary exosomes of patients with microabluminuria and in the 
subcutaneous muscle cells of patients with type 2 diabetes when compared to non-diabetic patients 
[238, 239]. This is indicative of the proposed key regulatory role miR 145 has in lipid biology and 
obesity and the findings reported here support this assertion.  
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Circulating levels of miR 122 did not correlate with BMI here, inconsistent with Ortega et al. who 
reported a decrease in plasma miR 122 in patients with morbid obesity [208]. However, positive 
correlations between miR 122 and baseline triglycerides, fasting blood glucose and bilirubin were 
observed. The predominant microRNA in the liver, miR 122 is a key regulator of cholesterol and fatty 
acid metabolism [172]. Inhibition of miR 122 in mice on both normal and high-fat diets led to 
decreased fatty-acid and cholesterol synthesis in the liver, as well as a decrease in plasma 
triglycerides, but not plasma glucose [172]. Inhibition also triggered the activation of the central 
metabolic sensor AMPK, an important regulator in energy balance which is deregulated in the 
metabolic syndrome and a novel therapeutic target for type 2 diabetes [240]. Circulating levels of 
miR 122 and 192 are reported markers of liver damage [241], which may explain their correlation 
with bilirubin, a common marker for impaired liver function. Miravirsen, a miR 122 inhibitor, has 
been successful in a phase II clinical trial in treating Hepatitis C, an infection that primarily targets 
the liver. [242]. 
Inverse correlations with weight were also found with serum levels of microRNAs 142-3p and 192. 
This is in stark contrast to Ortega et al. who found circulatory miR 142-3p increases in cases of 
obesity and morbid obesity [208]. Mir 142-3p is reported to be upregulated in the adipose tissue of 
obese mice [243], but downregulated in diabetic cardiomyopathy [244]. MiR 192 is an anti-fibrotic 
microRNA typical of the kidney [178, 183] and its decrease in circulation has been reported in 
patients with type 2 diabetes [210], consistent with the decrease with weight found here. Urinary 
levels of miR 200a and miR 200b also decreased with weight. Both are kidney anti-fibrotic 
microRNAs and are decreased in diabetic nephropathy [222, 245]. Obesity did not influence serum 
levels of miR 15a, miR 125b or miR 221 here. All three were found to be decreased in obesity by 
Ortega et al. [208]. 
Due to financial and time restraints, the expression of only 8 microRNAs in circulation and 3 in urine 
were measured. Ideally, more microRNAs need to be assessed, either in a targeted PCR approach or 
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preferably through profiling, by next generation deep sequence, through microarrays or using 
predesigned microRNA PCR panels. This would provide a more complete picture of the obesity 
microRNA profile. However, employing a targeted manner this chapter has provided potential novel 
circulating biomarkers of obesity, in particular miR 145 and miR 22.  
Determining a microRNA disease signature in biofluids is a field still in its infancy, as illustrated by 
the scant and differing findings. Validation of these findings is required in larger, more diverse, 
multicentre cohorts to with subgroups of the various obesity co-morbidities, including diabetes and 
cardiovascular disease. Temporal, prospective studies are required to assess the prognostic power of 
microRNAs in obesity. The role of microRNAs in biofluids is not fully understood and it is not known 
whether circulating microRNAs are functional factors in disease or simply biomarkers. Recently 
circulating microRNAs encompassed in exosomes and high- density lipoprotiens have been taken up 
in active form by recipient cells, suggesting a potential tissue-to-tissue communicative role for 
microRNAs [203, 204]. In vitro mechanistic studies are needed to decipher the precise function 
deregulated microRNAs have in obesity, to provide fresh mechanistic insights and to potentially 
uncover new avenues for obesity therapeutics. 
To summarise, in this chapter a method of accurately measuring and normalising microRNA levels in 
circulation and urine was established.  The expression levels of microRNAs associated with obesity 
was also determined, identifying potential novel circulating microRNA biomarkers for obesity and 
setting the phenotypic anchor for subsequent chapters assessing novel urinary and circulating 
microRNA biomarkers of the post-bariatric phenotype.  
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3 Urinary microRNA expression following bariatric surgery 
3.1 Justification 
Renal dysfunction is commonly associated with the metabolic syndrome [246]. Diabetes and obesity 
are independent risk factors of chronic kidney disease (CKD), characterised by decreased estimated 
glomerular filtration rate (eGFR) and increased urinary albumin. Obesity leads to a decline in renal 
function over time and increasing BMI leads to renal hyperfiltration and proteinuria which eventually 
culminates in hypofiltration and CKD. Diabetic nephropathy (DN) occurs in approximately one third 
of diabetics (both type 1 and type 2) and is the most common cause of CKD and end stage renal 
failure [247]. DN is characterised by microalbuminuria, thickening of the glomerular basement, 
mesangial expansion and tubulointerstitial fibrosis through accumulation of extracellular matrix 
proteins, namely collagen (encoded by Colα1) and fibronectin.  
DN is mediated by transforming growth factor-β1 (TGF-β1) and TGF-β1 promoted fibrosis is 
mediated by an increasing number of fibroblasts, which are the effecter cells in the production and 
accumulation of the extracellular matrix. Epithelial-to-mesenchymal transition (EMT) is increasingly 
recognised as a key component in this process by promoting the transition of resident renal 
epithelial cells to a fibroblast phenotype [248]. MiR 192 and the miR 200 family suppress EMT by 
targeting zinc E-box binding homeobox 1 and 2 (ZEB1 and ZEB2), which encode transcriptional 
repressors for E-cadherin, essential for maintaining epithelial phenotype [178-180]. 
Weight loss, including that achieved surgically, leads to an improvement in renal function [249-251]. 
This chapter hypothesises that this is mediated by microRNAs, and their expression in urine are 
biomarkers for improvements in health induced by bariatric surgery.  
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3.2 Aims 
1. To identify urinary microRNA biomarkers for clinical improvements following bariatric 
surgery 
2. To determine the post-bariatric biological role of these microRNAs 
3.3 Study design 
Twenty seven morbidly obese individuals undergoing laparoscopic bariatric surgery provided urine 
samples under ethics approval 08/H0711/123. Urine samples were obtained preoperatively and at 2 
periods postoperatively - between 2 and 6 months and between 1 and 2 years. Bariatric surgery was 
performed at Imperial College London. All patients fulfilled NICE qualifying criteria for bariatric 
surgery [49]. Twenty patients had a RYGB, 4 had a sleeve gastrectomy, 2 had a gastric band and 1 
had a hybrid sleeve-bypass operation. Fifteen out of the 27 were diabetic or pre-diabetic 
preoperatively. Patients were stratified by surgical procedure and diabetes status.  The average BMI 
was 51.6 kg/m2. Females made up 70.4% of participants. A study summary table can be found in 
Table 3.1.  
Table ‎3.1: Study Summary Tableⱡ 
All Patients Total T2DM/ 
Pre-
T2DM 
LRYGB Sleeve Gastric 
Band 
Sleeve/Bypass 
n 27 15 20 4 2 1 
Age 47.2 
(11.1) 
51.9 (9.4) 45 (10.4) 49.1 
(13.7) 
62.3 (3.73) 52.1 
Sex (Female)  19/27 10/27 14/27 2/4 2/2 1/1 
BMI (kg/m2) 50.9 
(7.29) 
47.5 
(6.44) 
50.3 
(7.53) 
55.7 
(6.17) 
43.4 53.5 
Diabetes   9/27 9/15 8/20 1/4 0 0 
Pre-diabetes  6/27 6/15 3/20 1/4 1/2 1/1 
ⱡValues represent mean. Values in parenthesis represent standard deviation. 
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RNA was extracted from urine samples and the preoperative and postoperative expression of miR 
192, 200a and 200b was measured by targeted qPCR. This was followed by in vitro functional studies 
manipulating expression of miR 192 in HK-2 cells, a human, non-cancerous cell line derived from the 
proximal tubule. Figure 3.1 is a flowchart outlining Chapter 3’s study design.  
 
Figure ‎3.1: Flow chart illustrating the study design of chapter 3. 
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3.4 Materials and methods 
3.4.1 Samples 
All urine samples were collected in urine donation tubes. Samples were aliquoted into 0.2ml and 
0.5ml aliquots. All samples were stored in -80⁰C and filtered through a 0.2µm filter prior to analysis. 
Surgical clinical outcomes were obtained in collaboration with performing surgeons. 
3.4.2 Urinary RNA extraction 
RNA was extracted from urine samples using the mirVana PARIS kit (Ambion). RNA was extracted 
from 250µl of urine. To normalise, 30 femtomoles of synthetic C. elegans miR-39 (Ambion) was 
spiked into the urine samples following denaturing. Cel. miR-39 was chosen as it lacks sequence 
homology with human miRNAs. RNA was eluted in 100µl nuclease free water. RNA extracts were 
stored at -20⁰C until use. A detailed, step-wise protocol can be found in section 2.4.3 in the previous 
chapter. 
3.4.3 Targeted quantitative PCR 
RNA product was reverse transcribed using TaqMan MicroRNA Reverse Transcription kits (Applied 
Biosystems). Relative microRNAs levels were determined by real time, quantitative PCR using 
TaqMan Fast Universal Master Mix (Applied Biosystems). Quantitative PCR was performed in 
triplicate on the Applied Biosystems 7500 Fast System. All PCR and RT probes were obtained from 
Applied Biosystems. MicroRNA expression was normalised to cel. miR-39 levels and urinary 
microRNA expression was further normalised to creatinine. Relative expression was calculated using 
the 2-∆Ct method [216]. A detailed, step-wise protocol can be found in section 2.4.4 in the previous 
chapter. 
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3.4.4 Creatinine assay 
To correct for diuretic effect, urinary microRNA expression was normalised to urinary creatinine 
levels. Creatinine is a product of creatine metabolism in muscle and under normal conditions is 
excreted by the kidneys into urine at a relatively constant rate. Urinary levels were determined using 
a creatinine assay kit (R&D Systems). Briefly, urine samples were diluted 1 in 20 in distilled water and 
treated with an alkaline picrate to produce an orange-red complex. Following incubation at room 
temperature for 30 minutes, absorbance was measured at 490nm. Creatinine levels were 
determined using a standard curve. A detailed, step-wise protocol can be found in section 2.4.5 in 
the previous chapter. 
3.4.5 Tissue culture 
To determine the functional role of the urinary microRNAs found to be differentially expressed 
following bariatric surgery, microRNA expression was manipulated in an in vitro cell culture model. 
3.4.5.1 Cell line 
The human kidney-2 (HK-2) cell line was purchased from the American Type Culture Collection 
(ATCC) through LGC Standards (Teddington, UK).  HK-2 cell line is a proximal tubular cell (PTC) line 
derived from a normal, adult, male, human renal cortex. The cell line was immortalised by 
transduction with human papilloma virus 16 E6/E7 genes and shares phenotypical and functional 
characteristics with well differentiated PTCs [252]. HK-2 cells are adherent, epithelial cells that 
double approximately every 48 hours (Figure 3.2). They have been used extensively as in vitro renal 
models to assess drug-induced nephrotoxicity and are capable of reproducing experimental results 
obtained from freshly isolated PTCs.  
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Figure ‎3.2: HK-2 cells in culture.  
The image was taken under a light microscope. 
3.4.5.2 Cell culture 
For the successful growth and maintenance of cells in vitro appropriate culture conditions are 
required that resemble in vivo physiological conditions. Cell culture was carried out in Class II 
biological safety cabinets using reagents supplied by Life Technologies (Paisley, UK) and propagated 
in Corning (Loughborough, UK) standard tissue culture treated plasticware unless otherwise stated. 
Cells were cultured at 37⁰C and 5% CO2 in a humidified incubator. HK-2 cells were maintained in 
DMEM/Ham’s F12, supplemented with 10% v/v foetal bovine serum (FBS), 1% 
Penicillin/Streptomycin antibiotics (100U/ml, 100µg/ml respectively) and 1% Insulin-Transferrin-
Sodium Selenite (Sigma-Aldrich, Gillingham, UK) to form complete media. Insulin-Transferrin-Sodium 
Selenite promotes glucose and amino acid uptake and reduces toxic oxidants and the need for FBS. 
FBS provides growth factors, hormones, essential fatty acids, binding and transport proteins and 
other supplements vital for cell growth, metabolism and proliferation [253].  
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3.4.5.3  Cell resuscitation 
HK-2 cells were stored in the liquid phase of liquid nitrogen at 1-2x106 cells per vial. Cells were 
resuscitated from frozen by rapidly thawing a vial at 37⁰C in a water bath. Cells were then 
transferred to a 15ml centrifuge tube. The vial was then washed with 1ml complete media, which 
was then added to the cells in the centrifuge tube, along with another 1ml of complete media. Cells 
were then centrifuged at 1,000g for 5 minutes. Storage media was aspirated and the cell pellet was 
suspended in 10ml complete media. Cells were transferred to a 25cm3 culture flask and placed in an 
incubator until confluent, when they were transferred to a 75cm3 culture flask. HK-2 cells typically 
double approximately every 48 hours. Media was refreshed every 2-3 days until confluence was 
reached. 
Cells were maintained in culture until ~80% confluent. To passage cells, culture media was removed 
by suction and the cell adherent monolayer was washed in 1ml sterile phosphate-buffer saline (PBS) 
solution. To detach cells from the culture flask 5ml 0.05% trypsin-EDTA was added to the monolayer 
and the flask was incubated at 37⁰C for 5 minutes. Trypsin was deactivated by the addition of equal 
volume complete media and the mixture was centrifuged at 1,000g for 5 minutes. The supernatant 
was removed by suction and the cell pellet was suspended in fresh complete media. Cells were then 
split into new culture flasks at a 1:3-1:4 ratio. 
Cells were counted using a Neubauer haemocytometer and the trypan blue exclusion assay. Viable 
cells exclude trypan blue and thus can be differentiated. A 100µl aliquot of cell suspension was 
mixed with 20µl of trypan blue (0.4%), a dilution factor of 1.2. Then 10µl of the mixture was loaded 
into a haemocytometer and viable cells were scored in 4 squares under a microscope and averaged. 
Cell concentration was determined using the following equation:  
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3.4.5.4 Frozen cell stocks 
Cells were harvested, scored and pelleted as described previously and suspended in 95% complete 
media plus 5% dimethylsulphoxide (DMSO), a cryoprotectant. Cells were aliquoted into cryovials at 
1-2x106 cells/ml and frozen at -80⁰C overnight before transfer to long-term storage in liquid 
nitrogen. 
3.4.6  Transfections 
Endogenous microRNA levels were manipulated in the HK-2 cells through the transfection of 
microRNA miR 192 mimic, a gain-of-function experiment designed to determine the biological 
function of miR 192. Two different transfection facilitators were used – Lipofectamine 2000 and 
siPORT NeoFX (both Life Technologies).   
3.4.6.1  Mimics, inhibitors and mimic control 
mIRIDIAN microRNA mimics, inhibitors and mimic controls were purchased from Dharmacon 
(Lafayette, CO, USA). RNA (5nmol) was diluted in 0.25ml siRNA dilution buffer to form a 20µM stock. 
Lipofectamine 2000 and siPORT NeoFX transfection reagents were used and transfection conditions 
were determined following protocol optimisation. 
3.4.6.2 Transfection optimisation 
Transfection conditions were optimised for volume of lipofectamine transfection reagent used. A 
fixed amount of a fluorescent FAM oligonucleotide (1µM) was incubated with 4 different volumes of 
lipofectamine reagent, forming transfection complexes of increasing strength. Transfection was 
performed over 24 hours as described in 3.4.6.3. Optimal transfection reagent volume was 
determined by balancing transfection efficiency, defined as the percentage of incubated 
oligonucleotide successfully transfected into cells, and cell viability, determined through the 
alamarBlue assay (Life Technologies). AlamarBlue is an indicator dye that can quantitatively assess 
proliferation of cells in culture and is used to determined cytotoxicity. The active compound in 
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alamarBlue is Resazurin, which is reduced to resorufin by viable cells, leading to a colour change 
from non-fluorescent blue to fluorescent red.  
Following 24 hours of transfection with FAM oligonucleotides, transfection media was removed, 
cells were washed twice with PBS and 500µl of fresh antibiotic free media was added. Fluorescence 
was measured at 485nm excitation and 520nm emission. To measure viability another 500µl fresh 
antibiotic free media was added to cells (total volume 1ml) and incubated with 100µl of alamarBlue 
for 1 hour at 37⁰C. Flourescence was read at 560nm excitation and 590nm emission. Viability was 
measured as a percentage of the viability of untreated cells.  
3.4.6.3 Lipofectamine 2000 
MicroRNA 192 mimic transfections were performed in a sterile 24 well cell culture plates following 
the manufacture’s protocol. Cells (50,000) were seeded in growth media minus 
penicillin/streptomycin and incubated overnight. Cells were at approximately 70% confluence the 
following day, when media was removed by suction and replaced with 400µl Opti-MEM. Then, 2.5µl 
RNA was added to 100µl Opti-MEM and 8 µl lipofectamine was added to 50 µl Opti-MEM. Both 
mixtures were incubated at room temperature for 10 minutes. Then, diluted RNA and diluted 
lipofectamine were mixed 1:1 and incubated for 20 minutes at room temperature to allow 
transfection complexes to form. Transfection complexes (100µl) were then added to the seeded cells 
and incubated at 37⁰C for 24 hours.   
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3.4.6.4 siPORT NeoFX 
Transfections were performed in a sterile 24 well cell culture plates, with 50,000 cells seeded per 
well, following the manufacture’s protocol. One hour prior to transfection HK-2 cells at 
approximately 80% confluence were trypsinised and suspended to 110,000 cells/ml in complete 
media. Three different mimic transfection concentrations were assessed – 10nM, 20nM and 50nM. 
The mimic:reagent ratio was kept constant across all 3 transfection concentrations. siPORT 
transfection reagent was diluted in Opti-MEM as described in Table 3.2.  
Table ‎3.2: siPORT/Opti-MEM dilutions 
Reagent Transfection concentration 
10nM 20nM 50nM 
siPORT (µl) 0.2 0.4 1 
Opti-MEM (µl) 25.8 25.6 25 
 
Mixtures were incubated at room temperature for 10 minutes. Transfected RNA was diluted in Opti-
MEM as described in Table 3.3.  
Table 3.3: RNA/Opti-MEM dilutions 
Reagent Transfection concentration 
10nM 20nM 50nM 
RNA (µl) 0.25 0.5 1.25 
Opti-MEM (µl) 29.75 29.5 28.75 
 
Diluted RNA and diluted siPORT were then mixed 1:1 and incubated for 10 minutes at room 
temperature to allow transfection complexes to form. Then, 50µl was dispensed into assigned wells 
of a 24 well plate and 450µl of cell suspension was overlaid onto the transfection complexes. Cells 
were incubated at 37⁰C for 48 hours. 
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3.4.7 Cell RNA extraction 
Two different RNA extraction protocols were performed on in vitro cell samples. Trizol was used to 
extract RNA following lipofectamine transfections and mirVANA PARIS was used following SiPORT. 
3.4.7.1 Trizol 
Trizol is a solution containing guanidinium thiocyanate, sodium acetate, phenol and choloroform and 
is one of the most commonly used methods to separate RNA from DNA. When Trizol is mixed with 
biological samples and centrifuged, RNA remains in the upper aqueous phase and DNA and protein 
remain in the lower interphase and organic phase. RNA harvested in the upper aqueous is then 
recovered following precipitation with isopropanol [254]. 
Following transfection, transfection media was removed by aspiration and each transfection well 
was washed twice with PBS. To each well 0.5ml Trizol was added to disrupt and homogenise cells 
and lysates were collected and stored at -80⁰C until extraction. To extract RNA samples were thawed 
and mixed with 100µl of chloroform and incubated at room temperature for 5 minutes before 
centrifugation at 12,000g for 15 minutes at 4⁰C. The aqueous phase was then collected and 
precipitated in 250µl isopropanol and 1µl of glucagon. The mixture was incubated for 10 minutes at 
room temperature and centrifuged at 12,000g for 10 minutes at 4⁰C. Following centrifugation the 
supernatant was discarded and the remnant RNA pellet was washed in 0.5ml 75% ethanol twice 
before being air dried under a sterile fume hood. Pellets were then dissolved in 50µl RNase free 
water and warmed at 55⁰C for 10 minutes. RNA extracts were stored at -80⁰C until use. RNA samples 
were quantified by nanadrop, micro-volume, ultraviolet visible spectrophotometry which measures 
absorbance between 220nm and 350nm to determine the concentration of nucleic acids and the 
presence of contaminates.   
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3.4.7.2 MirVANA PARIS 
Following SiPORT transfection RNA was extracted from cells using the mirVANA PARIS kit (Ambion). 
Transfection media was aspirated and the attached cells were washed with 0.5ml ice-cold PBS twice. 
The cell culture plate was then placed on ice and 250µl of ice-cold cell disruption buffer was added 
to each well to lyse the cells. The plate was then left on ice for 5 minutes and the cell lysates were 
dispensed into sterile 2ml centrifuge tubes. Equal volume of denaturing buffer was then added to 
cell lysates and the RNA extraction was continued from this step as previously described in 2.4.2. 
RNA was eluted in 75µl nuclease free water. 
3.4.7.3 RT-PCR 
MicroRNA was reverse transcribed into cDNA using the TaqMan MicroRNA Reverse Transcription kit 
(Applied Biosystems) as previously described in 2.4.4.1. Messenger RNA (mRNA) was reverse 
transcribed using the High Capacity Reverse Transcription kit (Applied Biosystems), which differs 
from microRNA RT due to the use of random primers instead of specific primers. The manufacture’s 
protocol was followed. Briefly, a master mix was made comprising of 2µl 10X RT buffer, 0.8µl 25x 
dNTP mix, 2µl 10x random primers, 1µl reverse transcriptase enzyme and 4.2µl RNase free water per 
sample (total volume 10µl). The master mix was then mixed manually and 10µl was dispensed into 
0.2ml PCR polypropylene reaction tubes per reaction. To this 10µl RNA was added and mixed 
manually. Reaction tubes were loaded onto a MJ Research PTC-200 Thermo Cycler (GMI) and 
reactions were incubated at 25⁰C for 10 minutes, 37⁰C for 120 minutes, 85⁰C for 5 minutes and 
finally 4⁰C until the samples tubes were retrieved. cDNA products were stored at -20⁰C until use. 
Real time, qPCR was performed in triplicate on the Applied Biosystems 7500 Fast System as outlined 
in 2.4.4.2. MicroRNA expression was normalised to U6 small nuclear RNA and mRNA expression was 
normalised to GAPDH, a frequently used housekeeping gene. 
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3.4.8 Statistical analysis 
All PCR data is expressed as fold change relative to preoperative levels. Data is represented as mean 
± standard error of mean (SEM). Statistical significance was determined using ANOVA (with a linear 
trend) and paired/unpaired Student’s t-test where appropriate. Significance was considered as 
p<0.05. Statistical analysis was performed using GraphPad Prism. 
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3.5 Results 
3.5.1 Clinical outcomes 
Bariatric surgery induced substantial clinical improvements in all patients (Figure 3.3). Reduction in 
BMI was significant within 100 days of surgery and mean BMI decreased by almost 30% 100 days or 
more after surgery (Figure 3.3A, p=0.031 and 0.0001 respectively, Student’s t-test). Mean levels of 
glycated haemoglobin (HbA1c) and fasting blood glucose, two established markers of diabetes, also 
decreased following bariatric surgery. HbA1c decreased from almost 7% preoperatively to 5.5% 100 
days or more following surgery (Figure 3.3B, p=0.027, Student’s t-test). Diabetes is defined as HbA1c 
equal to or greater than 6.5% [255]. Mean levels of fasting blood glucose decreased from 7.5mmol/L 
preoperatively to 5.6 mmol/L 100 days or more following surgery. Estimated glomerular filtration 
rate increased slightly from 73 ml/min/1.72msq preoperatively to 79.7ml/min/1.72msq at 100 days 
or more following surgery. Kidney function is often assessed by eGFR.  
3.5.2 Creatinine normalisation 
Urinary microRNA expression was corrected to urinary creatinine levels to account for diuretic 
effect. Mean creatinine levels were unchanged prior to and following bariatric surgery (Figure 3.4).  
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Figure ‎3.3: Clinical bariatric outcomes.  
(A) BMI (B) HbA1c (C) fasting blood glucose and (D) eGFR levels preoperatively and at <100 days and 
>100 days following bariatric surgery. Data represent mean ± SEM. n=17-19. *p<0.05, ****p<0.0001 
vs. preoperative level by Student’s t-test. 
 
 
91 
 
B a r ia tr ic  U r in e
P
re
2
 -
 6
 m
o
n
th
s
 p
o
s
t
1
 -
 2
 y
e
a
rs
 p
o
s
t
0
1 0 0
2 0 0
3 0 0
4 0 0
5 0 0
6 0 0
C
r
e
a
ti
n
in
e
 m
g
 /
 d
l
 
Figure ‎3.4: Urinary creatinine levels in bariatric urine.  
Urinary creatinine levels preoperatively, 2-6 months and 1-2 years following bariatric surgery. Data 
represents mean ± SEM. n=27. 
3.5.3 miR 192 
Initially the urinary expression of miR 192, the preeminent microRNA in the kidney [256], was 
assessed. In patients who had laparoscopic RYGB, levels of miR 192 increased 1.28 and 2.8 fold 
respectively at 2-6 months and 1-2 years following surgery (Figure 3.5A, p=0.19 and 0.0012 
respectively, paired t-test). A similar increase was observed in sleeve gastrectomy patients (Figure 
3.5B). MiR 192 levels increased 1.27 fold at 2-6 months following sleeve procedures and 4.7 fold at 
1-2 years postoperatively (p=0.68 and 0.013 respectively, paired t-test). Increase in urinary miR 192 
levels was consistent when patients were stratified by preoperative diabetic status. In diabetic 
patients urinary levels of miR 192 increased 1.46 fold at 2-6 months and 3.6 fold at 1-2 years 
following bariatric surgery (Figure 3.6A, p=0.098 and 0.039 respectively, paired t-test). Pre-diabetic 
patients demonstrated a 1.54 fold increase at 1-2 years following surgery, although this was not 
statistically significant (Figure 3.6B). Non-diabetic patients demonstrated a significant 3 fold increase 
in miR 192 levels at 1-2 years following surgery (Figure 3.6C, p=0.031, paired t-test). 
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Figure ‎3.5: Urinary miR 192 expression following RYGB and Sleeve.  
(A) RYGB patients. (B) Sleeve gastrectomy patients. Data represents mean fold change ± SEM relative 
to mean preoperative expression. n=20 for RYGB and n=4 for Sleeve. *p<0.05 vs. preoperative 
expression by paired t-test. 
 
Figure ‎3.6: Urinary miR 192 expression following bariatric surgery across diabetic status.  
(A) Non-diabetic, (B) pre-diabetic and (C) diabetic patients. Data represents mean ± SEM relative to 
mean preoperative expression. n=12 for non-diabetics, n=6 for pre-diabetics, n=9 for diabetics. 
*p<0.05 vs. preoperative expression by paired t-test.  
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Urinary miR 192 levels following bariatric surgery were compared to levels in a diverse BMI cohort 
described in the previous chapter. Relative to morbidly obese levels (BMI over 40), bariatric 
preoperative miR 192 levels were slightly lower (0.73 fold), likely reflecting the higher BMI in 
patients undergoing bariatric surgery (Figure 3.7A). MiR 192 expression was similar 2-6 months 
following surgery (0.76 fold). However, 1-2 years following bariatric surgery mean miR 192 level was 
nearly 2 fold higher relative to the morbidly obese cohort and was comparable to miR 192 levels in 
those with a healthy weight (BMI under 25). Although comparative two-way fold changes were not 
significant, the linear trend was (p=0.043, one-way ANOVA). An inverse correlation between fold 
change and BMI was also significant (p=0.0081, Pearson’s correlation, Figure 3.7B). It appears 
bariatric surgery shifts urinary miR 192 expressions from levels observed in a morbidly obese 
population to levels observed in a healthy population.  
 
Figure ‎3.7: Bariatric urinary miR 192 expression relative to a morbidly obese cohort.  
(A) Bariatric and healthy miR 192 expression relative to a morbidly obese population. Data 
represents mean ± SEM relative to mean preoperative expression. Morbidly obese is a BMI >40, 
healthy weight is a BMI <25. n=7 for morbidly obese, n=10 healthy weight, n=27 for preoperatively, 2 
- 6 months and 1 - 2 years postoperatively. (B) Pearson correlation of miR 192 fold change against 
BMI. n=63, **p<0.01. 
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Of the 27 individuals who made up the bariatric cohort, 22 had increased urinary miR 192 
expressions postoperatively relative to their preoperative levels, including 16 out of the 20 RYGB 
patients, 11 out of 15 diabetics and all 4 sleeve patients. A timecourse of postoperative miR 192 
expressions in RYGB patients relative to their individual preoperative miR 192 levels can be found in 
Figure 3.8. A significant correlation was demonstrated between individual, personalised fold 
changed in miR 192 levels and days follow surgery (p=0.029, Pearson’s correlation). This illustrates a 
trend of a gradual, general increase in miR 192 levels in urine which is enhanced and sustained with 
time. 
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Figure ‎3.8: Timecourse of miR 192 expression following surgery.  
Data represented as fold change relative to individual preoperative expression for 20 RYGB bariatric 
patients. 
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3.5.4 miR 200 family 
Urinary levels of miR 200a and miR 200b were also measured. Both are expressed in the kidney and 
are involved in diabetic nephropathy. MiR 200a urine levels increased 2.5 fold at 2-6 months and 3.4 
fold at 1-2 years following surgery (Figure 3.9A). Neither increase was statistically significant. MiR 
200b levels increased 5.8 fold at 2-6 months and significantly 28.6 fold at 1-2 years postoperatively 
(p=0.003, Figure 3.9B, paired t-test). All but one patient demonstrated a postoperative increase of 
urinary miR 200a and miR 200b relative to their individual preoperative level. Significant correlations 
were observed between both miR 200a and miR 200b and days follow bariatric surgery (Figure 3.10, 
p=0.0071 and 0.044 respectively, Pearson’s correlation). 
 
 
Figure ‎3.9: Urinary expression of miR 200 following bariatric surgery.  
(A) miR-200a. n=9 (B) miR-200b. n=8. Data represents mean fold change ± SEM relative to mean 
preoperative expression. **p<0.01 vs. preoperative expression by paired t-test. 
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Figure ‎3.10: Timecourse of miR 200 expression following surgery.  
(A) miR 200a. (b) miR 200b. Data represented as fold change relative to individual preoperative 
expression. 
 
3.5.5 Transfections 
3.5.5.1 Lipofectamine 
Four different volumes of lipofectamine transfection reagents were assessed to determine the 
optimal delivery method for a set concentration of fluorescent oligonucleotide into HK-2 cells. 
Lipofectamine proved cytotoxic as only 53% of cells were viable after 24 hours with 2µl of 
Lipofectamine (Figure 3.11). However, increasing lipofectamine volume did not appear to decrease 
viability substantially, as quadrupling lipofectamine volume to 8µl only decreased viability a further 
8% to 44%. However, transfection efficiency markedly increased with increasing lipofectamine. 
Transfection efficiency was 8% with 2µl of lipofectamine and that more than trebled to 26% with 8µl 
of lipofectamine. As a result 8µl of lipofectamine was used to transfect miR 192 mimic. 
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Figure ‎3.11: Transfection optimisation.  
Transfection efficiency (blue) and viability (red) with increasing lipofectamine concentrations after 
24 hours. Each point is a mean of two determinations.  
 
HK-2 cells were transfected with miR 192 mimic (50nM final concentration) for 24 hours and RNA 
was extracted using Trizol. Transfection with miR 192 mimic resulted in an approximately 1,500 fold 
increase relative to cells transfected with a scrambled control (Figure 3.12, p=0.0012, Student’s t-
test). Incubation of the miR 192 alone without lipofectamine did not increase miR 192 levels relative 
to control cells, indicating the absence of any significant gymnotic transfection [257]. Levels of miR 
192 were also unchanged in cells incubated with only lipofectamine and untreated cells. 
Successful transfection of miR 192 however had no effect on miR 200a levels or the mRNA levels of 
ZEB1, ZEB2 or Colα1 relative to control-transfected cells (Figure 3.13). 
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Figure ‎3.12: miR 192 expression following lipofectamine miR 192 mimic transfection.  
Data represents mean ± SEM relative to transfection with a scrambled control. **<p=0.01, n=4. 
 
Figure ‎3.13: Effects of lipofectamine miR 192 mimic transfection.  
Expression of (A) miR 200a (B) ZEB1 (C) ZEB2 and (D) Colα1 following after 24 hours of miR 192 
mimic transfection. Data represents mean ± SEM relative to transfection with a scrambled control. 
n=4. 
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3.5.5.2 SiPORT  
Due to the low transfection efficiency and considerable cytotoxicity observed with lipofectamine, 
HK-2 cells were also transfected with miR 192 mimic using siPORT NeoFX. Three transfection 
concentrations were assessed to determine the possibility of a dose response – 10nM, 20nM and 
50nM. The mimic:reagent ratio was kept constant across all 3 transfection concentrations. The 
transfection time was also increased from 24 hours to 48 hours, doubling the time for miR 192 
mimic to exert its activity. The mirVana PARIS kit was used to extract RNA instead of Trizol. 
Transfection with all three concentrations of miR 192 mimic was successful and increased miR 192 
expression 4,000 fold, 16,000 fold and 18,000 fold respectively relative to cells transfected with a 
scrambled control (Figure 3.14A, p<0.001 for all three, Student’s t-test). However, only 10nM 
significantly increased miR 200a levels (Figure 3.14B, p=0.015, Student’s t-test). Expression levels of 
ZEB1 and Colα1 were unaltered for all three miR 192 mimic concentrations (Figure 3.14C&E). 
However, transfection with 50nM miR 192 mimic concentration resulted in a significant 0.63 fold 
decrease in ZEB2 (Figure 3.14D, p=0.04, Student’s t-test).  
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Figure ‎3.14: SiPORT miR 192 mimic transfection.  
Expression of (A) miR 192 (B) miR 200a (C) ZEB1 (D) ZEB2 and (E) Colα1 following after 48 hours of 
10nM, 20nM and 50nM miR 192 mimic transfection. Data represents mean ± SEM relative to 
transfection with a scrambled control. *p<0.05, **<p0.01, ***p<0.001, ****p<0.0001, n=3. 
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3.6 Discussion 
Three kidney-expressed microRNAs, miR 192, miR 200a and miR 200b, were shown to be 
upregulated in urine following bariatric surgery, an increase that was consistent across surgical type 
and diabetic status and was sustained and enhanced with time. Upregulation of miR 192 and the miR 
200 family was also accompanied by improvement in clinical parameters, including HbA1c. Bariatric 
surgery shifts urinary miR 192 expression from morbidly obese levels to levels seen in a healthy 
cohort, and the transfection of miR 192 in a kidney PTC cell line increased miR 200a and decreased 
ZEB2, a key transcriptional promoter of kidney fibrosis. These three microRNAs could potentially 
represent non-invasive, anti-fibrotic biomarkers for surgery-induced improvement in renal function. 
The kidney-specific deletion of Dicer in mice leads to proteinuria, glomerular disease and tubular 
injury, illustrating the important functional roles of microRNAs in kidney pathophysiology [258-260]. 
MiR 192 is one of 5 microRNAs whose expression is higher in the kidney relative to other organs 
[256], and its levels are reduced in human renal biopsies from patients with advanced diabetic 
nephropathy, levels that correlate with tubulointerstitial fibrosis and decreased GFR, reflecting miR 
192’s key anti-fibrotic role [178]. In vitro incubation of PTCs with TGF-β1 decreases miR 192 
expression and the overexpression of miR 192 suppresses ZEB1 and ZEB2, decreasing TGF-β1 
mediated E-cadherin suppression [178]. In diabetic apoE mice, miR 192 expression was 
downregulated in the kidney and treatment of PTCs with TGF-β1 results in a reduction of miR 192 
[183]. Renal levels of the miR 200 family are decreased in mouse models of renal scarring and by 
TGF-β1 in rat PTCs [222]. Injection of miR 200b precursor antagonises ZEB1/ZEB2 induction, 
decreases collagen synthesis and ameliorates fibrosis [245]. p53 tumor suppressor increases 
expression of miR 192 and miR 200, suppressing EMT [261]. MiR 200 expression is a strong 
biomarker for epithelial versus mesenchymal phenotype in cancer [262]. MiR 200 overexpression 
leads to mesenchymal to epithelial transition in mouse carcinomas and overexpressing miR 200 in 
vitro increases E-cadherin and represses EMT [179, 180]. Here, miR 192 transfection led to an 
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increase in miR 200a, indicating miR 192 acts upstream to miR 200 in a hierarchical regulation 
pathway, suggesting miR 192 is a master microRNA regulator in the kidney. Previously miR 192 has 
been shown to upregulate miR 200b/c expression in mesangial cells [263]. 
In contrast, miR 192 and miR 200 appear to have pro-fibrotic effect in mesangial cells. TGF-β1 
increases miR 192 in mouse mesangial cells and repression of ZEB1/ZEB2 expression by miR 192 
leads to collagen synthesis [181]. The inhibition of miR 192 in streptozotin-induced diabetic mice 
reduces proteinuria [182]. In mesangial cells, miR 200 family represses ZEB1/ZEB2, promoting 
fibrosis [263]. This likely reflects the complexity of the kidney and the pleiotropic roles miR 192 and 
miR 200 play in renal physiology appear to be cell specific. Indeed, the renal cortex and the medulla 
have different microRNA expression profiles [264]. It is worth noting that proximal tubular cells are 
further along the urinary tract than mesangial cells of the glomerulas and that urinary levels of miR 
192 and miR 200 are decreased in patients with bladder cancer, correlating with increased EMT 
[265]. 
This study was only able to show a slight increase with eGFR following surgery, but other studies 
have found bariatric surgery significantly improves renal function. Weight loss is associated with a 
reduction in proteinuria, including weight loss achieved surgically [249-251]. Bariatric surgery 
improves renal function in patients with pre-existing glomerular hyperfiltration [250]. Surgery also 
leads to reduced levels of albuminuria one year postoperatively, and levels continue to decrease up 
to two years and were maintained up to 5 years post-surgery [79, 266]. Remission of 
microalbuminuria in diabetics can reach 60% 5 years following surgery. Surgery also has preventive 
effects, reducing the incidence of microalbuminuria by 80% and diabetic nephropathy by 60% 
compared to patients treated medically [79]. Bariatric surgery can also lead to improvement and 
remission in patients with established chronic kidney disease [267]. The results presented here 
suggest miR 192 may mediate these renal improvements following bariatric surgery.  
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Figure ‎3.15: MiR 192 and 200 in renal function. 
 (Left) Mechanism for glucose-mediated renal fibrosis in the proximal tubular cells. Diabetes 
increases TGF-β which inhibits miR 192/200, lifting the suppression on ZEB and EMT. (Right) 
Mechanism following bariatric surgery. 
The early detection of DN is important in preventing progression to renal failure. There are 
considerable limitations of conventional markers of kidney function. The sensitivity and specificity of 
proteinuria and eGFR is poor, particularly in obese patients, and only manifest late in the disease 
process. Novel markers of DN have been reported, including proteins, peptides and growth factors 
[268]. A number of studies have reported distinct microRNA profiles in urine, urinary sediments and 
circulation in cases of kidney diseases. MicroRNA 145 is upregulated in the urinary exosomes of type 
1 diabetics with microalbuminuria [238] and urinary microRNA profiles can be used to differentiate 
various stages of diabetic nephropathy in individuals with type 1 diabetes [211]. In circulation, 
increased levels of miR 25, miR 27, miR 152 and miR 182 has been reported in patients with type 1 
diabetes [269], and a recent report identified 10 elevated and 2 lowered microRNAs in diabetic 
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patients with DN relative to healthy controls [270]. Circulating microRNAs can select diabetic 
patients with DN from those with good renal function, suggesting prognostic potential [270]. This 
has led to interest in microRNAs as potential novel drug targets. The successful manipulation of miR 
192 expression in the renal cortex of normal and diabetic mice suggests the same may be possible in 
humans [271].  
Other microRNAs have been reported to be involved in DN, including miR 21, miR 25 and miR 29 
[272-274]. The expression of more microRNAs need to be assessed in bariatric urine to get a more 
comprehensive representation of the post bariatric urinary microRNA profile. Over-expressing miR 
192 decreased ZEB2 but the effects on fibronectin and collagen protein levels need to be assessed, 
as does the effects of glucose treatment of PTCs on microRNA. However, there are limitations to 
using in vitro models of renal function, as EMT is more commonly observed in immortalised cell lines 
than in vivo renal fibrosis [275]. The role of microRNAs in mediating the post-bariatric improvements 
in renal health needs to be confirmed in larger, prospective, multi-centre studies of bariatric patients 
including cohorts with varying degrees of kidney dysfunction. 
To summarise, bariatric surgery increased the urinary expression of the anti-fibrotic microRNAs miR 
192 and miR 200, providing fresh insights into the mechanisms behind improvements in renal 
function following bariatric surgery. MiR 192 and miR 200 represent potential novel, non-invasive 
biomarkers of obesity-associated renal function and could potentially be used to monitor operative 
outcomes and aid in patient selection. 
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4 Circulating microRNA profiling following bariatric surgery 
4.1 Justification 
Bariatric surgery is the most effective intervention strategy at achieving sustained weight loss. In 
addition, bariatric surgery leads to the remission of type 2 diabetes and a reduction in cancer risk 
[26, 116]. However, the precise mechanisms behind these beneficial effects are not completely 
understood. Recently, a microRNA study in a bariatric rat model found that surgery altered the 
expression of 14 circulating microRNAs and provided a mechanistic role for microRNAs in the altered 
postoperative metabolic changes and suggested an involvement in a gut-brain signalling axis [214]. 
Another study in humans reported that RYGB also modulates circulating microRNAs, but did not 
offer mechanistic insights [208].  
The objective of this chapter was to assess the effect of RYGB on circulating microRNA expression 
profiles across a number of post-bariatric timepoints and to identify potential microRNA biomarkers 
associated with the health benefits of bariatric surgery. Consequently, a plasma sample was 
obtained preoperatively and at 1 month, 3 months, 6 months, 9 months and 12 months after RYGB 
(during standard postoperative check-up visits) and a circulatory microRNA profile was 
characterised. 
4.2 Aim 
To assess the effect of Roux-en-Y gastric bypass on circulating microRNA expression profiles. 
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4.3 Study design 
Plasma samples were collected from 4 men and 5 women undergoing laparoscopic Roux-en-Y gastric 
bypass at Hull and East Yorkshire NHS Trust in the United Kingdom under ethics approval 
10/H1304/13. All patients were morbidly obese prior to surgery and met qualifying criteria for 
bariatric surgery set out by NICE [49]. Plasma samples were collected and BMI and blood glucose 
were measured immediately preoperatively and at one month, three months, six months, nine 
months and one year postoperatively. All participants provided informed written consent prior to 
the study. A study summary table can be found in Table 4.1.  
Table ‎4.1: Study Summary Table ⱡ 
Patients Total 
n 9 
Age (years) 46.1 (9.8) 
Sex  (female) 5/9 
Diabetics (T2DM) 2/9 
BMI (kg/m2) 49 (10) 
Blood glucose (mmol/L) 7.5 (5.4) 
ⱡValues represent mean unless otherwise stated. Values in parenthesis represent standard deviation. 
 
RNA was extracted from plasma samples and circulating microRNA profiles were characterized at all 
time points using Exiqon's miRCURY LNA plasma/serum PCR panels, measuring expression of 179 
microRNAs known to be expressed in circulation [276]. A study design flow chart can be found in 
Figure 4.1. 
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Figure ‎4.1: Flow chart illustrating the study design of chapter 4. 
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4.4 Materials and methods 
4.4.1 Samples preparation and extraction 
Plasma samples were acquired by standard venipuncture and centrifugation in EDTA-coated 
vacutainer tubes (Becton Dickinson) by collaborators at the University of Hull. Samples were stored 
in -80⁰C until use. RNA was extracted from 100µl plasma using the mirVana PARIS Isolation Kit (Life 
Technologies) and eluted in 100µl nuclease free water. A detailed, step-wise protocol can be found 
in section 2.4.2 in Chapter 2.  
4.4.2 Profiling 
Plasma samples were profiled using Exiqon’s miRCURY locked nucleic acid (LNA) platform and 
Serum/Plasma Focus microRNA PCR panels. Panels consisted of two 96-well plates preloaded with 
LNA microRNA primers for 179 microRNAs, selected for their typical expression in circulation [276]. 
Panels also include primers for UniSp3 inter-plate calibrators and RNA spike-ins as well as blank wells 
as negative controls. This platform was selected for its high specificity, reproducibility and sensitivity 
in profiling circulating microRNAs [277].   
Profiling was a two-step process: 
1. Universal Reverse Transcription - a one first-strand cDNA synthesis that can be used as a 
template for multiple microRNA PCR reactions. 
2. LNA PCR amplification with specific forward and reverse microRNA cDNA primers detected 
through the SYBR Green dye. 
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4.4.2.1 Universal reverse transcription 
RNA was reverse transcribed into cDNA using the Universal cDNA Synthesis Kit (Exiqon). The 
manufacture’s protocol was followed. A master mix was initially made consisting of 5X reaction 
buffer (which includes universal reverse transcription primer), enzyme mix, a synthetic UniSp6 RNA 
spike-in (108 copies/µl) and nuclease-free water as described in Table 4.2. 
Table ‎4.2: RT Master Mix components 
Component Volume, per reaction (µl) 
5X Reaction buffer (manufacturer’s 
specification) 
4 
Enzyme mix 2 
Synthetic UniSp6 RNA Spike in 1 
Nuclease-free water 9 
Total volume 16 
 
Once created the master mix was manually mixed and 10µl was dispensed into a 0.2ml PCR 
polypropylene reaction tube per reaction. To this 4µl of RNA was added to produce a 20µl RT 
reaction. Reaction tubes were loaded onto an MJ Research PTC-200 Thermo Cycler (GMI) and 
reactions were incubated at 42⁰C for 60 minutes, then 95⁰C for another 5 minutes to heat-inactivate 
the reverse transcriptase, and finally 4⁰C until the samples tubes were retrieved. cDNA products 
were stored at -20⁰C until use. 
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4.4.2.2 Profiling of circulating microRNA 
Before Serum/Plasma Focus microRNA PCR panels were used, the plates were centrifuged briefly. 
cDNA (20µl) was diluted 50X in 940µl nuclease-free water and 40µl ROX Dye, a passive reference dye 
whose fluorescence does not change during the reaction. Equal volume (1,000 µl) of SYBR Green PCR 
master mix was then added, which included DNA polymerase, dNTPs and the SYBR Green dye. This 
master mix was then manually mixed and 10µl was added to each well across the 2 plates that made 
up the panels. Once fully loaded, PCR plates were sealed with an optical film and centrifuged briefly. 
Quantitative PCR was carried out on the StepOnePlus 7500 PCR system (Life Technologies). 
Quantitative PCR reactions consisted of 95⁰C for 10 minutes to allow for polymerase 
activation/denaturation, 45 amplification cycles of 95⁰C for 10 seconds followed by 60⁰C for 1 
minute. Quantitative PCR reactions were concluded with a melting curve to disassociate the SYBR 
Green dye from amplification product, allowing the specificity of the amplification to be assessed.  
4.4.2.3 Pre-processing 
A threshold of 0.2 ΔRn was arbitrarily set and this remained consistent for every PCR reaction 
(explained in section 2.4.4.3). A Ct was obtained for every reaction, measured at the point the 
threshold is met by the amplification curve. Pre-processing and initial analysis of profiling data was 
performed with GenEx6 software (Exiqon) [278]. All data were subject to inter-plate calibration 
(through expression of UniSp3). Synthetic UniSp6 was added at the RT stage and this served as cDNA 
synthesis quality control. Threshold for expression was set as Ct <37, and microRNAs not expressed 
under this criteria in over 60% of samples were removed from consideration. All microRNA 
expression was normalised to four endogenous microRNAs, miR 223-3p, miR 26a, miR 101-3p and 
miR 19a, selected for their relative expression stability (see section 4.5.2) as determined by the 
geNorm [279] and Normfinder [280] algorithms. All microRNA expression levels were log 
transformed and expressed relative to preoperative mean. 
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4.4.3 Target prediction and pathway analysis 
Each microRNA has hundreds of potential mRNA targets. Bioinformatic computational modelling was 
used to predict mRNA targets for each microRNA found to be differentially expressed following 
bariatric surgery. The miRWalk (v.2) database of predicted and validated microRNA targets [281] and 
the PANTHER (protein annotation through evolutionary relationship) classification system [282] was 
used to predict regulated pathways as previously described [214]. MiRWalk compiles putative mRNA 
targets from 10 target prediction algorithms – DIANA-mT, miRanda, miRDB, miRWalk, RNAhybrid, 
PICTAR4, PICTAR5, PITA, RNA22 and TargetScan. These algorithms predict mRNA targets by assessing 
3’/5’ UTR and coding sequence binding, sequence conservation, free energy stability and site 
accessibility and differ by their stringency criteria [283, 284]. To ensure confidence and accuracy in 
predicted targets only targets predicted by 2 or more algorithms were included in the analysis.  
The PANTHER classification system is a comprehensive library of all protein coding genes from over 
80 organisms (including humans) that have been annotated into 176 pathways [282]. Predicted 
targets obtained by miRWALK were uploaded into PANTHER’s (v.10) gene list analysis tool and 
compared to PANTHER’s datasets to determine which pathways were statistically overrepresented 
or underrepresented. 
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4.4.4 Data analysis 
Principal component analysis (PCA) pattern recognition was applied to visualise differences in whole 
microRNA profiles prior to and following RYGB. PCA reduces multivariate data into components; the 
first component describes the greatest variation in the dataset, the second component describes the 
second greatest of variation and so on. MicroRNA profiles were converted into coordinates and 
plotted on a principal component space to allow clustering of similar profiles and separation of 
dissimilar profiles [285, 286]. 
Data is represented as mean ± SEM. Statistical significance was determined by Student’s t-tests. The 
relationship between microRNA expression and clinical parameters was determined by Pearson’s 
correlation. Significance was considered as p<0.05. All statistical analysis was performed on 
GraphPad Prism or R (www.r-project.org). 
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4.5 Results 
4.5.1 Clinical outcomes 
All patients demonstrated substantial time-dependent reduction in BMI following surgery (Figure 
4.2A). Reduction in BMI was significant within 3 months following RYGB (p=0.02, Student’s t-test) 
and continued to gradually decrease. Mean BMI at 12 months was 37% lower than mean 
preoperative BMI (p=0.0056, Student’s t-test). Patients lost on average 15.7% of their preoperative 
BMI by 1 month postoperatively, 21.9% by 3 months postoperatively, 26.2% by 6 months 
postoperatively, 31.8% by 9 months postoperatively and 29.6% by 12 months postoperatively 
(Figure 4.2B). There were no significant changes in mean blood glucose following surgery (Figure 
4.2C). Only 2 out of the 9 patients in this study were diabetic and both demonstrated decreases in 
postoperative blood glucose relative to their individual preoperative level (Figure 4.2D). 
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Figure ‎4.2: Clinical bariatric outcomes.  
Changes in (A) BMI, (B) % preoperative BMI lost, (C) blood glucose following RYGB and (D) blood 
glucose following RYGB for patients that were diabetic preoperatively only. Data represent mean ± 
SEM. n=1-9. *p<0.05, **p<0.01, ****p<0.0001 vs. preoperative level by Student’s t-test. 
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4.5.2 PCR validation 
As the Exiqon plasma/serum microRNA panels are a quantitative PCR profiling platform, validation of 
profiling results with TaqMan PCR (section 2.4.4) was deemed unnecessary. The expression of only 
miR 122 was determined by both methods. Expression levels of miR 122 as measured by the two 
methods were comparable and correlated well (Figure 4.3, r=0.8252, p=0.0009, Pearson’s 
correlation). 
 
Figure ‎4.3: Raw Ct values of miR 122 expression as determined by Exiqon’s PCR panel microRNA 
profiling and TaqMan quantitative PCR.  
Pearson’s correlation. ***p<0.001.  
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4.5.3 Normalisation 
Profiling found 159 microRNAs that surpassed detection threshold. The large nature of profiling data 
leads to multiple normalising options to minimise technical variation. Four different normalising 
techniques were assessed. MicroRNA expressions were (1) not normalised, (2) normalised to the 
mean expression of all expressed microRNAs (global mean), (3) normalised to UniSp6, a synthetic 
RNA spiked in at the reverse transcription stage and (4) normalised to miR 223-3p, miR 26a, miR 
101-3p and miR 19a, four endogenous microRNAs deduced and selected with the aid of GeNorm and 
Normfinder algorithms due to their relative stability in expression across all samples (Table 4.3). 
Overall variation was assessed through coefficient of variances (CV), calculated for each expressed 
microRNA for both the preoperative and postoperative groups. This was plotted against the 
cumulative distribution, as previously described [287] (Figure 4.4A). 
Normalisation to global mean and UniSp6 significantly decreased mean CVs of the 50% least variable 
microRNAs compared to no normalisation (p <0.0001 for both, unpaired t test; Figure 4.4B). 
However, the optimum method was normalisation to the four stable endogenous microRNAs, which 
displayed significantly lower mean CVs of the 50% least variable microRNAs compared to all other 
assessed methods (Figure 4.4B, p < 0.0001 v non normalised and global mean, p= 0.0006 v UniSp6, 
unpaired t test). As a result all profiling data was normalised to the miR 223-3p, miR 26a, miR 101-3p 
and miR 19a combination.  
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 Figure ‎4.4: Normalisation of profiling data.  
(A) Coefficient of variance against cumulative distribution for each expressed microRNA not 
normalised (black), normalised to global mean (blue), UniSp6 (red) and 4 endogenous 
microRNAs (green). (B) Mean coefficient of variance of the 50% least expressed microRNAs 
for the four different normalisation methods. Data represent mean ± SEM. ***p<0.001, 
****p<0.0001 by Student’s t-test. (C) Boxplots of raw Ct values of the 4 endogenous 
microRNAs used to normalise microRNA expression. 
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Table ‎4.3: Candidate normalising microRNAs ⱡ. 
GeNorm Normfinder 
MicroRNA M-Value MicroRNA SD 
miR-223-3p 0.532906148 miR-101-3p 0.4955 
miR-26a-5p 0.532906148 miR-19a-3p 0.5597 
miR-142-3p 0.69187472 miR-19b-3p 0.6936 
miR-23a-3p 0.741792291 miR-16-5p 0.7727 
miR-191-5p 0.895876676 miR-191-5p 1.0457 
miR-19b-3p 1.006804913 miR-142-3p 1.1094 
miR-19a-3p 1.051823548 miR-23a-3p 1.1125 
miR-101-3p 1.110009752 miR-106b-5p 1.1482 
miR-16-5p 1.135564234 miR-21-5p 1.2116 
miR-451a 1.220766682 miR-26a-5p 1.2194 
miR-144-3p 1.302659919 miR-451a 1.242 
miR-106b-5p 1.365558024 miR-144-3p 1.2891 
miR-21-5p 1.420741101 miR-92a-3p 1.357 
miR-92a-3p 1.467133819 miR-223-3p 1.3766 
miR-486-5p 1.51592891 miR-486-5p 1.5031 
miR-320a 1.575285976 miR-320a 1.7919 
miR-103a-3p 1.642058753 miR-103a-3p 1.8358 
miR-425-5p 1.739905629 miR-425-5p 2.3032 
miR-423-5p 1.855075269 miR-423-5p 2.7486 
miR-93-5p 2.006345475 miR-93-5p 3.3277 
ⱡM-Value is the GeNorm stability value, defined as the variation of a microRNA compared to all 
other microRNAs [279]. SD is the Normfinder stability value, calculated as the sum of the 
estimated intragroup and intergroup variation [280].  
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4.5.4 Profiling  
Multivariate pattern recognition algorithms are commonly used to visualise the similarities and 
differences in large datasets consisting of a large number of variables. PCA scores plot demonstrated 
separation between the preoperative and 5 postoperative groups (Figure 4.5A). There appeared to 
be discrete clustering of preoperative profiles (pink), 1 month postoperative profiles (red), 3 months 
postoperative profile (green), 6 month postoperative profiles (light blue), 9 month postoperative 
profiles (dark blue) and 12 month postoperative profiles (black). This is clearer in the trajectory PCA 
which plots the mean components of all 6 groups (Figure 4.5B). The preoperative and 1 month 
postoperative microRNA profiles are the most alike but there’s a notable shift of increasing 
separation with each sequential postoperative timepoint.  
A preoperative-postoperative comparative heatmap of relative expression of every expressed 
microRNA can be found in Figure 4.6A, presented with the clustering of microRNAs. The associated 
group cluster denodrogram (Figure 4.6B) illustrated distinct clustering of preoperative and 1m 
postoperative profiles and separate clustering of 3 months, 6 months, 9 months and 12 months 
postoperative profiles. Within the second cluster 3 month and 6 month profiles group together and 
9 month and 12 month profiles group together. This, together with the PCA scores plots indicates 
bariatric circulating microRNA profiles display increasing variation from preoperative levels with 
each passing month. 
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Figure ‎4.5: Principal Component Analysis of bariatric circulating microRNA profiles. 
(A) PCA scores plot of preoperative (green), 1 month postoperative (blue), 3 month 
postoperative (red), 6 month postoperative (yellow), 9 month postoperative (light blue) and 
12 month postoperative (purple). (B) Trajectory PCA scores plot of mean components ± 
standard deviation. 
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Figure ‎4.6: Comparative heat map of preoperative and postoperative mean relative microRNA expression and associated cluster dendrogram. 
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The majority of circulating microRNAs remained unaltered following RYGB. However, 49 out of the 
159 detected microRNAs were differentially expressed in at least one post-bariatric timepoint 
compared to preoperative levels. A series of volcano plots of log microRNA fold change at each 
postoperative timepoint relative to preoperative levels can be found in Figure 4.7. At 1 month 
following surgery circulating microRNA levels were largely unchanged, with only one microRNA 
significantly upregulated and one microRNA significantly downregulated relative to preoperative 
levels. At 3 months only one microRNA was significantly increased and 4 microRNAs were 
significantly decreased relative to preoperative levels. The number of differentiated microRNAs 
continued to increase with each sequential timepoint following RYGB. The number of deregulated 
microRNAs at 6 months was 10 (4 increased, 6 decreased). At 9 months 28 microRNAs were 
significantly deregulated (1 increased, 27 decreased) and at 12 months 31 microRNAs were 
significantly deregulated (1 increased, 30 decreased).  
All microRNAs significantly altered following RYGB are tabulated in Table 4.4 and all detected 
microRNA expression data is tabulated in Table 7.12 in the appendices. 
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Figure ‎4.7: Volcano plots.  
Log fold change against log p value by Student’s t test of postoperative microRNA expression at (A) 1 
month, (B) 3 months, (C) 6 months, (D) 9 months and (E) 12 month following RYGB relative to 
preoperative levels. Each data point represents an individual microRNA that has passed expression 
threshold. Data points in yellow are statistically significant.
124 
 
Table ‎4.4: Circulating microRNAs significantly deregulated following RYGB. 
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4.5.5 Univariate analysis 
The changes in circulating microRNA expression following RYGB can be categorised broadly into 5 
types of response that are temporally dependent, referred to here as phases of response.  
4.5.5.1 First phase 
The first phase of the bariatric response with respect to circulating microRNAs occurred in the first 
few months following RYGB. The expression of the majority of circulating microRNAs were not 
significantly changed 1 month and 3 months following RYGB, and the circulating microRNA profiles 
at those two post-bariatric timepoints most resembled the preoperative stage. The few microRNAs 
that were differentially expressed during this phase were characterised by a significant change in 
expression at the early postoperative months before reverting back to preoperative expression 
levels at later postoperative months. This is best illustrated by miR 338, which relative to 
preoperative levels significantly decreased 4.48 fold at 1 month following RYGB relative to 
preoperative levels (p=0.039, Student’s t test) but expression levels at subsequent timepoints 
following surgery were comparable to preoperative levels (Figure 4.8A). A similar pattern was 
observed with miR 93-5p, which relative to preoperative expression decreased 4.17 fold 1 month 
following RYGB and decreased significantly 11.4 fold at 3 months following RYGB (p=0.27 and 0.048 
respectively, Student’s t test) before reverting back to preoperative levels at 6 months, 9 months 
and 12 months following bariatric surgery (Figure 4.8B). Expression levels of neither miR 338 nor miR 
93-5p correlated with BMI, % of preoperative BMI lost or blood glucose levels. As the expression of 
miR 338 and miR 93-5p was not transient following bariatric surgery this was expected. 
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Figure ‎4.8: First phase of the bariatric circulating microRNA response. 
Normalised logarithmic relative preoperative and postoperative expression of differentiated 
microRNAs. (A) miR 338 and (B) miR 93-5p. Data represents mean ± standard error of mean. *p<0.05 
by Student’s t test. 
 
 
 
 
 
 
 
 
127 
 
4.5.5.2 Second phase 
The second phase of response followed a similar pattern to the first phase but with a later significant 
manifestation of the differentiated microRNA. Relative to preoperative expression circulating 
expression of miR 27a increases gradually 4 fold 1 month following RYGB, 3 fold 3 months following 
RYGB and significantly 13.5 fold 6 months following RYGB (p=0.21, 0.36 and 0.023 respectively, 
Student’s t test) before returning to levels comparable to preoperative expression 9 months and 12 
months following surgery (Figure 4.9A). Similarly circulating miR 33a expression increases 1.29 fold 1 
month following surgery, 2.99 fold 3 months following surgery and significantly 4.74 fold 6 months 
following surgery (p=0.73, 0.12 and 0.024 respectively, Student’s t test)  before decreasing 9 months 
and 12 months following RYGB (Figure 4.9B). The inverse was observed for miR 590 which decreased 
gradually following RYGB to 1.2 fold 1 month following surgery, 1.19 fold 3 months following surgery 
and significantly 2.73 fold 6 months following surgery (p=0.82, 0.65 and 0.022 respectively, Student’s 
t test) before gradually increasing back towards preoperative expression levels 9 months and 12 
months following RYGB (Figure 4.9C). Circulating expression of miR 33a negatively correlated with 
BMI (r=-0.41, p=0.0085, Pearson’s correlation) but not percentage of preoperative BMI lost nor 
blood glucose. Blood levels of miR 590 positively correlated with blood glucose (r=0.46, p=0.0054, 
Pearson’s correlation). Expression of circulating miR 27a did not correlated with any of the measure 
clinical parameters. 
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Figure ‎4.9: Second phase of the bariatric circulating microRNA response. 
Normalised logarithmic relative preoperative and postoperative expression of differentiated 
microRNAs. (A) miR 27a, (B) miR 33a and (C) miR 590. Data represents mean ± standard error of 
mean. *p<0.05 by Student’s t test. 
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4.5.5.3 Third phase 
The third circulating microRNA bariatric phase consisted of microRNAs whose deregulation 
significantly manifested 6 months following surgery but unlike the microRNAs in the second 
response these changes in expression were maintained in subsequent post-bariatric timepoints. This 
includes miR 125b which relative to preoperative expression initially increased 1.22 fold 1 month 
after RYGB but then decreased 1.94 fold 3 months following RYGB, (neither significantly), decreased 
significantly 7.14 fold 6 months following RYGB, decreased significantly 3 fold 9 months following 
surgery and decreased significantly 3.7 fold 12 months following surgery (Figure 4.10A, p=0.75, 0.28, 
0.0077, 0.033 and 0.048 respectively, Student’s t test). MiR 192 followed a similar pattern, increasing 
initially 1.08 fold 1 month following surgery before decreasing 2.1 fold 3 months following surgery, 
significantly 3.98 fold 6 months following surgery, significantly 3.68 fold 9 months following surgery 
and significantly 3.46 fold 12 months following surgery (Figure 4.10B, p=0.87, 0.21, 0.0069, 0.015 
and 0.047 respectively, Student’s t test). Likewise miR 320a initially increased 2 fold following RYGB 
before decreasing 1.75 fold 3 months following surgery, significantly 4.93 fold 6 months following 
surgery, significantly 5.05 fold 9 months following surgery and significantly 5.64 fold 12 months 
following surgery (Figure 4.10D, p=0.31, 0.38, 0.037, 0.0072 and 0.024 respectively, Student’s t test). 
MiR 378a circulating levels also decreased following RYGB, initially increasing 1.51 fold 1 month 
following surgery before decreasing 5.12 fold 3 months following surgery, significantly 11.1 fold 6 
months following surgery, significantly 9.02 fold 9 months following surgery and significantly 35.2 
fold 12 months following surgery (Figure 4.10, p=0.57, 0.16, 0.032, 0.0059 and 0.0033 respectively, 
Student’s t test). Inversely, circulating miR 301a increased following RYGB. Relative to preoperative 
expression miR 301a initially decreased 1.05 fold 1 month following surgery before increasing 1.94 
fold 3 months after surgery, increasing significantly 5.38 fold 6 months following surgery, increasing 
2.77 fold 9 months following surgery and increasing significantly 6.23 following RYGB (Figure 4.10C, 
p=0.95, 0.34, 0.018, 0.14 and 0.046 respectively, Student’s t test). 
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All 5 microRNAs demonstrated correlation with at least one assessed post-bariatric clinical 
parameter. Circulating miR 125b was found to positively correlate with BMI (r=035, p=0.29, 
Pearson’s correlation) and to negatively correlate with percentage of preoperative BMI lost (r=-0.42, 
p=0.0065, Pearson’s correlation). Negative correlations with percentage of preoperative BMI lost 
was also found with circulating miR 192 (r=-0.39, p=0.12, Pearson’s correlation), miR 320a (r=-0.44, 
p=0.0041, Pearson’s correlation) and miR 378a (r=-0.46, p=0.0031, Pearson’s correlation). A positive 
correlation was also found between miR 320a and blood glucose (r=0.38, p=0.024). On the other 
hand, a negative correlation was demonstrated between circulating miR 301a and BMI (r=-0.59, 
p<0.0001, Pearson’s correlation). A positive correlation was demonstrated between miR 301a and 
percentage of preoperative BMI lost (r=0.43, p=0.0057, Pearson correlation).  
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Figure ‎4.10: Third phase of the bariatric circulating microRNA response. 
Normalised logarithmic relative preoperative and postoperative expression of differentiated 
microRNAs. (A) miR 125ba, (B) miR 192, (C) miR 301a, (D) miR 320a and (E) miR 378a. Data 
represents mean ± standard error of mean. *p<0.05, **p<0.01 by Student’s t test. 
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4.5.5.4 Fourth phase 
The fourth circulating microRNA bariatric phase consisted of microRNAs whose significant 
deregulation didn’t manifest until 9 months following surgery but this deregulation not only 
persisted but was enhanced 12 month following surgery. Relative to preoperative levels circulating 
levels of miR 15a initially increased slightly 1.7 fold before gradually decreasing with each sequential 
post-bariatric timepoint. At 3 months following RYGB miR 15a decreased 2.4 fold and at 6 months 
following RYGB miR 15a decreased 2.22 fold. At 9 months following surgery miR 15a levels 
decreased significantly 6.52 fold and decreased further to 85 fold relative to preoperative levels 12 
months following bariatric surgery (Figure 4.11A, p=0.53, 0.2, 0.3, 0.013 and 0.019 respectively, 
Student’s t test). A similar trend was found with circulating levels if miR 22-5p, which increased 1.44 
fold 1 month following surgery but then decreased 1.56 fold 3 months following surgery, decreased 
1.96 fold 6 months following surgery, decreased significantly 5.35 fold and decreased significantly 
19.1 fold 12 months following surgery (Figure 4.11B, p=0.61, 0.4, 0.31, 0.018 and 0.0017 
respectively, Student’s t test). Circulating miR 629 also initially increased following bariatric surgery 
before a gradual and eventually significant decrease. At 1 month following surgery miR 629 blood 
levels increased 2.13 fold but then decreased 3.54 fold 3 months following surgery, decreased 2.53 
fold 6 months following surgery, decreased significantly 34.8 fold 9 months following surgery and 
decreased 30.3 fold 12 months following surgery (Figure 4.11C, p=0.44, 0.18, 0.29, 0.00061 and 
0.0015, Student’s t test). MiR 502 demonstrated a similar pattern. Circulating levels increased 1.33 
fold 1 month following RYGB then decreased 2.39 fold 3 months postoperatively, 3 fold 6 months 
postoperatively, significantly 5.75 fold 9 months postoperatively and 13.2 fold 12 months following 
surgery (Figure 4.11D, p=0.68, 0.13, 0.13, 0.038 and 0.0036 Student’s t test).  
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Although no correlations were found between circulating miR 15a and measured postoperative 
clinical outcomes, miR 22-5p circulating expression negatively correlated with percentage of 
preoperative BMI lost (r=-0.44, p=0.0042, Pearson’s correlation). Similarly negative correlation were 
found between circulating levels of miR 629 (r=-0.4, p=0.0032) and miR 502 (r=-0.33, p=0.04) and 
percentage of preoperative BMI lost. 
 
Figure ‎4.11: Fourth phase of the bariatric circulating microRNA response. 
Normalised logarithmic relative preoperative and postoperative expression of differentiated 
microRNAs. (A) miR 15a, (B) miR 22-5p, (C) miR 629 and (D) miR 502. Data represents mean ± 
standard error of mean. *p<0.05, **p<0.01, ***p<0.001 by Student’s t test. 
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4.5.5.5 Fifth phase 
The fifth phase was characterised by microRNAs that remained unchanged relative to preoperative 
levels at the first few timepoints following bariatric surgery but demonstrated significant decreases 
at 12 months following surgery. These include miR 130b which relative to preoperative levels 
demonstrated comparable expression at 1 month, 3 months, 6 months and 9 months following 
RYGB. However, at 12 months following surgery miR 130b levels decreased significantly 13.9 fold 
(Figure 4.12A, p=0.0055 Student’s t test). MiR 532-3p circulating levels remained stable at 1 month, 
3 months and 6 months following surgery. An insignificant 3.32 fold decrease was followed by a 
significant 16.7 fold decrease 12 months after RYGB (Figure 4.12B, p=0.081 and 0.007 respectively, 
Student’s t test). Similarly miR 339-6p levels were unchanged 1 month, 3 months and 6 months 
following surgery but decreased 4.3 fold 9 months postoperatively and significantly 12 fold 12 
months postoperatively (Figure 4.12C, p=0.084 and 0.016 respectively, Student’s t test). Circulating 
expression of miR 29a-5p also remained unchanged 1 month, 3 months and 6 months following 
RYGB. Levels decreased insignificantly 3.82 fold 9 months following surgery and decreased 
significantly 5.75 fold 12 months following RYGB (Figure 4.12D, p=0.066 and 0.01 respectively, 
Student’s t test). No correlations were observed between these 4 microRNAs and any of the 
measured postoperative clinical outcomes. 
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Figure ‎4.12: Fifth phase of the bariatric circulating microRNA response. 
Normalised logarithmic relative preoperative and postoperative expression of differentiated 
microRNAs. (A) miR 130b, (B) miR 532-3p, (C) miR 339-3p and (D) miR 29a-5p. Data represents mean 
± standard error of mean. *p<0.05, **p<0.01 by Student’s t test. 
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Table ‎4.5: Circulating microRNA expression correlated with bariatric clinical outcomesⱡ. 
Phase MicroRNA BMI % BMI lost Blood glucose 
r p  r p r p  
1 miR-338-3p -0.2318 0.15 0.07554 0.6432 0.1006 0.5653 
miR-93-5p 0.02307 0.8876 0.1185 0.4665 0.02092 0.9051 
2 miR-33a-5p -0.4107 0.0085 0.228 0.1572 0.07564 0.6658 
miR-27a-3p -0.0966 0.5533 0.07968 0.625 0.05217 0.766 
miR-590-5p 0.00154 0.9925 -0.2055 0.2033 0.4602 0.0054 
3 miR-301a-3p -0.5925 0.0001 0.4295 0.0057 0.1962 0.2587 
miR-125b-5p 0.3457 0.0289 -0.4235 0.0065 0.2246 0.1945 
miR-192-5p 0.2986 0.0613 -0.3929 0.0121 0.1238 0.4787 
miR-378a-3p 0.264 0.0997 -0.4564 0.0031 0.2314 0.1812 
miR-320a 0.2579 0.1081 -0.4439 0.0041 0.3817 0.0237 
4 miR-22-5p 0.2064 0.2013 -0.4428 0.0042 0.2581 0.1344 
miR-15a-5p 0.1907 0.2384 -0.3005 0.0595 0.1948 0.262 
miR-629-5p 0.1834 0.2572 -0.4548 0.0032 0.321 0.0601 
miR-502-3p 0.1458 0.3692 -0.3263 0.0399 0.2487 0.1497 
5 miR-532-5p 0.1111 0.4951 -0.1417 0.383 -0.1326 0.4476 
miR-29a-5p 0.0834 0.6089 -0.2452 0.1273 0.2563 0.1373 
miR-130b-3p 0.07258 0.6563 -0.2099 0.1937 -0.1307 0.4544 
miR-339-3p -0.0037 0.9818 -0.2411 0.1339 0.09719 0.5786 
ⱡPearson correlations. Correlations in red are statistically significant. 
 
4.5.6 Clinical correlations 
Correlations of the expression of microRNAs involved in the 5 post-bariatric phases and clinical 
outcomes can be found in Table 4.5. However, significant correlations were found between clinical 
parameters and microRNAs that were not classified into the 5 post-bariatric phases. A total of 16 
microRNAs significantly correlated with BMI, 23 significantly correlated with percentage 
preoperative BMI lost and 8 significantly correlated with blood glucose. All significant correlations 
are tabulated in Table 4.6 and all correlations are tabulated in Table 7.13 in the appendices.  
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Table ‎4.6: Significant Pearson correlation between circulating microRNA expression and measured 
clinical parameters.  
 BMI 
 
% Preoperative BMI lost  
MicroRNA r p Significance 
 
MicroRNA r p Significance 
miR-148a-3p 0.5195 0.0006 *** 
 
miR-99a-5p -0.4939 0.0012 ** 
miR-33a-5p -0.4107 0.0085 ** 
 
miR-148a-3p -0.4731 0.002 ** 
miR-148b-3p 0.4008 0.0104 * 
 
miR-378a-3p -0.4564 0.0031 ** 
miR-136-5p -0.3881 0.0133 * 
 
miR-629-5p -0.4548 0.0032 ** 
miR-191-5p -0.3831 0.0147 * 
 
miR-320a -0.4439 0.0041 ** 
miR-199a-5p -0.3812 0.0152 * 
 
miR-22-5p -0.4428 0.0042 ** 
let-7d-3p 0.3466 0.0285 * 
 
miR-301a-3p 0.4295 0.0057 ** 
miR-125b-5p 0.3457 0.0289 * 
 
let-7d-3p -0.4277 0.0059 ** 
miR-107 -0.3347 0.0348 * 
 
miR-125b-5p -0.4235 0.0065 ** 
miR-424-5p 0.3329 0.0358 * 
 
miR-365a-3p -0.4165 0.0075 ** 
miR-20a-5p -0.3319 0.0364 * 
 
let-7i-5p -0.4127 0.0081 ** 
miR-103a-3p -0.3231 0.042 * 
 
miR-374b-5p 0.4081 0.0089 ** 
miR-30d-5p 0.3203 0.0439 * 
 
miR-660-5p -0.4026 0.01 * 
miR-142-5p -0.32 0.0441 * 
 
miR-192-5p -0.3929 0.0121 * 
let-7i-5p 0.3165 0.0466 * 
 
miR-194-5p -0.369 0.0191 * 
miR-23b-3p -0.3159 0.0471 * 
 
miR-423-3p -0.3669 0.0199 * 
     
miR-148b-3p -0.3638 0.021 * 
Blood glucose 
 
miR-92a-3p -0.3394 0.0322 * 
MicroRNA r p Significance 
 
miR-32-5p -0.3308 0.0371 * 
let-7b-3p 0.4951 0.0025 ** 
 
miR-320b -0.3264 0.0399 * 
miR-590-5p 0.4602 0.0054 ** 
 
miR-502-3p -0.3263 0.0399 * 
miR-30a-5p 0.4038 0.0162 * 
 
miR-424-5p -0.3216 0.043 * 
miR-346 -0.3917 0.02 * 
 
miR-486-5p -0.3174 0.0459 * 
miR-320a 0.3817 0.0237 * 
     miR-1 0.3594 0.034 * 
     miR-133a 0.356 0.0358 * 
     miR-30c-5p 0.3467 0.0413 * 
     miR-320b 0.3355 0.0488 * 
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4.5.7 Pathway analysis 
Pathways predicted to be regulated following bariatric surgery were determined for each of the five 
post-bariatric response phases described by a combination of miRWalk and PANTHER and are 
summarised in Tables 4.7-4.11. Affected pathways were ranked by number of microRNAs involved 
and by statistical significance. The top 6 predicted pathways regulated by both microRNAs involved 
in the first phase were angiogenesis, p53 pathway, PDGF (platelet derived growth factor) signalling 
pathway, Integrin signalling pathway and the apoptosis signalling pathway. All are pathways involved 
in cellular growth and proliferation. In fact, pathways involved in cell growth and proliferation form 
the majority of the top rank predicted affected pathways across all 5 response phases. Other 
regulated pathways include the TGF-β signalling pathway, Wnt signalling pathway, interleukin 
signalling pathway and chemokine/cytokine signalling pathways, all processes commonly associated 
with inflammation. 
The top ranked pathway in the second phase was the gonadotropin releasing hormone receptor 
(GnRHR) pathway. In fact, the GnRHR pathway was found to be in the top 3 predicted affected 
pathways in the third, fourth and fifth phases, suggesting it has an important role in the post-
bariatric phenotype.   Despite not making the list of predicted pathways in the first, second or third 
phase, the Cholecystokinin receptor (CCKR) pathway was ranked 8th in the fourth phase and 7th in 
the fifth phase. The fourth and fifth phases were also predicted to activate β1 and β2 adrenergic 
receptor pathways. In addition, the later post-bariatric phases are predicted to regulate the cadherin 
signalling pathway. 
Activation of pathways involved in the neurological process were predicted across all post-bariatric 
phases, including the metabotropic glutamate receptor group III pathway, Alzheimer disease-
presenilin pathway, dopamine receptor mediated signalling pathway and the 5HT2 type receptor 
mediated signalling pathway.  
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Table ‎4.7: Regulated pathways in the first post-bariatric phase. 
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Table ‎4.8: Regulated pathways in the second post-bariatric phase. 
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Table ‎4.9: Regulated pathways in the third post-bariatric phase. 
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Table ‎4.10: Regulated pathways in the fourth post-bariatric phase. 
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Table ‎4.11: Regulated pathways in the fifth post-bariatric phase. 
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4.6 Discussion 
The pathways predicted here to be regulated following RYGB include those involved in cell growth, 
inflammation and neurological processes, and at the later phases receptor pathways involved in gut 
hormone signalling, lipolysis and diabetic nephropathy. The link between inflammation and obesity 
is well established [288], and bariatric surgery alters transcription factors and microRNA profiles in 
adipose tissues [289, 290]. An obesity role in neurodegenerative disorders is also being increasingly 
recognised, as the metabolic syndrome contributes mechanistically to both Alzheimer’s and 
Parkinson’s diseases [291].   
The GnRHR pathway was consistently one of the top predicted regulated pathways across the later 
bariatric microRNA phases. The GnRHR is a G-protein coupled receptor responsible for the release of 
gonadotropic luteinizing hormone (LH) and follicle stimulating hormone (FSH) and is therefore a key 
regulator of fertility [292]. Hyperinsulinemia resulting from obesity disrupts fertility through GnRH 
signalling [293]. Hypogonadism is common in morbidly obese males and this is reversed after 
bariatric surgery [294, 295], which may explain the activation of the GnRHR pathway and suggests 
the involvement of microRNAs in this process. MicroRNAs are essential for the proper gonadal 
function as the Gonadotrope-specific deletion of Dicer suppresses the release of gonadotropic 
hormones and impairs fertility [296].   
The later bariatric phases were also predicted to regulate the β-adrenergic receptor pathways 
through miR 15a and miR 532. The β adrenergic receptors are a family of G protein coupled 
receptors that are key regulators of adipocyte lipid metabolism. Activation of the β2 adrenergic 
receptor stimulates lipolysis and the release of insulin [297]. Polymorphism in the β2 adrenergic 
receptor gene is common in obesity [298]. The β2 adrenergic receptor also modulates preprandial, 
postprandial and total energy expenditure [299]. MiR 532 is also predicted to regulate the β1 
adrenergic receptor pathway, which promotes the secretion of ghrelin in the stomach when 
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activated [300]. The third bariatric phase is also predicted to regulate the cadherin signalling 
pathway through miR 192, which as described in the previous chapter has a central role in diabetic 
nephropathy [178]. 
Despite not making an appearance as the predicted affected pathways in the first three phases, the 
Cholecystokinin receptor pathway was ranked 8th in the fourth phase and 7th in the fifth phase. CCK 
is a gut hormone released after a meal in response to dietary fat and protein and acts on CCK 
receptors in the gastrointestinal tract and the central nervous system to inhibit gastric emptying and 
food intake and promote gallbladder contraction [301, 302]. CCK also regulates glucose homeostasis 
by promoting pancreatic glucagon release and pancreatic β cell differentiation [303]. In addition, 
CCK also stimulates the release of PYY [304] and suppresses the release of ghrelin [305]. The 
administration of exogenous CCK upregulates the Peptide YY type 2 receptor [306] and the appetite 
suppression neuropeptide transmitter cocaine and amphetamine regulated transcript (CART) [307] 
and inhibits synthesis of orexigenic neuropeptide transmitter melanin-concentrating hormone 
(MCH) and its receptor [307, 308]. CCK function is also modulated by leptin and insulin [309, 310]. 
Together this suggests CCK is a key master regulator of the vagal gut-brain satiety signalling axis. 
Although high fat diets and obesity impairs CCK sensitivity and decreases its satiating effects [311-
313], the bariatric role of CCK was initially largely dismissed [314, 315]. However, recently studies 
have demonstrated that RYGB increases the postprandial release of CCK within 2 weeks 
postoperatively [316] and this increase is maintained over 16 months following surgery [317]. Sleeve 
gastrectomy also increases postprandial CCK [318]. It has also been shown that RYGB passively 
increases the number of CCK releasing enteroendocrine cells in the Roux-limb but not the 
biliopancreatic limb [319]. This is consistent with the findings presented here that the CKK signalling 
pathway is regulated in the later bariatric phases by miR 22 and miR 130b, and suggests a microRNA 
role in the gut hormone modulated post-bariatric control of satiety and improved glucose 
homeostasis.  
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The benefits of bariatric surgery are plentiful and the mechanisms behind them are complex, multi-
factorial, synergistic and enhanced with time. This is reflected in the bariatric microRNA profiles and 
the diverse array of pathways microRNAs are predicted to activate following RYGB. Here, it has been 
shown for the first time that bariatric surgery persistently and increasingly modulates circulating 
microRNAs with time so that there’s an increasing departure in sequential postoperative profiles 
from the preoperative stage. In total, RYGB led to the differentiated expression of 49 circulating 
microRNAs across 5 post-bariatric phases characterised by the selective, time-dependent 
differentiation of specific circulating microRNAs and the predicted activation of pathways and 
physiological processes associated with obesity and T2DM. As such, circulating microRNAs are not 
only novel, minimally invasive biomarkers for bariatric surgery, they can also map the post-bariatric 
response and the development of the beneficial post-bariatric phenotype, activating specific 
pathways at different post-bariatric phases that may contribute to the establishment of the post-
bariatric phenotype (Figure 4.13).  
 
Figure ‎4.13: The post-bariatric circulating microRNA response in five phases.   
Each line represents a microRNA. 
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A recently published study from our lab described circulating microRNA profiles in rat bariatric 
profiles and also concluded that altered gut-brain signalling established following bariatric surgery is 
mediated by microRNAs.  Wu et al. found the differentiated expression of 14 circulating microRNAs 
in RYGB-operated Spreague Dawley rats compared to sham-operated rats, the predominant of which 
was miR 122 which decreased almost 60 fold [214]. MiR 122 is a liver microRNA responsible for 
regulating lipid metabolism [172]. Wu et al. demonstrated that diminished miR 122 was responsible 
for increase glucose transportation, accelerated glycolysis and the inhibition of gluconeogenesis 
following RYGB in rats [214]. This is supportive of the recent discovery that RYGB reprograms 
intestinal glucose metabolism by increasing glycolysis and glucose uptake [119], and suggests miR 
122 could contribute to this effect. This study also found a consistent decrease in circulating miR 122 
in humans following RYGB from 3 months onwards, although this was not statistically significant 
(Table 7.12, appendices). However, significant decreases in circulating levels of miR 93, miR 30e and 
miR 320 following RYGB were found both here and in Wu et al.  
To our knowledge the only other study assessing post-bariatric circulating  microRNAs was published 
in 2013 by Ortega and colleagues assessing 6 morbidly obese patients (3 men and 3 women) before 
and 12 months after RYGB [208]. They reported a significant modulation of 14 circulating microRNAs 
12 months following RYGB, including a decrease in miR 122. Both Ortega et al. and this study found 
significant decreases in miR 125b and miR 16. Ortega et al. also reported increased circulating miR 
221 expression, which in this study was consistently increased albeit not significantly across all post-
operative timepoints (Table 7.12, appendices). However, Ortega et al. reported significant increases 
in the circulating levels of miR 130b and miR 21. Both microRNAs were significantly decreased in this 
study 12 months following RYGB. Ortega et al. were also unable to detect a change in miR 15a 
following surgery. In contrast, in this study miR 15a decreased almost 85 fold 12 months following 
RYGB, the most of any detected microRNA.  
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Many of the circulating microRNAs found here to be deregulated by RYGB have also been reported 
as circulating biomarkers of T2DM, including of miR 15a, miR 192, miR 130b and miR 125b [207, 210, 
320]. The loss of circulating miR 126 in particular is reportedly a strong selector T2DM [320]. MiR 126 
increased over 10 fold in each of the first 4 post-bariatric time points relative to preoperative levels, 
although none of the increases were statistically significant (Table 7.12, appendices). Blood glucose 
levels positivity correlated with circulating miR 320a, consistent with previous findings [207] and 
supporting its candidacy as a novel diabetic biomarker. In total, circulating levels of 9 microRNAs 
significantly correlated with blood glucose levels. It is important to note that of the 9 patients in this 
study only 2 were diabetic preoperatively. A larger, multi-centre, follow-up study with a bigger 
diabetic subset and more robust clinical endpoints are needed for the future development of this 
field. 
MicroRNA profiles are rich in biological information as physiological responses and the mechanism 
behind them can be captured in the expression of the handful of microRNAs that regulate them. As 
such the deregulation of circulating microRNAs by bariatric surgery provides fresh mechanistic 
insights behind these procedures. MicroRNA can act as mediators or effectors in positive and 
negative feedback loops in wider regulation networks, but their precise function in circulation is still 
being debated. The presence of circulating microRNAs in exosomes and high-density lipoprotein 
complexes that can be taken up in the active form by recipient cells is suggestive of a potential 
tissue-to-tissue communicative role [203, 204] and that microRNAs have hormonal as well as 
biomarker potential [321]. Mechanistic in vitro studies and experimental validation of predicted 
microRNA targets are required to determine the exact role each differentiated microRNA plays 
following bariatric surgery. However, although the field is still in its infancy, bariatric surgery has 
been shown consistently to significantly alter circulating microRNA levels. Here, the deregulation of 
specific microRNAs at different post-bariatric phases leads to the time-dependent activation of 
obesity-associated pathways which may contribute to the beneficial effects of bariatric surgery. 
149 
 
5 Discussion 
The underlying hypothesis of this thesis was that microRNAs are biomarkers of the beneficial effects 
of bariatric surgery. To this effect studies were designed and detailed in the preceding chapters that 
demonstrated the following: 
1 After optimising a protocol to measure and normalise microRNA levels in urine and 
circulation, an obesity urinary and circulating microRNA baseline was established. Circulating 
levels of miR 22-5p and miR 145-5p, regulators of cancer and lipolysis respectively, both 
correlated with BMI were identified as potential biomarkers of obesity. 
2 Bariatric surgery increased urinary levels of miR 192, miR 200a and miR 200b, regardless of 
operative procedure or diabetes status. All three microRNAs are expressed in the kidney and 
protect against fibrosis and diabetic nephropathy. Transfection of miR 192 into a kidney cell 
line inhibits ZEB2, a key transcriptional promoter of kidney fibrosis. 
3 RYGB profoundly modulates circulating microRNA levels and produces distinct bariatric 
microRNA profiles that display increasing variation from the preoperative profile with time. 
Significant correlations were found between circulating microRNA expression and BMI, 
percentage of preoperative BMI lost and blood glucose. Post-bariatric phases are 
characterised by the selective differentiation of specific microRNAs and the accompanied 
activation of anti-obesity pathways including those that promote gut-hormone signalling and 
lipolysis.  
 
 
 
 
150 
 
MicroRNAs are a relatively new but an exceptionally exciting and fast moving area of gene regulation 
research. Over the past decade the role of microRNAs as important regulators of physiological 
processes in both health and disease has been increasingly recognised. Understanding changes in 
the expression patterns of this complex, wide-ranging network of post-transcriptional regulators is a 
key to understanding the processes behind physiological changes, such as those produced by 
bariatric surgery. Bariatric surgery has a number of beneficial effects on health beyond weight-loss, 
including the resolution of type 2 diabetes, improved cardiovascular health, improved kidney 
function and reduction in cancer risk. As outlined in the introduction the mechanisms by which these 
improvements of health are achieved are complex, multi-factorial and synchronistical. They include 
the suppression of appetite, modulation of gut hormone secretion, improved glucose management 
and increased energy expenditure. 
The results outlined in this thesis demonstrate that both obesity and bariatric surgery deregulate 
microRNA expression in biofluids and that these microRNAs are involved in regulating pathways that 
are associated with obesity, the metabolic syndrome and the development of the beneficial post-
bariatric phenotype. Bariatric surgery deregulates microRNAs that regulate pathways involved in 
kidney fibrosis, glucose homeostasis, gut hormone signalling and adipocyte lipolysis (Figure 5.1). This 
suggests that urinary and circulating microRNAs not only represent novel, minimally invasive 
biomarkers of health, they are potential post-bariatric biological effectors and can offer fresh 
mechanistic insights into the mechanisms behind bariatric surgery. 
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Figure ‎5.1: A summary of the main findings of this thesis. 
Circulating microRNA changes are boxed in pink. Urinary microRNA changes are boxed in yellow. 
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One question that arises from this thesis is whether bariatric surgery shifts microRNA expression 
from an obesity state to levels similar to or approaching a healthy state, as the urinary miR 192 data 
suggests, or whether bariatric surgery produces microRNA expression profiles unique to bariatric 
patients. Bariatric surgery is often called metabolic surgery due to its profound health benefits 
beyond weight-loss and has also been suggested as a possible autobionic therapy, enhancing 
physiological function beyond normality [322]. Although the obesity microRNA baseline established 
in Chapter 2 demonstrated decreased levels of miR 22-5p and miR 145, miR 145 was unchanged 
following bariatric surgery and miR 22-5p decreased significantly at 9 months and 12 months 
following RYGB, forming part of the fourth post-bariatric phase. Similarly, Ortega et al. reported 
decreased miR 125b levels both in obesity and 12 months following RYGB [208] (here miR 125b 
remained unchanged with obesity but decreased at 6, 9 and 12 months following RYGB). As such 
subsequent profiling studies should include a healthy control group with a normal BMI. 
There is increasing evidence to suggest microRNAs help to maintain system robustness, fine-tuning 
or ‘buffering’ gene expression in response to subtle internal or external stimuli [323]. Interestingly, 
as illustrated by the PCA scores plot of circulating microRNA profiles (Figure 3.7), at 1 month 
following RYGB the microRNA circulating profile shifts one way from the preoperative profile, before 
a pronounced and gradual shift in the opposite direction from 3 months onwards. A possible 
explanation is that the initial physiological response to bariatric surgery was to maintain the 
morbidly obese status quo which was reflected in the overall microRNA circulating profile. However, 
once a tipping point has been reached this homeostatic safety mechanism was overridden, placing 
the individual on the path to the post-bariatric phenotype. The early post-bariatric months 
demonstrated the fewest differentiated microRNAs, but the number of differentiated microRNAs 
increased with each passing month as the individual moved further physiologically and 
phenotypically from the morbidly obese state. 
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To date only one other study has attempted to assess the role of microRNAs in bariatric surgery 
[208]. Therefore, the findings presented here need to be confirmed in larger, prospective, 
randomised studies across international bariatric centres with a greater number of subgroups 
covering different bariatric procedures and obesity co-morbidities. Only a small number of patients 
in the studies outlined here were diabetic preoperatively and none presented with kidney 
dysfunction. Longer post-bariatric follow-ups and more robust clinical endpoints are required to 
affirm the bariatric biomarker and diagnostic potential of microRNAs. 
MicroRNA targets and regulated pathways were largely predicted computationally through 
bioinformatics. Experimental mechanistic studies are required to validate these predictions, such as 
the gain or loss-of-function in vitro manipulation of microRNA used in Chapter 3. However, bariatric 
surgery altered the expression of a swathe of circulating microRNA, suggesting the post-bariatric 
microRNA response is holistic and not characterised by specific microRNAs. Of the 159 circulating 
microRNAs that passed the profiling detection threshold, 49 were differentially expressed in at least 
one timepoint following RYGB. That’s over 30% of all assessed microRNAs, many of which shared not 
only regulatory pathways but specific mRNA targets, suggesting they function synergistically in a 
large, complex network. This concept is reflected in individual microRNA gene knockout studies that 
have show no significant changes in phenotype [324]. Focusing on individual or a few microRNAs 
may aid in the development of novel drug targets and diagnostic or prognostic biomarkers, however.   
The question of whether urinary and circulating microRNAs are simply biomarkers of bariatric 
surgery or are causative players remains. As has been mentioned previously, there is evidence that 
extracellular microRNAs are packaged in membrane-covered exosomes or are present in complexes 
with high-density lipoproteins or argonaute protein, protecting them from ribonuclease degradation, 
and circulating miRNAs can be taken up in active form by recipient cells, suggesting a potential 
hormonal tissue-to-tissue communicative role [202-204]. One possible method to answer this 
question is to knock-out Dicer in rodent bariatric models, assessing whether this inhibits the 
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beneficial effects of bariatric surgery. Dicer-deficient mice have been used to demonstrate the 
essential roles of microRNA in angiogenesis, stem cell development and renal function. [140, 258-
260, 325]. In humans, microRNA profiles could be determined in liver and adipose tissues obtained 
intraoperatively and through postoperative biopsies.  
A PCR profiling platform that covered 179 microRNAs that are routinely found in circulation [276] 
was selected to profile circulating microRNAs. However, great strides have been made recently to 
improve the applicability and sensitivity of next generation profiling platforms and plasma/serum 
microRNA deep sequencing is now possible with as little as 500µl starting volume [326]. Urinary 
microRNA can also be deep sequenced but requires 20ml starting volume of urine [327]. Deep 
sequencing is high throughput and can detect novel microRNAs [193] and would provide a more 
comprehensive picture of the bariatric microRNA profile.  
5.1 Conclusion 
In conclusion, this thesis has demonstrated that microRNAs can act as biomarkers and are possible 
mediators of the beneficial bariatric effects, potentially contributing to the epigenetic development 
of the post-bariatric phenotype. Further development of this young field could eventually lead to the 
use of microRNAs as diagnostic tools, aiding in selecting patients for bariatric surgery and monitoring 
operative outcomes. Understanding the nature of their differential expression following bariatric 
surgery will help uncover the regulatory processes behind the mechanisms by which the beneficial 
effects of bariatric surgery are achieved, including potentially mechanisms previously unrecognised. 
Reverse engineering bariatric surgery will help improve bariatric procedures, accentuating and 
optimising their benefits and may lead to the development of a successful knifeless metabolic 
therapy for obesity and its many co-morbidites, encompassing all the benefits of bariatric surgery 
without the surgery itself. This possibility has been demonstrated recently by the transfer of gut 
microbiota from RYGB-treated mice to nonoperated, germ free mice, leading to weight loss and 
decreased fat mass [133]. 
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7 Appendices 
 
Tables 7.1-7.11 are Pearson correlations between circulating and urinary microRNA expressions 
measured in an obese cohort described in Chapter 2 and blood biochemistry markers.  
Table 7.12 tabulates mean fold changes in post-bariatric circulating microRNA expressions relative to 
mean preoperative levels. Table 7.13 tabulates Pearson correlations between circulating microRNA 
expressions in a bariatric cohort described in chapter 4 and measured clinical outcomes.  
Red signifies statistical significance. Fold change statistical significance was determined by Student’s 
t-tests.  
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Table ‎7.1: Serum miR 15a Pearson correlations with blood biochemistry markers. 
  miR 15a 
Clinical Parameter  r p p significance 
BMI (kg/m2) -0.2024 0.1725 ns 
Weight (kg) -0.2386 0.1063 ns 
Fasting Glucose (mmol/L) -0.08298 0.6516 ns 
Insulin (µIU/mL) -0.2441 0.1711 ns 
CRP (mg/L) -0.2625 0.1611 ns 
Hb (g/L) 0.09144 0.6187 ns 
WCC (x10^9/L) -0.1908 0.2955 ns 
Platelet Count (x10^9/L) -0.141 0.4415 ns 
Sodium (mmol/L) 0.3114 0.0828 ns 
Potassium (mmol/L) -0.07898 0.6674 ns 
Chloride (mmol/L) 0.06262 0.7335 ns 
BiCarb (mmol/L) 0.03555 0.8468 ns 
Urea (mmol/L) -0.1723 0.3458 ns 
Creatinine (umol/L) 0.01132 0.951 ns 
eGFR (mL/min) -0.1591 0.5283 ns 
Calcium (mmol/L) -0.0258 0.8885 ns 
Phospate (mmol/L) -0.1034 0.5735 ns 
Bilirubin (umol/L) 0.09269 0.6139 ns 
Alk Phos (iu/L) -0.198 0.2774 ns 
Albumin (g/L) -0.011 0.9524 ns 
Total protein (g/L) -0.1936 0.2884 ns 
Cholestrol (mmol/l) 0.02108 0.9088 ns 
Triglycerides (mmol/l) -0.0994 0.5883 ns 
HDL (mmol/l) 0.09526 0.604 ns 
LDL (mmol/L) 0.03185 0.8626 ns 
L-Tyr (µM) -0.261 0.1562 ns 
L-Phe (µM) -0.06536 0.7269 ns 
L-Phe : L-Tyr Ratio 0.2925 0.1103 ns 
GLP-1 (pM) -0.2192 0.2445 ns 
GIP (pg/mL) -0.0783 0.6809 ns 
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Table ‎7.2: Serum miR 22-5p Pearson correlations with blood biochemistry markers. 
  miR 22-5p 
Clinical Parameter  r p p significance 
BMI (kg/m2) -0.4085 0.0109 * 
Weight (kg) -0.4596 0.0037 ** 
Fasting Glucose (mmol/L) -0.2417 0.2444 ns 
Insulin (µIU/mL) -0.2628 0.1945 ns 
CRP (mg/L) -0.3046 0.1478 ns 
Hb (g/L) 0.08977 0.6696 ns 
WCC (x10^9/L) -0.06112 0.7717 ns 
Platelet Count (x10^9/L) 0.0229 0.9135 ns 
Sodium (mmol/L) 0.1137 0.5883 ns 
Potassium (mmol/L) -0.005556 0.979 ns 
Chloride (mmol/L) 0.09567 0.6492 ns 
BiCarb (mmol/L) 0.02642 0.9002 ns 
Urea (mmol/L) -0.124 0.5549 ns 
Creatinine (umol/L) -0.0445 0.8327 ns 
eGFR (mL/min) -0.08625 0.7794 ns 
Calcium (mmol/L) -0.11 0.6008 ns 
Phospate (mmol/L) 0.1517 0.4691 ns 
Bilirubin (umol/L) 0.02286 0.9136 ns 
Alk Phos (iu/L) -0.2131 0.3064 ns 
Albumin (g/L) -0.02086 0.9212 ns 
Total protein (g/L) 0.0188 0.9289 ns 
Cholestrol (mmol/l) 0.1268 0.537 ns 
Triglycerides (mmol/l) -0.361 0.07 ns 
HDL (mmol/l) 0.1096 0.5939 ns 
LDL (mmol/L) 0.3005 0.1359 ns 
L-Tyr (µM) -0.206 0.3232 ns 
L-Phe (µM) 0.0681 0.7464 ns 
L-Phe : L-Tyr Ratio 0.3882 0.0551 ns 
GLP-1 (pM) -0.2581 0.2234 ns 
GIP (pg/mL) -0.1686 0.431 ns 
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Table ‎7.3: Serum miR 122 Pearson correlations with blood biochemistry markers. 
  miR 122 
Clinical Parameter  r p p significance 
BMI (kg/m2) -0.1912 0.1979 ns 
Weight (kg) -0.2195 0.1383 ns 
Fasting Glucose (mmol/L) 0.3804 0.0317 * 
Insulin (µIU/mL) -0.03652 0.8401 ns 
CRP (mg/L) 0.1043 0.5833 ns 
Hb (g/L) 0.1209 0.5098 ns 
WCC (x10^9/L) 0.02181 0.9057 ns 
Platelet Count (x10^9/L) 0.1244 0.4975 ns 
Sodium (mmol/L) 0.2456 0.1754 ns 
Potassium (mmol/L) -0.1116 0.5431 ns 
Chloride (mmol/L) -0.1163 0.526 ns 
BiCarb (mmol/L) 0.1195 0.5148 ns 
Urea (mmol/L) -0.2858 0.1128 ns 
Creatinine (umol/L) -0.03351 0.8555 ns 
eGFR (mL/min) 0.3849 0.1148 ns 
Calcium (mmol/L) 0.1213 0.5085 ns 
Phospate (mmol/L) -0.03198 0.862 ns 
Bilirubin (umol/L) 0.4235 0.0157 * 
Alk Phos (iu/L) 0.1663 0.363 ns 
Albumin (g/L) 0.2297 0.2061 ns 
Total protein (g/L) 0.175 0.3381 ns 
Cholestrol (mmol/l) 0.2357 0.1941 ns 
Triglycerides (mmol/l) 0.4153 0.0181 * 
HDL (mmol/l) -0.1766 0.3337 ns 
LDL (mmol/L) 0.1496 0.4138 ns 
L-Tyr (µM) 0.01483 0.9369 ns 
L-Phe (µM) 0.08123 0.664 ns 
L-Phe : L-Tyr Ratio -0.01044 0.9556 ns 
GLP-1 (pM) 0.1879 0.3202 ns 
GIP (pg/mL) 0.08403 0.6589 ns 
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Table ‎7.4: Serum miR 125b Pearson correlations with blood biochemistry markers. 
  miR 125b 
Clinical Parameter  r p p significance 
BMI (kg/m2) -0.1692 0.2665 ns 
Weight (kg) -0.2252 0.1369 ns 
Fasting Glucose (mmol/L) -0.1745 0.3477 ns 
Insulin (µIU/mL) -0.1955 0.2835 ns 
CRP (mg/L) -0.1848 0.3372 ns 
Hb (g/L) 0.06376 0.7333 ns 
WCC (x10^9/L) -0.167 0.3691 ns 
Platelet Count (x10^9/L) 0.0001546 0.9993 ns 
Sodium (mmol/L) 0.1044 0.5763 ns 
Potassium (mmol/L) -0.1026 0.5827 ns 
Chloride (mmol/L) 0.05065 0.7867 ns 
BiCarb (mmol/L) -0.1523 0.4135 ns 
Urea (mmol/L) -0.1719 0.355 ns 
Creatinine (umol/L) -0.1591 0.3926 ns 
eGFR (mL/min) -0.1571 0.547 ns 
Calcium (mmol/L) 0.05488 0.7694 ns 
Phospate (mmol/L) -0.06099 0.7445 ns 
Bilirubin (umol/L) 0.0251 0.8934 ns 
Alk Phos (iu/L) -0.07366 0.6937 ns 
Albumin (g/L) 0.1369 0.4627 ns 
Total protein (g/L) 0.1404 0.4513 ns 
Cholestrol (mmol/l) 0.2864 0.1183 ns 
Triglycerides (mmol/l) -0.05043 0.7876 ns 
HDL (mmol/l) 0.1569 0.3992 ns 
LDL (mmol/L) 0.3025 0.0981 ns 
L-Tyr (µM) -0.08076 0.6658 ns 
L-Phe (µM) -0.04568 0.8072 ns 
L-Phe : L-Tyr Ratio 0.1539 0.4085 ns 
GLP-1 (pM) 0.07855 0.6799 ns 
GIP (pg/mL) -0.05084 0.7896 ns 
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Table ‎7.5: Serum miR 142-3p Pearson correlations with blood biochemistry markers. 
  miR 142-3p 
Clinical Parameter  r p p significance 
BMI (kg/m2) -0.2509 0.089 ns 
Weight (kg) -0.312 0.0328 * 
Fasting Glucose (mmol/L) -0.1752 0.3375 ns 
Insulin (µIU/mL) -0.2135 0.2328 ns 
CRP (mg/L) -0.2767 0.1388 ns 
Hb (g/L) 0.01486 0.9357 ns 
WCC (x10^9/L) -0.167 0.3611 ns 
Platelet Count (x10^9/L) -0.007512 0.9675 ns 
Sodium (mmol/L) 0.3729 0.0356 * 
Potassium (mmol/L) -0.04443 0.8092 ns 
Chloride (mmol/L) 0.1775 0.3311 ns 
BiCarb (mmol/L) -0.001698 0.9926 ns 
Urea (mmol/L) -0.2127 0.2425 ns 
Creatinine (umol/L) -0.03333 0.8563 ns 
eGFR (mL/min) -0.1524 0.546 ns 
Calcium (mmol/L) -0.03377 0.8544 ns 
Phospate (mmol/L) 0.1346 0.4626 ns 
Bilirubin (umol/L) 0.09447 0.6071 ns 
Alk Phos (iu/L) -0.09721 0.5966 ns 
Albumin (g/L) -0.1377 0.4524 ns 
Total protein (g/L) -0.1974 0.2788 ns 
Cholestrol (mmol/l) 0.1282 0.4845 ns 
Triglycerides (mmol/l) -0.1356 0.4592 ns 
HDL (mmol/l) 0.1208 0.5101 ns 
LDL (mmol/L) 0.1724 0.3454 ns 
L-Tyr (µM) -0.2206 0.233 ns 
L-Phe (µM) -0.034 0.8559 ns 
L-Phe : L-Tyr Ratio 0.243 0.1878 ns 
GLP-1 (pM) -0.3332 0.072 ns 
GIP (pg/mL) -0.1256 0.5085 ns 
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Table ‎7.6: Serum miR 145-5p Pearson correlations with blood biochemistry markers. 
  miR 145-5p 
Clinical Parameter  r p p significance 
BMI (kg/m2) -0.3277 0.028 * 
Weight (kg) -0.373 0.0116 * 
Fasting Glucose (mmol/L) -0.1974 0.2872 ns 
Insulin (µIU/mL) -0.2244 0.217 ns 
CRP (mg/L) -0.3087 0.1033 ns 
Hb (g/L) -0.1896 0.3069 ns 
WCC (x10^9/L) -0.1865 0.315 ns 
Platelet Count (x10^9/L) 0.04471 0.8113 ns 
Sodium (mmol/L) -0.04803 0.7975 ns 
Potassium (mmol/L) -0.1516 0.4157 ns 
Chloride (mmol/L) -0.001392 0.9941 ns 
BiCarb (mmol/L) -0.05184 0.7818 ns 
Urea (mmol/L) -0.05991 0.7489 ns 
Creatinine (umol/L) -0.05129 0.7841 ns 
eGFR (mL/min) -0.3704 0.1433 ns 
Calcium (mmol/L) -0.1185 0.5256 ns 
Phospate (mmol/L) 0.06655 0.7221 ns 
Bilirubin (umol/L) -0.09866 0.5975 ns 
Alk Phos (iu/L) -0.1672 0.3687 ns 
Albumin (g/L) 0.04768 0.799 ns 
Total protein (g/L) -0.03342 0.8583 ns 
Cholestrol (mmol/l) 0.1609 0.3871 ns 
Triglycerides (mmol/l) -0.3049 0.0954 ns 
HDL (mmol/l) 0.4175 0.0194 * 
LDL (mmol/L) 0.1453 0.4354 ns 
L-Tyr (µM) -0.3098 0.0898 ns 
L-Phe (µM) -0.1571 0.3987 ns 
L-Phe : L-Tyr Ratio 0.3723 0.0392 * 
GLP-1 (pM) -0.1755 0.3535 ns 
GIP (pg/mL) -0.2536 0.1763 ns 
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Table ‎7.7: Serum miR 192 Pearson correlations with blood biochemistry markers. 
 miR 192 
Clinical Parameter  r p p significance 
BMI (kg/m2) -0.2565 0.1712 ns 
Weight (kg) -0.3984 0.0292 * 
Fasting Glucose (mmol/L) 0.2448 0.2849 ns 
Insulin (µIU/mL) -0.2271 0.3221 ns 
CRP (mg/L) -0.01676 0.9474 ns 
Hb (g/L) -0.07402 0.7498 ns 
WCC (x10^9/L) 0.106 0.6474 ns 
Platelet Count (x10^9/L) 0.274 0.2293 ns 
Sodium (mmol/L) 0.263 0.2493 ns 
Potassium (mmol/L) 0.003236 0.9889 ns 
Chloride (mmol/L) -0.316 0.1628 ns 
BiCarb (mmol/L) 0.1636 0.4785 ns 
Urea (mmol/L) -0.2298 0.3163 ns 
Creatinine (umol/L) 0.1293 0.5764 ns 
eGFR (mL/min) -0.0745 0.8277 ns 
Calcium (mmol/L) 0.2929 0.1976 ns 
Phospate (mmol/L) 0.1242 0.5917 ns 
Bilirubin (umol/L) 0.4465 0.0425 * 
Alk Phos (iu/L) 0.1619 0.4832 ns 
Albumin (g/L) 0.2285 0.3191 ns 
Total protein (g/L) 0.04143 0.8585 ns 
Cholestrol (mmol/l) 0.2763 0.2383 ns 
Triglycerides (mmol/l) 0.3526 0.1273 ns 
HDL (mmol/l) -0.003744 0.9875 ns 
LDL (mmol/L) 0.1001 0.6747 ns 
L-Tyr (µM) -0.3321 0.1526 ns 
L-Phe (µM) -0.2452 0.2975 ns 
L-Phe : L-Tyr Ratio 0.1857 0.4331 ns 
GLP-1 (pM) 0.167 0.4944 ns 
GIP (pg/mL) 0.0255 0.9175 ns 
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Table ‎7.8: Serum miR 221 Pearson correlations with blood biochemistry markers. 
 miR 221 
Clinical Parameter  r p p significance 
BMI (kg/m2) 0.169 0.256 ns 
Weight (kg) 0.1496 0.3156 ns 
Fasting Glucose (mmol/L) -0.1075 0.5582 ns 
Insulin (µIU/mL) -0.1821 0.3105 ns 
CRP (mg/L) 0.0436 0.819 ns 
Hb (g/L) 0.2373 0.191 ns 
WCC (x10^9/L) -0.03578 0.8459 ns 
Platelet Count (x10^9/L) -0.1816 0.32 ns 
Sodium (mmol/L) 0.2635 0.145 ns 
Potassium (mmol/L) 0.1623 0.3749 ns 
Chloride (mmol/L) 0.2807 0.1196 ns 
BiCarb (mmol/L) -0.5822 0.0005 *** 
Urea (mmol/L) 0.007609 0.967 ns 
Creatinine (umol/L) 0.2576 0.1546 ns 
eGFR (mL/min) -0.3238 0.1899 ns 
Calcium (mmol/L) 0.2665 0.1404 ns 
Phospate (mmol/L) -0.1071 0.5597 ns 
Bilirubin (umol/L) 0.09852 0.5917 ns 
Alk Phos (iu/L) 0.0023 0.99 ns 
Albumin (g/L) 0.1049 0.5677 ns 
Total protein (g/L) 0.05587 0.7614 ns 
Cholestrol (mmol/l) -0.006004 0.974 ns 
Triglycerides (mmol/l) 0.3474 0.0514 ns 
HDL (mmol/l) -0.1577 0.3886 ns 
LDL (mmol/L) -0.1233 0.5015 ns 
L-Tyr (µM) -0.2097 0.2575 ns 
L-Phe (µM) -0.1684 0.3653 ns 
L-Phe : L-Tyr Ratio 0.1183 0.5262 ns 
GLP-1 (pM) -0.121 0.524 ns 
GIP (pg/mL) -0.02148 0.9103 ns 
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Table ‎7.9: Urine miR 192 Pearson correlations with blood biochemistry markers. 
 miR 192 
Clinical Parameter  r p p significance 
BMI (kg/m2) -0.2307 0.1274 ns 
Weight (kg) -0.285 0.0577 ns 
Fasting Glucose (mmol/L) -0.05647 0.7629 ns 
Insulin (µIU/mL) -0.222 0.2219 ns 
CRP (mg/L) 0.2087 0.2772 ns 
Hb (g/L) -0.3424 0.0594 ns 
WCC (x10^9/L) 0.1575 0.3974 ns 
Platelet Count (x10^9/L) 0.1069 0.567 ns 
Sodium (mmol/L) -0.1126 0.5465 ns 
Potassium (mmol/L) -0.3078 0.0921 ns 
Chloride (mmol/L) -0.001099 0.9953 ns 
BiCarb (mmol/L) -0.01878 0.9201 ns 
Urea (mmol/L) -0.4491 0.0113 * 
Creatinine (umol/L) -0.2623 0.154 ns 
eGFR (mL/min) 0.299 0.2436 ns 
Calcium (mmol/L) -0.1057 0.5714 ns 
Phospate (mmol/L) 0.169 0.3634 ns 
Bilirubin (umol/L) -0.1206 0.5182 ns 
Alk Phos (iu/L) -0.117 0.5308 ns 
Albumin (g/L) -0.1624 0.3829 ns 
Total protein (g/L) -0.2245 0.2248 ns 
Cholestrol (mmol/l) -0.07378 0.6933 ns 
Triglycerides (mmol/l) -0.2108 0.2551 ns 
HDL (mmol/l) 0.2303 0.2126 ns 
LDL (mmol/L) -0.1144 0.5401 ns 
L-Tyr (µM) -0.2018 0.2849 ns 
L-Phe (µM) -0.02369 0.9011 ns 
L-Phe : L-Tyr Ratio 0.1914 0.3109 ns 
GLP-1 (pM) -0.2916 0.1248 ns 
GIP (pg/mL) -0.2458 0.1987 ns 
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Table ‎7.10: Urine miR 200a Pearson correlations with blood biochemistry markers. 
 miR 200a 
Clinical Parameter  r p p significance 
BMI (kg/m2) -0.3326 0.0726 ns 
Weight (kg) -0.3747 0.0413 * 
Fasting Glucose (mmol/L) -0.132 0.5685 ns 
Insulin (µIU/mL) -0.3292 0.1451 ns 
CRP (mg/L) -0.02221 0.9303 ns 
Hb (g/L) -0.2015 0.3811 ns 
WCC (x10^9/L) 0.3102 0.1711 ns 
Platelet Count (x10^9/L) 0.2166 0.3456 ns 
Sodium (mmol/L) -0.1564 0.4985 ns 
Potassium (mmol/L) -0.263 0.2493 ns 
Chloride (mmol/L) 0.003867 0.9867 ns 
BiCarb (mmol/L) -0.1804 0.4339 ns 
Urea (mmol/L) -0.4162 0.0606 ns 
Creatinine (umol/L) -0.1458 0.5283 ns 
eGFR (mL/min) 0.3913 0.234 ns 
Calcium (mmol/L) 0.1464 0.5265 ns 
Phospate (mmol/L) 0.286 0.2088 ns 
Bilirubin (umol/L) -0.05784 0.8034 ns 
Alk Phos (iu/L) -0.1867 0.4177 ns 
Albumin (g/L) 0.07435 0.7487 ns 
Total protein (g/L) -0.08569 0.7119 ns 
Cholestrol (mmol/l) -0.1115 0.6397 ns 
Triglycerides (mmol/l) -0.1759 0.4582 ns 
HDL (mmol/l) 0.2895 0.2158 ns 
LDL (mmol/L) -0.1356 0.5688 ns 
L-Tyr (µM) -0.3979 0.0823 ns 
L-Phe (µM) -0.07222 0.7622 ns 
L-Phe : L-Tyr Ratio 0.4972 0.0257 * 
GLP-1 (pM) -0.3684 0.1207 ns 
GIP (pg/mL) -0.4228 0.0713 ns 
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Table ‎7.11: Urine miR 200b Pearson correlations with blood biochemistry markers. 
 miR 200b 
Clinical Parameter  r p p significance 
BMI (kg/m2) -0.2873 0.0502 ns 
Weight (kg) -0.3067 0.036 * 
Fasting Glucose (mmol/L) -0.05534 0.7636 ns 
Insulin (µIU/mL) -0.1258 0.4856 ns 
CRP (mg/L) -0.006918 0.9711 ns 
Hb (g/L) -0.1855 0.3095 ns 
WCC (x10^9/L) 0.1815 0.3201 ns 
Platelet Count (x10^9/L) 0.2185 0.2295 ns 
Sodium (mmol/L) -0.1354 0.46 ns 
Potassium (mmol/L) -0.1451 0.4281 ns 
Chloride (mmol/L) 0.003286 0.9858 ns 
BiCarb (mmol/L) -0.06468 0.7251 ns 
Urea (mmol/L) -0.3515 0.0485 * 
Creatinine (umol/L) -0.1437 0.4328 ns 
eGFR (mL/min) -0.08875 0.7262 ns 
Calcium (mmol/L) 0.08932 0.6269 ns 
Phospate (mmol/L) 0.2353 0.1949 ns 
Bilirubin (umol/L) -0.09331 0.6115 ns 
Alk Phos (iu/L) -0.1474 0.4209 ns 
Albumin (g/L) 0.06188 0.7365 ns 
Total protein (g/L) -0.1042 0.5703 ns 
Cholestrol (mmol/l) -0.1399 0.4451 ns 
Triglycerides (mmol/l) -0.1616 0.377 ns 
HDL (mmol/l) 0.1113 0.5442 ns 
LDL (mmol/L) -0.1424 0.4368 ns 
L-Tyr (µM) -0.2368 0.1996 ns 
L-Phe (µM) -0.01756 0.9253 ns 
L-Phe : L-Tyr Ratio 0.2986 0.1028 ns 
GLP-1 (pM) -0.2644 0.158 ns 
GIP (pg/mL) -0.3305 0.0744 ns 
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Table ‎7.12: Post-bariatric circulating microRNA fold changes relative to preoperative levels. 
MicroRNA 
1 month 3 months 6 months 9 months 12 months 
FC p FC p FC p FC p FC p 
let-7a-5p -1.192 0.901 1.259 0.865 2.500 0.433 2.310 0.476 2.575 0.546 
let-7b-3p 1.142 0.886 1.111 0.905 -3.172 0.145 -5.349 0.081 -1.505 0.629 
let-7b-5p -2.229 0.269 -1.827 0.044 -1.335 0.291 1.057 0.886 -1.213 0.585 
let-7c 1.083 0.942 1.718 0.521 4.297 0.133 -1.002 0.990 -5.706 0.160 
let-7d-3p 1.299 0.557 -1.729 0.286 -2.003 0.172 -2.147 0.038 -2.760 0.035 
let-7d-5p -2.045 0.328 -1.714 0.336 1.683 0.405 1.079 0.875 -1.240 0.750 
let-7e-5p -1.123 0.884 -1.169 0.774 -1.301 0.629 -1.983 0.341 1.039 0.959 
let-7f-5p -1.071 0.893 -1.303 0.664 -1.509 0.581 -1.214 0.760 -1.481 0.695 
let-7g-5p 1.065 0.782 -1.138 0.551 -2.554 0.255 1.176 0.429 -1.081 0.745 
let-7i-5p 1.903 0.102 -2.051 0.087 -1.921 0.039 -2.154 0.032 -2.054 0.091 
miR-1 -1.225 0.663 1.354 0.594 1.369 0.648 -2.567 0.234 -2.600 0.170 
miR-103a-3p -5.757 0.085 -1.123 0.693 1.294 0.379 1.051 0.877 1.314 0.479 
miR-106a-5p 3.763 0.459 -3.164 0.558 9.581 0.142 1.392 0.861 11.202 0.242 
miR-106b-3p 1.137 0.890 2.289 0.301 2.411 0.415 -3.096 0.205 -1.533 0.661 
miR-106b-5p -1.031 0.956 -2.247 0.028 -1.002 0.990 -2.425 0.103 -3.740 0.040 
miR-107 -1.031 0.951 -1.184 0.674 -1.082 0.863 -1.004 0.990 1.132 0.797 
miR-10b-5p 4.244 0.193 -1.299 0.742 -1.376 0.708 -1.261 0.798 -9.328 0.078 
miR-122-5p 1.911 0.343 -3.666 0.092 -1.382 0.572 -2.554 0.195 -4.186 0.070 
miR-125a-5p 6.584 0.059 1.009 0.988 1.216 0.715 1.191 0.770 1.190 0.771 
miR-125b-5p 1.221 0.755 -1.943 0.280 -7.144 0.008 -3.067 0.033 -3.701 0.048 
miR-126-3p 12.599 0.167 13.881 0.099 12.412 0.136 12.175 0.139 1.355 0.907 
miR-128 3.660 0.288 -1.741 0.642 1.092 0.938 -4.261 0.278 -1.767 0.695 
miR-130a-3p 2.410 0.470 -1.297 0.850 1.300 0.819 -8.377 0.122 -6.195 0.280 
miR-130b-3p -1.115 0.875 -2.095 0.267 -1.082 0.904 -2.268 0.240 -13.871 0.006 
miR-132-3p -1.593 0.654 -1.247 0.834 -1.003 0.990 -1.468 0.698 -1.966 0.544 
miR-133a -1.762 0.362 -1.810 0.489 1.613 0.599 -3.487 0.148 -3.521 0.175 
miR-133b 1.412 0.743 1.826 0.568 3.551 0.256 1.127 0.918 -1.429 0.789 
miR-136-5p -3.043 0.198 1.447 0.603 3.975 0.118 -1.483 0.702 1.305 0.771 
miR-139-5p -2.385 0.291 2.421 0.205 2.858 0.147 1.008 0.990 1.250 0.787 
miR-140-3p 2.075 0.665 1.264 0.878 6.278 0.201 3.633 0.340 -1.263 0.903 
miR-140-5p -2.505 0.200 -2.639 0.171 1.580 0.468 -1.877 0.437 -1.852 0.415 
miR-142-3p -1.237 0.565 1.216 0.557 1.267 0.470 -1.102 0.781 1.419 0.412 
miR-142-5p 1.113 0.926 1.241 0.824 3.164 0.363 2.086 0.500 1.345 0.828 
miR-143-3p 3.094 0.252 1.422 0.699 2.561 0.271 3.574 0.159 1.913 0.602 
miR-144-3p 2.228 0.200 -1.295 0.631 -1.232 0.678 -1.705 0.445 -2.002 0.413 
miR-144-5p 2.636 0.306 -1.208 0.816 1.490 0.693 -2.913 0.287 -7.657 0.090 
miR-145-5p -1.047 0.957 1.262 0.653 1.751 0.339 -2.753 0.295 -1.319 0.786 
miR-146a-5p -1.208 0.725 1.660 0.227 1.302 0.546 -1.112 0.813 1.249 0.681 
miR-146b-5p -1.156 0.804 1.596 0.256 2.829 0.147 -2.082 0.273 -2.454 0.179 
miR-148a-3p 1.278 0.648 -1.717 0.230 -2.309 0.076 -2.575 0.038 -3.092 0.061 
miR-148b-3p 1.349 0.420 1.047 0.880 -1.501 0.151 -1.862 0.050 -1.967 0.077 
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MicroRNA 
1 month 3 months 6 months 9 months 12 months 
FC p FC p FC p FC p FC p 
miR-150-5p 1.129 0.871 1.506 0.576 -1.249 0.788 -9.519 0.099 -2.036 0.424 
miR-151a-3p -2.391 0.157 1.563 0.364 2.160 0.230 -1.100 0.859 -1.147 0.849 
miR-151a-5p -1.117 0.683 -1.630 0.496 1.099 0.642 1.109 0.681 1.191 0.523 
miR-152 1.451 0.541 -1.061 0.908 -1.637 0.248 -1.410 0.372 -2.125 0.140 
miR-154-5p 1.192 0.839 3.330 0.095 2.868 0.291 -1.031 0.969 -2.193 0.451 
miR-15a-5p 1.710 0.528 -2.412 0.200 -2.226 0.301 -6.522 0.013 -84.905 0.019 
miR-15b-3p 1.628 0.712 -2.457 0.448 -1.092 0.939 -1.183 0.876 -2.801 0.468 
miR-15b-5p 1.220 0.766 -1.162 0.769 1.412 0.612 -2.087 0.309 -8.795 0.062 
miR-16-2-3p -1.074 0.939 -1.642 0.412 -1.897 0.465 -4.056 0.045 -5.841 0.078 
miR-16-5p 1.370 0.493 -1.696 0.183 -1.415 0.380 -1.117 0.799 -1.375 0.542 
miR-17-5p -1.524 0.545 -1.437 0.480 1.881 0.279 1.297 0.594 1.411 0.600 
miR-181a-5p -1.039 0.954 1.249 0.700 1.034 0.950 1.213 0.680 1.147 0.825 
miR-185-5p -1.054 0.931 -1.528 0.112 -1.058 0.835 -1.507 0.314 -1.098 0.764 
miR-186-5p -1.156 0.830 -1.199 0.751 1.353 0.561 -1.428 0.654 1.203 0.779 
miR-18a-3p 2.397 0.168 -1.104 0.810 1.179 0.834 -4.555 0.056 -1.253 0.670 
miR-18a-5p 1.114 0.925 1.483 0.692 6.756 0.078 1.396 0.785 1.706 0.682 
miR-18b-5p -1.326 0.710 -1.237 0.737 1.743 0.255 2.002 0.160 1.868 0.333 
miR-191-5p -1.136 0.806 1.577 0.194 1.504 0.256 1.351 0.415 1.301 0.574 
miR-192-5p 1.084 0.873 -2.103 0.206 -3.976 0.007 -3.680 0.016 -3.458 0.047 
miR-194-5p -1.935 0.297 -6.792 0.001 -3.465 0.141 -7.387 0.006 -8.758 0.003 
miR-195-5p 2.764 0.255 -1.308 0.709 -1.176 0.787 -3.095 0.124 -1.107 0.883 
miR-197-3p -2.506 0.350 3.074 0.181 4.635 0.084 2.776 0.267 1.503 0.733 
miR-199a-3p -4.064 0.210 1.532 0.475 2.062 0.248 -1.469 0.673 1.511 0.619 
miR-199a-5p -4.574 0.144 1.717 0.511 5.884 0.065 1.493 0.653 1.348 0.782 
miR-19b-3p 1.049 0.890 -1.061 0.821 -1.081 0.778 1.092 0.780 -1.015 0.967 
miR-205-5p 1.458 0.689 1.011 0.990 1.981 0.558 -2.540 0.352 -2.127 0.526 
miR-20a-5p 1.847 0.498 1.429 0.638 1.521 0.614 -1.958 0.666 2.068 0.509 
miR-20b-5p 1.502 0.581 -1.009 0.989 1.626 0.565 -1.564 0.541 -5.580 0.050 
miR-210 1.695 0.519 -3.081 0.123 -1.268 0.811 -2.526 0.343 -2.331 0.375 
miR-2110 1.107 0.900 -1.383 0.607 1.151 0.858 -1.296 0.685 -3.563 0.146 
miR-215 1.311 0.750 -1.591 0.570 -3.044 0.177 -1.961 0.436 -1.878 0.521 
miR-21-5p 1.102 0.870 -1.507 0.371 -1.304 0.671 -2.993 0.026 -4.990 0.016 
miR-221-3p 2.535 0.404 2.104 0.529 3.212 0.345 5.139 0.109 6.730 0.159 
miR-222-3p 2.599 0.069 -2.909 0.377 -3.298 0.236 -1.213 0.648 1.015 0.978 
miR-223-5p 1.365 0.635 -1.352 0.665 1.669 0.554 -1.397 0.702 -1.900 0.484 
miR-22-3p 3.746 0.234 1.355 0.737 -1.040 0.967 -1.402 0.723 -2.079 0.571 
miR-22-5p 1.437 0.609 -1.558 0.396 -1.958 0.305 -5.348 0.018 -19.128 0.002 
miR-23a-3p 1.023 0.957 1.408 0.247 1.233 0.495 1.080 0.814 1.031 0.938 
miR-23b-3p 1.449 0.721 -1.637 0.697 5.006 0.120 2.213 0.403 -2.331 0.568 
miR-24-3p -1.188 0.613 -1.952 0.505 1.022 0.936 -1.111 0.719 -1.099 0.791 
miR-25-3p 1.022 0.986 1.193 0.838 -2.120 0.538 1.184 0.861 1.266 0.848 
miR-26b-5p -1.967 0.530 2.161 0.280 1.719 0.472 3.296 0.106 -2.085 0.585 
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MicroRNA 
1 month 3 months 6 months 9 months 12 months 
FC p FC p FC p FC p FC p 
miR-27a-3p 4.039 0.216 2.994 0.363 13.533 0.023 -2.634 0.513 -3.982 0.443 
miR-27b-3p -1.053 0.954 -2.062 0.545 -1.001 0.990 2.052 0.239 2.366 0.283 
miR-28-3p -1.583 0.480 1.736 0.163 2.881 0.078 -3.387 0.027 -1.631 0.507 
miR-28-5p -2.393 0.365 1.025 0.974 2.220 0.417 -2.022 0.476 1.507 0.708 
miR-29a-3p -1.231 0.792 -1.394 0.598 1.094 0.889 -1.351 0.615 -2.461 0.278 
miR-29a-5p -1.474 0.502 1.175 0.784 -1.119 0.818 -3.828 0.066 -5.746 0.010 
miR-29b-3p -1.836 0.317 -1.462 0.410 1.202 0.751 -1.866 0.279 -3.096 0.035 
miR-29c-3p -1.012 0.983 -1.888 0.142 -1.436 0.562 -4.366 0.011 -7.437 0.005 
miR-301a-3p -1.050 0.953 1.937 0.338 5.379 0.018 2.765 0.137 6.227 0.046 
miR-30a-5p -1.926 0.413 -2.347 0.318 -1.221 0.743 -1.963 0.439 -3.178 0.123 
miR-30b-5p 3.854 0.275 2.006 0.536 3.569 0.263 2.830 0.359 3.660 0.395 
miR-30c-5p 1.195 0.692 -1.211 0.695 1.290 0.502 -3.454 0.219 1.217 0.632 
miR-30d-5p -2.164 0.132 -1.767 0.196 -1.235 0.331 -1.516 0.124 -1.203 0.461 
miR-30e-3p -2.089 0.132 1.082 0.851 1.837 0.257 -2.612 0.103 -4.250 0.021 
miR-30e-5p -1.716 0.478 -1.605 0.300 -1.967 0.351 -7.573 0.100 -1.033 0.829 
miR-320a 2.079 0.313 -1.752 0.383 -4.931 0.037 -5.058 0.007 -5.639 0.024 
miR-320b 1.202 0.889 -2.035 0.291 -2.760 0.128 -3.363 0.040 -4.339 0.059 
miR-324-3p -1.861 0.425 -1.577 0.405 1.393 0.712 -1.303 0.703 -4.435 0.105 
miR-324-5p -1.686 0.354 -1.049 0.905 -1.445 0.504 1.272 0.564 1.082 0.888 
miR-32-5p 1.634 0.523 -3.121 0.091 -1.499 0.569 -5.872 0.025 -11.797 0.008 
miR-326 -1.449 0.564 1.195 0.715 1.250 0.782 -3.281 0.126 -3.131 0.172 
miR-328 -1.210 0.800 -2.304 0.351 2.169 0.318 -1.635 0.406 -1.384 0.674 
miR-331-3p 2.114 0.302 2.159 0.192 -1.009 0.990 -2.479 0.286 2.114 0.384 
miR-335-5p 1.859 0.440 1.239 0.771 1.004 0.990 1.379 0.563 -1.983 0.382 
miR-338-3p -4.482 0.039 -1.230 0.737 1.967 0.274 -1.857 0.525 1.977 0.371 
miR-339-3p -1.080 0.936 -1.724 0.387 -1.476 0.576 -4.306 0.084 -11.956 0.016 
miR-339-5p 1.020 0.979 1.420 0.550 1.249 0.743 -2.095 0.331 -2.041 0.422 
miR-33a-5p 1.288 0.733 2.995 0.124 4.739 0.024 1.271 0.800 2.661 0.265 
miR-342-3p -1.139 0.848 1.494 0.502 -2.725 0.336 -6.749 0.107 -1.141 0.817 
miR-34a-5p -1.200 0.875 -2.275 0.426 -3.108 0.284 -5.222 0.167 -13.774 0.087 
miR-363-3p 1.176 0.830 -2.919 0.055 -2.838 0.265 -4.165 0.039 -6.015 0.037 
miR-365a-3p -1.544 0.442 -2.269 0.164 -1.480 0.628 -14.393 0.000 -2.425 0.224 
miR-374a-5p -2.219 0.137 -1.404 0.308 1.292 0.653 -1.543 0.247 -1.703 0.244 
miR-374b-5p 1.070 0.946 4.933 0.050 6.262 0.035 6.420 0.027 8.699 0.052 
miR-376a-3p -3.139 0.184 -1.012 0.987 1.954 0.412 -1.624 0.563 -1.247 0.821 
miR-378a-3p 1.507 0.571 -5.183 0.156 -11.137 0.032 -9.024 0.006 -35.243 0.003 
miR-382-5p 1.166 0.869 1.627 0.571 1.897 0.565 1.144 0.895 -1.696 0.675 
miR-409-3p -2.077 0.332 1.068 0.907 2.599 0.176 1.217 0.797 -2.966 0.270 
miR-421 1.010 0.984 1.427 0.567 1.418 0.564 -1.401 0.543 -2.078 0.328 
miR-423-3p -1.671 0.465 -2.111 0.145 -1.660 0.418 -4.642 0.021 -4.013 0.017 
miR-423-5p 8.054 0.132 1.595 0.674 1.029 0.981 -3.294 0.391 -1.689 0.732 
miR-424-5p 1.516 0.473 -2.320 0.085 -5.042 0.063 -3.069 0.029 -2.873 0.099 
miR-425-3p 1.609 0.472 -1.355 0.481 -1.085 0.901 -2.939 0.086 -3.326 0.155 
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MicroRNA 
1 month 3 months 6 months 9 months 12 months 
FC p FC p FC p FC p FC p 
miR-425-5p 1.547 0.718 1.154 0.886 2.494 0.436 -1.470 0.751 -1.240 0.878 
miR-451a 1.716 0.448 -2.016 0.282 -1.727 0.374 -1.271 0.731 -1.558 0.592 
miR-484 14.798 0.151 4.038 0.377 2.231 0.635 4.137 0.351 1.057 0.979 
miR-485-3p 1.858 0.477 1.556 0.580 2.032 0.299 -3.134 0.180 -1.091 0.918 
miR-486-5p 3.296 0.148 -1.854 0.343 -2.311 0.188 -2.796 0.111 -3.505 0.116 
miR-495-3p -1.512 0.609 2.221 0.287 2.078 0.338 -1.284 0.745 -1.486 0.637 
miR-497-5p 2.616 0.244 1.405 0.641 1.244 0.806 -2.613 0.238 -7.824 0.039 
miR-501-3p 1.183 0.877 1.693 0.569 -1.393 0.742 -6.811 0.057 -7.161 0.115 
miR-502-3p 1.335 0.681 -2.393 0.135 -3.069 0.129 -5.755 0.038 -13.228 0.004 
miR-505-3p -1.029 0.981 -3.760 0.265 -1.625 0.660 -5.377 0.190 -21.453 0.042 
miR-532-3p -1.511 0.470 -1.769 0.397 1.078 0.923 -3.319 0.081 -16.700 0.007 
miR-532-5p 1.171 0.828 -2.052 0.167 -1.199 0.848 -5.651 0.011 -2.192 0.347 
miR-543 1.909 0.485 4.442 0.117 5.423 0.091 2.410 0.267 2.268 0.376 
miR-574-3p 2.743 0.049 1.581 0.393 2.996 0.264 1.076 0.872 -1.267 0.740 
miR-584-5p 2.759 0.303 2.068 0.443 1.450 0.687 -1.451 0.670 -3.960 0.244 
miR-590-5p -1.202 0.816 -1.190 0.648 -2.729 0.022 -2.087 0.065 -2.233 0.106 
miR-629-5p 2.131 0.435 -3.544 0.180 -2.531 0.287 -34.772 0.001 -30.336 0.001 
miR-652-3p -1.090 0.888 -1.591 0.291 -1.903 0.376 -1.246 0.532 -1.270 0.579 
miR-660-5p 1.478 0.642 -3.184 0.121 -4.952 0.110 -12.738 0.003 -16.147 0.009 
miR-766-3p -1.568 0.494 1.605 0.285 2.505 0.145 -1.327 0.622 -3.765 0.044 
miR-885-5p 1.413 0.737 -2.183 0.474 -2.155 0.512 -6.271 0.076 -15.316 0.050 
miR-92a-3p 1.236 0.747 -2.280 0.116 -1.882 0.350 -4.509 0.015 -7.404 0.016 
miR-93-3p 1.655 0.371 1.283 0.430 2.139 0.282 -2.081 0.205 -5.518 0.007 
miR-93-5p -4.168 0.272 -11.421 0.048 -1.182 0.848 1.891 0.383 1.875 0.516 
miR-99a-5p 1.772 0.461 -5.110 0.064 -4.344 0.055 -11.744 0.018 -6.782 0.047 
miR-99b-5p 2.574 0.350 2.583 0.276 1.084 0.941 -2.574 0.385 1.026 0.982 
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Table ‎7.13: Pearson correlations between bariatric circulating microRNA expressions 
and clinical parameters. 
MicroRNA 
BMI % Preop BMI lost Blood glucose 
r p r p r p 
 let-7b-3p 0.02469 0.8798 -0.1838 0.2562 0.4951 0.0025 
 let-7b-5p 0.252 0.1168 -0.03617 0.8246 0.0275 0.8754 
 let-7c 0.074 0.65 0.009722 0.9525 -0.04249 0.8085 
 let-7d-3p 0.3466 0.0285 -0.4277 0.0059 0.09429 0.5901 
 let-7d-5p -0.1591 0.3267 0.1148 0.4805 0.07089 0.6857 
 let-7e-5p 0.2546 0.1128 -0.2403 0.1353 0.08388 0.6319 
 let-7f-5p -0.06739 0.6795 -0.1775 0.2731 0.2927 0.088 
 let-7g-5p -0.1967 0.2237 -0.04721 0.7724 0.0679 0.6983 
 let-7i-5p 0.3165 0.0466 -0.4127 0.0081 0.1742 0.3168 
 miR-1 -0.2418 0.1328 0.01092 0.9467 0.3594 0.034 
 miR-103a-3p -0.3231 0.042 0.1461 0.3685 0.1728 0.321 
 miR-106a-5p -0.2061 0.202 0.1956 0.2265 -0.04955 0.7774 
 miR-106b-3p -0.000729 0.9964 0.03009 0.8538 -0.009695 0.9559 
 miR-106b-5p -0.09802 0.5474 -0.1599 0.3245 0.07866 0.6533 
 miR-107 -0.3347 0.0348 0.008081 0.9605 0.2033 0.2415 
 miR-10b-5p 0.1376 0.3972 -0.08126 0.6182 0.009655 0.9561 
 miR-122-5p 0.2242 0.1642 -0.2938 0.0658 0.2039 0.24 
 miR-125a-5p 0.08062 0.621 -0.147 0.3654 0.1924 0.2681 
 miR-125b-5p 0.3457 0.0289 -0.4235 0.0065 0.2246 0.1945 
 miR-126-3p -0.247 0.1244 0.2654 0.098 0.1971 0.2565 
 miR-128 0.1282 0.4305 -0.173 0.2857 -0.05962 0.7337 
 miR-130a-3p -0.0191 0.9069 -0.1837 0.2565 0.2375 0.1696 
 miR-130b-3p 0.07258 0.6563 -0.2099 0.1937 -0.1307 0.4544 
 miR-132-3p -0.06356 0.6968 -0.05333 0.7438 0.3316 0.0516 
 miR-133a -0.1824 0.26 -0.175 0.2802 0.356 0.0358 
 miR-133b -0.08481 0.6029 0.05313 0.7447 0.005138 0.9766 
 miR-136-5p -0.3881 0.0133 0.1255 0.4405 0.1953 0.2608 
 miR-139-5p -0.1835 0.2571 0.1146 0.4815 0.161 0.3556 
 miR-140-3p -0.2101 0.1932 0.1276 0.4327 0.1432 0.4119 
 miR-140-5p 0.00656 0.968 0.005003 0.9756 -0.2752 0.1097 
 miR-142-3p -0.2293 0.1547 0.05257 0.7473 0.2257 0.1923 
 miR-142-5p -0.32 0.0441 0.1897 0.241 0.06127 0.7266 
 miR-143-3p -0.276 0.0848 0.2805 0.0795 0.009366 0.9574 
 miR-144-3p -0.1361 0.4022 -0.07119 0.6625 0.106 0.5445 
 miR-144-5p -0.1749 0.2805 -0.09053 0.5785 0.2958 0.0844 
 miR-145-5p -0.06614 0.6851 -0.06063 0.7102 0.0672 0.7013 
 miR-146a-5p 0.05593 0.7318 -0.03155 0.8468 0.2216 0.2008 
 miR-146b-5p -0.09773 0.5485 0.07658 0.6386 0.04566 0.7945 
 miR-148a-3p 0.5195 0.0006 -0.4731 0.002 0.04618 0.7922 
 miR-148b-3p 0.4008 0.0104 -0.3638 0.021 0.05604 0.7492 
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MicroRNA 
BMI % Preop BMI lost Blood glucose 
r p r p r p 
 miR-150-5p 0.1481 0.3618 -0.1504 0.3542 0.04913 0.7793 
 miR-151a-3p -0.1307 0.4214 0.07835 0.6308 -0.0878 0.616 
 miR-151a-5p -0.01637 0.9201 0.06388 0.6954 0.06326 0.7181 
 miR-152 0.2464 0.1254 -0.2273 0.1584 0.08336 0.634 
 miR-154-5p 0.07499 0.6456 0.09192 0.5727 -0.02518 0.8858 
 miR-15a-5p 0.1907 0.2384 -0.3005 0.0595 0.1948 0.262 
 miR-15b-3p -0.01747 0.9148 -0.04106 0.8014 0.05954 0.734 
 miR-15b-5p 0.09232 0.571 -0.1724 0.2873 0.08834 0.6138 
 miR-16-2-3p 0.001143 0.9944 -0.2115 0.1901 0.1952 0.2612 
 miR-16-5p 0.2089 0.1958 -0.099 0.5433 -0.2058 0.2356 
 miR-17-5p -0.2066 0.201 0.2155 0.1818 0.07083 0.686 
 miR-181a-5p -0.05945 0.7156 0.0407 0.8031 0.1863 0.2838 
 miR-185-5p -0.1887 0.2435 -0.02768 0.8654 0.1432 0.4119 
 miR-186-5p 0.1052 0.5183 0.04153 0.7991 -0.05657 0.7469 
 miR-18a-3p 0.04131 0.8002 -0.1466 0.3668 0.02919 0.8678 
 miR-18a-5p -0.1958 0.2259 0.2374 0.1402 -0.1344 0.4415 
 miR-18b-5p -0.2205 0.1715 0.2619 0.1025 0.1803 0.2999 
 miR-191-5p -0.3831 0.0147 0.2118 0.1895 0.1909 0.272 
 miR-192-5p 0.2986 0.0613 -0.3929 0.0121 0.1238 0.4787 
 miR-194-5p 0.193 0.2328 -0.369 0.0191 0.1291 0.4597 
 miR-195-5p 0.1886 0.2438 -0.2711 0.0906 0.1665 0.339 
 miR-197-3p 0.001588 0.9922 0.182 0.261 0.1624 0.3513 
 miR-199a-3p 0.04054 0.8038 1.128E-05 0.9999 0.1181 0.4991 
 miR-199a-5p -0.3812 0.0152 0.2265 0.16 0.04164 0.8123 
 miR-19b-3p -0.2402 0.1355 0.1324 0.4155 0.0065 0.9704 
 miR-205-5p -0.08123 0.6183 0.02167 0.8944 -0.06271 0.7204 
 miR-20a-5p -0.3319 0.0364 0.03544 0.8281 0.1167 0.5043 
 miR-20b-5p 0.06079 0.7094 -0.04246 0.7948 0.02331 0.8942 
 miR-210 -0.2856 0.074 -0.1064 0.5135 0.1622 0.3518 
 miR-2110 0.001971 0.9904 -0.04752 0.7709 0.1659 0.341 
 miR-215 0.03707 0.8204 -0.2454 0.1269 0.2024 0.2437 
 miR-21-5p 0.1557 0.3373 -0.2901 0.0694 0.2766 0.1078 
 miR-221-3p -0.302 0.0582 0.1743 0.282 0.1311 0.4528 
 miR-222-3p -0.06203 0.7038 -0.03221 0.8436 0.1832 0.2921 
 miR-223-5p -0.06849 0.6745 -0.06866 0.6738 0.03172 0.8564 
 miR-22-3p -0.1225 0.4513 -0.1116 0.4931 0.2023 0.2438 
 miR-22-5p 0.2064 0.2013 -0.4428 0.0042 0.2581 0.1344 
 miR-23a-3p 0.09437 0.5624 -0.005878 0.9713 0.08711 0.6188 
 miR-23b-3p -0.3159 0.0471 0.1646 0.3102 0.155 0.3739 
 miR-24-3p 0.144 0.3753 -0.1043 0.5217 -0.04015 0.8189 
 miR-25-3p -0.01727 0.9158 -0.003357 0.9836 0.03555 0.8393 
 miR-26b-5p -0.1027 0.5281 0.09525 0.5588 0.09634 0.582 
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 miR-27a-3p -0.09657 0.5533 0.07968 0.625 0.05217 0.766 
 miR-27b-3p -0.122 0.4531 -0.008877 0.9566 0.06936 0.6921 
 miR-28-3p 0.07332 0.653 -0.04745 0.7712 0.05087 0.7717 
 miR-28-5p -0.1589 0.3275 0.001163 0.9943 0.226 0.1917 
 miR-29a-3p 0.2509 0.1184 -0.1014 0.5336 -0.06196 0.7237 
 miR-29a-5p 0.0834 0.6089 -0.2452 0.1273 0.2563 0.1373 
 miR-29b-3p -0.1263 0.4373 -0.09505 0.5596 0.23 0.1838 
 miR-29c-3p 0.186 0.2504 -0.2977 0.0621 0.05115 0.7704 
 miR-301a-3p -0.5925 0.0001 0.4295 0.0057 0.1962 0.2587 
 miR-30a-5p -0.06924 0.6712 -0.1173 0.4709 0.4038 0.0162 
 miR-30b-5p -0.1341 0.4094 0.2281 0.157 -0.07413 0.6722 
 miR-30c-5p -0.1916 0.2364 -0.09934 0.5419 0.3467 0.0413 
 miR-30d-5p 0.3203 0.0439 -0.2471 0.1242 0.1678 0.3354 
 miR-30e-3p -0.03267 0.8414 -0.1936 0.2314 0.2505 0.1467 
 miR-30e-5p -0.2121 0.189 -0.09929 0.5422 0.1545 0.3754 
 miR-320a 0.2579 0.1081 -0.4439 0.0041 0.3817 0.0237 
 miR-320b 0.268 0.0945 -0.3264 0.0399 0.3355 0.0488 
 miR-324-3p -0.02865 0.8607 -0.07504 0.6454 -0.1438 0.4098 
 miR-324-5p -0.2259 0.1611 0.04119 0.8008 -0.06882 0.6945 
 miR-32-5p 0.09184 0.573 -0.3308 0.0371 0.2246 0.1945 
 miR-326 -0.06072 0.7097 -0.1227 0.4509 0.02954 0.8662 
 miR-328 -0.07584 0.6418 0.02052 0.9 -0.07006 0.6892 
 miR-331-3p -0.1768 0.2752 0.01331 0.935 0.1524 0.3821 
 miR-335-5p 0.005219 0.9745 -0.05853 0.7198 0.1818 0.2959 
 miR-338-3p -0.2318 0.15 0.07554 0.6432 0.1006 0.5653 
 miR-339-3p -0.003726 0.9818 -0.2411 0.1339 0.09719 0.5786 
 miR-339-5p -0.1663 0.305 -0.1278 0.4318 0.1669 0.3379 
 miR-33a-5p -0.4107 0.0085 0.228 0.1572 0.07564 0.6658 
 miR-342-3p -0.0822 0.6141 -0.0942 0.5632 0.1834 0.2915 
 miR-34a-5p 0.1511 0.352 -0.2672 0.0956 0.08434 0.63 
 miR-363-3p 0.02072 0.899 -0.2731 0.0882 0.2308 0.1823 
 miR-365a-3p 0.2311 0.1514 -0.4165 0.0075 0.07643 0.6626 
 miR-374a-5p -0.1778 0.2724 -0.04062 0.8035 0.0529 0.7628 
 miR-374b-5p -0.1509 0.3527 0.4081 0.0089 0.1614 0.3544 
 miR-376a-3p -0.202 0.2112 0.03087 0.85 0.09109 0.6028 
 miR-378a-3p 0.264 0.0997 -0.4564 0.0031 0.2314 0.1812 
 miR-382-5p -0.03511 0.8297 0.09181 0.5731 0.04492 0.7978 
 miR-409-3p -0.2093 0.1949 0.04353 0.7897 -0.03217 0.8544 
 miR-421 -0.03206 0.8443 0.01591 0.9224 0.08119 0.6429 
 miR-423-3p 0.1308 0.4212 -0.3669 0.0199 0.07069 0.6866 
 miR-423-5p -0.09214 0.5717 -0.1307 0.4215 0.3027 0.0772 
 miR-424-5p 0.3329 0.0358 -0.3216 0.043 0.1519 0.3838 
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r p r p r p 
 miR-425-3p -0.1108 0.4962 -0.2046 0.2053 0.2698 0.117 
 miR-425-5p -0.04609 0.7776 0.007535 0.9632 0.1092 0.5323 
 miR-451a 0.2027 0.2098 -0.1116 0.4932 -0.1094 0.5315 
 miR-484 0.03356 0.8371 0.1021 0.5309 0.1048 0.5492 
 miR-485-3p -0.01253 0.9388 -0.1151 0.4795 0.03507 0.8415 
 miR-486-5p 0.2955 0.0642 -0.3174 0.0459 0.266 0.1224 
 miR-495-3p -0.06544 0.6883 0.08412 0.6058 -0.09751 0.5773 
 miR-497-5p -0.1013 0.5339 -0.1019 0.5315 0.2197 0.2047 
 miR-501-3p 0.103 0.5269 -0.2985 0.0613 0.3104 0.0695 
 miR-502-3p 0.1458 0.3692 -0.3263 0.0399 0.2487 0.1497 
 miR-505-3p 0.1514 0.3511 -0.2921 0.0674 0.2263 0.1911 
 miR-532-3p 0.2847 0.0749 -0.2897 0.0698 0.1737 0.3182 
 miR-532-5p 0.1111 0.4951 -0.1417 0.383 -0.1326 0.4476 
 miR-543 -0.238 0.1391 0.184 0.2557 0.02228 0.8989 
 miR-574-3p 0.004511 0.978 0.04306 0.7919 -0.07358 0.6744 
 miR-584-5p 0.1216 0.4549 -0.1308 0.4212 0.001279 0.9942 
 miR-590-5p 0.001537 0.9925 -0.2055 0.2033 0.4602 0.0054 
 miR-629-5p 0.1834 0.2572 -0.4548 0.0032 0.321 0.0601 
 miR-652-3p -0.1262 0.4377 -0.115 0.4799 0.1643 0.3458 
 miR-660-5p 0.1562 0.3358 -0.4026 0.01 0.2701 0.1166 
 miR-766-3p -0.03222 0.8435 -0.08905 0.5848 0.212 0.2214 
 miR-885-5p 0.2426 0.1314 -0.2981 0.0617 0.06254 0.7212 
 miR-92a-3p 0.1935 0.2317 -0.3394 0.0322 0.08189 0.64 
 miR-93-3p 0.1319 0.4171 -0.1108 0.4962 -0.09724 0.5784 
 miR-93-5p 0.02307 0.8876 0.1185 0.4665 0.02092 0.9051 
 miR-99a-5p 0.3101 0.0515 -0.4939 0.0012 0.2539 0.1411 
 miR-99b-5p 0.01307 0.9362 -0.06759 0.6786 0.1593 0.3606 
 
 
